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Abstract 
Anabolic androgenic steroids (AAS) are a class of compounds which include the 
parent compound testosterone, and are well-known for their misuse as 
performance enhancing substances in sport. Over the last decade there has a push 
towards the illicit use of so-called “designer steroids” which are manufactured 
with the express aim of rendering these compounds undetectable by existing anti-
doping methods. These compounds are readily accessible online in “dietary” or 
“nutritional” supplements containing compounds which have never been tested or 
approved as veterinary agents. Despite considerable focus in human sports, there 
has been limited investigation into these compounds in equine systems. As such, 
developing new tools to detect these compounds is of high priority. 
 
Chapter One presents a summary of the literature detailing the metabolism of 
designer steroid compounds in equine systems, with an aim to identify metabolites 
suitable for incorporation into screening protocols by anti-doping laboratories. 
Future directions for anti-doping laboratories are also proposed, highlighting the 
importance of alternate testing matrices, improved in vitro methodologies which 
can faithfully replicate in vivo metabolism, and the development of untargeted 
screening methods which can detect new instances of steroid misuse. 
 
Chapter Two presents new methodology for the synthesis of steroid sulfate 
compounds, suitable for use in analytical laboratories. Key to this synthetic 
methodology is the use of solid-phase extraction (SPE), a technique routinely used 
in anti-doping laboratories but with untapped potential in chemical synthesis. This 
methodology was applied to the synthesis of sixteen steroid mono-sulfate, and 
twelve steroid bis-sulfate reference materials, which encompass a representative 
range of steroid substitution patterns and configurations. The mass spectrometry 
behaviour of these bis-sulfate compounds has been studied, and used to develop a 
constant ion loss (CIL) scan method for the untargeted detection of all major 
classes of steroid bis-sulfate metabolites. 
xiii 
Chapter Three presents a study detailing the discovery of a novel anabolic agent 
3α/β-chloro-17α-methyl-5α-androstan-17β-ol, in samples seized by law-
enforcement, and the subsequent investigations to elucidate its structure, identify 
the primary human and equine metabolites, and to incorporate these into routine 
anti-doping screening protocols. This study highlights a workflow suitable for 
adoption by anti-doping laboratories which allows for the development of suitable 
screening protocols in the event that new designer steroids are identified. 
 
Chapter Four presents in vivo and in vitro studies of the designer steroid furazadrol 
([1’,2’]isoxazolo[4’,5’:2,3]-5α-androstan-17β-ol). Following a controlled equine 
in vivo administration, these investigations have identified the key urinary 
metabolites of furazadrol, many of which have been confirmed by comparison to 
synthetically-derived reference materials. These metabolites can be incorporated 
into anti-doping screening and confirmation procedures. Comparative in vitro 
studies were also undertaken alongside this work. A second study is presented in 
this chapter which investigates alternative conditions for in vitro phase II 
metabolism, and employs adenosine 5’-triphosphate (ATP) and Na2SO4 in place of 
the expensive phase II co-factor 3'-phosphoadenosine-5'-phosphosulfate (PAPS). 
Although the ability to replicate in vivo metabolism using in vitro methods is 
currently limited, it is hoped that this work will allow for the prediction of in vivo 
metabolism of unknown compounds solely from in vitro results. 
 
Chapter Five presents an in vivo study of the designer steroid hemapolin (2α,3α-
epithio-17α-methyl-5α-androstan-17β-ol). Following a controlled equine in vivo 
administration, these investigations have identified the key urinary metabolites of 
hemapolin, many of which have been confirmed by comparison to an extensive 
library of synthetically-derived reference materials. The excretion profiles of the 
major enone metabolites 17β-hydroxy-17α-methyl-5α-androst-3-en-2-one, and 17β-
hydroxy-17α-methyl-5α-androst-2-en-4-one have been established through a MRM 
method. These metabolites can be incorporated into anti-doping screening and 
confirmation procedures, allowing for the future detection of hemapolin misuse. 
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Introduction 
  
2 
Publication: 
Waller, C. C., McLeod, M. D. Drug Testing and Analysis 2016, submitted 
for review 
 
1.1 Foreword 
The following manuscript has been submitted for review in the journal Drug 
Testing and Analysis for their special edition entitled “Advances in Equine Anti-
Doping”. This manuscript gives an introduction to anti-doping analysis, 
summarises some of the key techniques currently in use today, and reviews the 
available literature on designer steroid metabolism in equine sports. This 
manuscript was authored by Mr Christopher Waller and Associate Professor 
Malcolm McLeod. C. Waller undertook the literature review, and prepared the 
initial and revised drafts of the manuscript. Assoc. Prof. McLeod assisted in 
determining the content and scope of the review, and also assisted in revising the 
manuscript prior to submission. 
 
Figure 1.1: “Designer” anabolic steroids in equine sports 
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Anabolic androgenic steroids (AAS) are a class of compounds which include the 
parent compound testosterone, and are well-known for their misuse as 
performance enhancing substances in sport. Over the last decade as anti-doping 
laboratories have developed analytical methods in order to be able to monitor for 
the misuse of these compounds in sport, there has a push towards so-called 
“designer steroids” which are manufactured with the express aim of rendering 
these compounds undetectable by existing analytical methods. These compounds 
are readily accessible online in “dietary” or “nutritional” supplements containing 
compounds which have never been tested or approved as veterinary agents. 
 
Despite considerable focus in human sports there has been limited investigation 
into these compounds in equine systems. In order to effectively respond to the 
threat of designer steroids, a detailed understanding of their metabolism is needed 
to identify markers and metabolites related to their misuse. In this chapter a 
summary of the literature detailing the metabolism of designer steroid compounds 
in equine systems is presented with an aim to identify metabolites suitable for 
incorporation into screening protocols by anti-doping laboratories. A brief 
exploration of the future directions of anti-doping analysis is also presented 
intending to highlight important areas of current and future research, and provide 
context to the work presented in the remaining chapters. 
  
4 
 
 
 
 
 
 
 
 
 
 
 
1.2 A review of designer anabolic steroids in 
equine sports 
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Abstract: 
In recent years the potential for anabolic steroid abuse in equine sports has 
increased due to the growing availability of “designer steroids”. These compounds 
are readily accessible online in “dietary” or “nutritional” supplements and contain 
steroidal compounds which have never been tested or approved as veterinary 
agents. They typically have unusual structures or substitution and as a result may 
pass undetected through current anti-doping screening protocols, making them a 
significant concern for the integrity of the industry. Despite considerable focus in 
human sports, until recently there has been limited investigation into these 
compounds in equine systems. In order to effectively respond to the threat of 
designer steroids, a detailed understanding of their metabolism is needed to 
identify markers and metabolites arising from their misuse. A summary of the 
literature detailing the metabolism of these compounds in equine systems is 
presented with an aim to identify metabolites suitable for incorporation into 
screening protocols by anti-doping laboratories. The future of equine anti-doping 
research is likely to be guided by the incorporation of alternate testing matrices 
into routine screening, the improvement of in vitro technologies that can faithfully 
replicate in vivo equine metabolism, and the improvement of instrumentation or 
analytical methods that allow for the development of untargeted screening, and 
metabolomics approaches for use in anti-doping screening protocols.  
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History of doping in sport 
Among the earliest known examples of doping in sport come from the ancient 
Greek and Roman cultures which are known to have held sporting competition in 
high regard. Competitors devoted themselves to winning at any cost and were said 
to have consumed numerous substances as a part of the strict diet and exercise 
regimes that accompanied preparation for these competitions. Alcohol, 
hallucinogenic mushrooms, leaves and syrups derived from opium-containing 
plants, bull urine, and raw animal testicles were favourites of these competitors 1,2. 
Animal sports were also quite common during this time and although records 
relating to the doping of animal competitors during this period are scarce, it is 
unlikely that they would not have been subject to the same types of treatment as 
their human-counterparts 3,4. Among the first known instances of doping in equine 
sports comes from the fifteenth century where a mixture containing anise seed, 
honey and red arsenic sulfide (sandarac) was reportedly given to horses as a 
stimulant 3, and later from an English regulation reported in 1666 banning the use 
of “exciting substances” in competitive races 3,5. The first well-documented cases of 
doping in equine sports however came to light during the nineteenth century and 
in response such substances were soon outlawed 3,6. These bans were ineffective 
without a means to police them however, so this lead to the rapid development of 
saliva-based tests to detect alkaloids such as cocaine and heroin 4–7.  
 
With the new discovery of testosterone (17β-hydroxyandrost-4-en-3-one) and the 
other anabolic steroids in 1935 8, sports doping began to change as the effects of 
these drugs were quickly realised. Anabolic steroids became widely misused by 
athletes over the coming decades and after several deaths allegedly linked to 
doping 9, the International Olympic Committee (IOC) established a medical 
commission in 1967 to combat doping. Urine and blood screening became 
mandatory from the 1968 Olympic games and in subsequent competitions the 
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number of cases of doping fell as a result 9. In order to more effectively combat the 
doping problem, the World Anti-Doping Agency (WADA) was formed in 1999 and 
developed a strict “Olympic Standard” drug testing regime which includes regular 
and random drug tests throughout the entire course of an Olympic games for all 
competitors. This has become a template for all anti-doping testing currently in use 
today 10.  
 
Reports of anabolic steroid misuse in equine sports date back to 1941, where an 
eighteen-year-old standardbred US trotter named Holloway was treated with 
testosterone for several months during training, and as a result reportedly 
regained much of his former racing ability 11. More recently, the trainer of the US 
champion thoroughbred Big Brown admitted to injecting his horses with the 
synthetic anabolic steroid stanozolol ([1',2’]-1’H-pyrazolo[4’,5’:2,3]-17α-methyl-
5α-androstan-17β-ol) during the 2008 Kentucky Derby, although stanozolol was 
legal in US racing at the time 11. Big Brown won the first two races of the series 
under the effects of stanozolol; however, the horse failed to perform as expected in 
the third race where he was run steroid-free. To combat the growing problem of 
doping in equine sports, the Horseracing Authorities of the United States of 
America, France, Great Britain and Ireland jointly decided in 1961 to coordinate 
their resources to better manage the future of the industry, as equine sports have 
traditionally been governed by the local authorities in each jurisdiction 12. In 1993 
the International Federation of Horseracing Authorities (IFHA) was formed and 
included over 60 members. They meet annually to update the International 
Agreement on Breeding, Racing and Wagering, first endorsed in 1974, which 
outlines the recommended best practice for all jurisdictions, including protocols 
for how to effectively address the problem of doping in equine sports 13. 
 
Anabolic androgenic steroids 
Steroids are a class of chemical compounds characterised by their tetracyclic fused 
ring system consisting of three cyclohexane rings (Rings A, B and C) and a 
cyclopentane ring (Ring D), conferring chemical stability and conformational 
rigidity to the molecule. Furthermore, the rings can be modified at many possible 
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positions, and also occur as a variety of stereochemistries and degrees of 
unsaturation. As a result, they occur widely in nature as lipids, hormones and other 
natural products 14. The structure of anabolic steroids is typified in the example of 
17α-methyltestosterone (17β-hydroxy-17α-methylandrost-4-en-3-one) below 
(Figure 1). 
 
Figure 1: 17α-methyltestosterone showing steroid ring structure and IUPAC-
recommended atom and ring labelling 
 
Steroid compounds can be categorised into number of subclasses, typically based 
on the number of carbon atoms present in their basic framework. The common 
core structures of most interest to anti-doping laboratories include; cholestanes 
(C27), which are typified by cholesterol, that are the steroid precursors from 
which most others are ultimately derived; cholanes (C24), which primarily consist 
of the steroid bile acids; pregnanes (C21), which consist of the progestogens and 
the corticosteroids; androstanes (C19), which form the basic framework of most 
androgens; and estranes (C18), which form the basic framework of some 
androgens, and the estrogens 14,15. Representative examples of each steroid class 
are shown in Figure 2. 
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Figure 2: Representative examples of the major steroid classes 
 
Anabolic androgenic steroids, which include the parent compound testosterone, 
have legitimate uses in the medical treatment of human and animal diseases; 
however, they are widely-known for their misuse in sporting competition. The 
term anabolic androgenic steroid refers to the two distinct classes of biological 
activities possessed by these compounds: namely the anabolic effects and the 
androgenic effects, both of which are important for their natural functions. 
Anabolic effects promote anabolism and typically manifest as an increase in muscle 
strength and endurance, primarily due to increased protein synthesis, more 
efficient use of dietary nutrients, and increased red blood cell production 16–19. In a 
medical setting, these effects are of interest in the treatment of chronic wasting 
conditions such as the victims of severe burns and cancer patients 16. Androgenic 
effects on the other hand promote virilisation and manifest in the development 
and maintenance of male sex organs and secondary sex characteristics 19–21, and 
these effects typically find use in the treatment of various hormone deficiencies 16.  
 
Based on WADA detection statistics from 2014, anabolic steroids accounted for 
48% of all adverse analytical findings of banned substances in competing athletes 
22. The main agents of misuse were stanozolol, 19-norandrosterone, and 
metandienone, which comprised 46% of all anabolic steroids detected. With the 
wide range of performance-enhancing drugs available to athletes today, it is 
interesting that a significant proportion that chose to dope used steroids, which 
suggests that they offer benefits that other types of compounds do not. Unlike 
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other classes of drugs, such as stimulants, which usually offer benefits only for as 
long as they remain active in the body, the effects of anabolic steroids can be long-
lasting. Whilst the compounds themselves may no longer be present in the body, 
athletes can use these compounds to train; gaining muscle mass which will be 
retained for a period after steroid use is discontinued, allowing athletes to keep the 
majority of the benefits without putting themselves at risk of being caught during 
in-competition screening. 
 
Anabolic steroids in equine sports 
In contrast to the well-documented advantages that anabolic steroids offer to 
human athletes, the effects of anabolic steroids in equine competitors are not well-
established 23. A study has shown that short-term nandrolone administration 
increased the glycogen content of post-exercise muscle tissue 24, however this is in 
contrast with two studies that found no observable changes resulting from 
nandrolone administration 25,26. It has been shown that steroid administration 
delayed closure of epiphyseal growth plates in standardbreds, and suggested that 
this could lead to a potential increase to the long-term risks of injury during 
training 23. Additionally, it has been suggested that testosterone may not be 
involved in muscle development or maintenance in horses, as horses that 
experienced weight loss from maladaptation to training were observed to have 
similar testosterone levels compared to a control group 27. Aggressive behavioural 
changes resulting from anabolic steroid administrations have been noted 23,25 
which could lead to more competitive horses that perform better in training and 
competition, however they may also lead to injury and accidents with other horses, 
riders or trainers. Nonetheless, even if the evidence for anabolic steroids acting as 
performance-enhancing substances in horses is currently unclear, there is clear 
evidence that anabolic steroid misuse can result in serious animal health and 
welfare consequences for competing horses, riders and trainers 23. These concerns, 
as well as the overwhelming evidence of the effects of anabolic steroids in other 
species (including humans) more than warrant their banning in competitive 
equine sports by IFHA. 
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Designer anabolic steroids 
Since the first synthesis of testosterone over 80 years ago, there has been 
substantial work aiming to produce steroid compounds with differing and useful 
biological properties. During the so-called “golden age” of steroid research during 
the 1950-60s, numerous potent analogues of testosterone were synthesised some 
of which were published 28–32 whilst others were patented. The majority of these 
compounds however were only briefly tested for their anabolic activity and were 
never subsequently evaluated through clinical testing or approved for sale. As a 
result, they were forgotten, and then subsequently rediscovered in the past decade 
where they have been exploited by chemists who would seek to use the knowledge 
in the older steroid literature and bring these compounds to market in a 
clandestine fashion. 
 
Figure 3: Structures of the first “designer” steroids: norbolethone, 
tetrahydrogestrinone, and madol 
 
The term “designer steroid” can be defined as any anabolic steroid which has been 
prepared in such a way that it can evade detection by anti-doping laboratories. 
This typically involves chemical modification to the steroid core. The term itself 
was first coined in 2002 where Catlin et al. reported the first instance of a designer 
anabolic steroid compound detected in an athlete’s urine 33. This designer steroid 
was norbolethone (18β-homo-17β-hydroxy-19-nor-17α-pregn-4-en-3-one), a 
synthetic anabolic steroid compound first synthesised in 1966 and subsequently 
found in clinical studies to be a highly potent anabolic agent 33,34, but which had 
never been approved for clinical use. Two years later, the same group detected 
tetrahydrogestrinone (18β-homo-17β-hydroxy-19-nor-17α-pregna-4,9,11-trien-3-
one; THG) another designer steroid, following analysis of a spent syringe 
containing an allegedly undetectable anabolic steroid which was provided 
12 
anonymously to the United States Anti-Doping Agency (USADA) by a former 
sporting coach 35–37. A third designer steroid, madol (17α-methyl-5α-androst-2-en-
17β-ol; desoxymethyltestosterone), was also detected in a crude oily preparation 
received by the same laboratory in 2005 38. A transdermal preparation called “The 
Cream” was also identified, which contained a mixture of testosterone and 
epitestosterone in a controlled ratio. At this time the testosterone-epitestosterone 
ratio (T/E ratio) was an important marker used within WADA laboratories to 
identify samples suspected of doping with testosterone, and application of “The 
Cream” provided an increase in testosterone levels without altering the T/E ratio, 
making it harder to detect 39. These preparations were subsequently found in an 
investigation by the United States Federal Government to have been distributed by 
the Bay Area Laboratory Co-Operative (BALCO) alongside other anabolic steroids 
and performance enhancing substances in a secret program that supplied elite 
athletes with “undetectable drugs” to provide a competitive advantage 39. Although 
BALCO is now defunct, its legacy has changed the way anti-doping laboratories 
must approach the problem of anabolic steroid abuse in the world today. 
 
Despite an increase in awareness and research to combat designer steroid misuse, 
their usage is becoming more widespread, in part due to the ease in which these 
compounds can be obtained. These compounds are typically present in “dietary” or 
“nutritional” supplements which are widely marketed online and often contain 
unusual structures and substitution patterns that may render them more difficult 
to detect by existing analytical methods. These supplements are also often 
discontinued and replaced by new products when they become detectable by anti-
doping laboratories or law enforcement. These structural changes to the core 
steroid structure also help suppliers evade legal restrictions and penalties 
regarding their manufacture and sale in some jurisdictions 40,41. As a result, these 
designer anabolic steroids pose a number of problems. They are often prepared in 
a clandestine fashion and as a result there is often minimal data available detailing 
the purity, safety or efficacy of these products. Users are forced to rely on advice 
from other users reporting their outcomes in online forums, or as is common, to 
experiment on themselves. This environment also encourages underreporting of 
side-effects and health complications, often with serious consequences 42. This is 
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compounded by another major problem in that the labelling detailing the contents 
of these products is often falsified or omitted in an attempt to circumvent their 
control by law-enforcement 40,41. This can hinder the work of health practitioners 
who are required to treat any complications that may arise from supplement usage 
42, and also prevent customs or border authorities from identifying potentially 
dangerous or illicit materials that may be entering their jurisdiction. With their 
widespread use by human athletes, it is highly likely that the problem of designer 
steroid misuse will find its way into the realm of equine sports as well. 
 
Equine steroid metabolism 
An understanding of the metabolism of anabolic steroid compounds is essential to 
develop methods for the detection of these compounds in equine sports. Anti-
doping analysis typically requires the detection of known steroid markers and 
metabolites, as the parent compounds are often rapidly metabolised after 
administration. As such these metabolites form the basis of the majority of anti-
doping screening protocols currently in use today. Such markers have historically 
been identified from urine, due to the relative ease of which samples can be 
obtained from competing animals, as well as the higher concentrations of drugs 
and drug metabolites that may be present. In recent times, blood samples have 
become another valuable biological matrix to detect steroid misuse, although this 
is less common due to the invasive sample collection required. Hair 43–45, faeces 46, 
and saliva 7 can also be used for the detection of drug compounds, although they 
are not currently used routinely.  
 
Steroid metabolism typically proceeds by two complementary pathways, named 
phase I and phase II metabolism. By definition these are two distinct metabolic 
pathways, and although commonly occur in concert, they are known to occur 
independently as well. Phase I metabolic processes typically involve functional 
group manipulations such as hydrolysis, oxidation, reduction, or hydroxylation. 
Metabolism primarily occurs on the steroid A- and D-rings, although if these 
positions are inaccessible (as is often the case in designer steroids) then the B- and 
C-rings can be metabolised 46,47. Of particular interest to the equine metabolism of 
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anabolic steroid compounds is the tendency for C3-ketone reduction, and C16-
hydroxylation to occur, particularly if the C17-position is alkylated 46. Additionally, 
A-ring metabolism is commonly inhibited through extended conjugation as is seen 
in the case of the steroid trenbolone (17β-hydroxyestra-4,9,11-trien-3-one) which 
produces multiple hydroxylated metabolites 46. The phase I metabolism of these 
compounds can also have an effect on their biological activity, as it has been 
reported in androgen bioassay studies that the metabolism of anabolic steroids can 
either activate or deactivate the steroid molecule 41,48. 
 
Phase II metabolism involves the conjugation of highly polar groups to the steroid 
metabolites. The conjugation of small, charged or highly polar compounds to the 
hydrophobic steroid backbone confers an increase in the aqueous solubility of 
these compounds, allowing for their rapid and efficient excretion via the urine. The 
two main phase II steroid conjugation pathways are glucuronylation and sulfation; 
steroid glucuronide metabolites form via enzyme-mediated transfer of glucuronic 
acid from a uridine diphosphate glucuronic acid (UDPGA) donor, while steroid 
sulfate metabolites form via enzyme-mediated transfer of sulfate from a 3'-
phosphoadenosine-5'-phosphosulfate (PAPS) donor 47. Minor conjugates of other 
small molecules are also known including phosphate, sugars, and amino acids 49,50, 
although they are considered minor components in anti-doping analysis and are 
not routinely investigated. Although phase II conjugates are the primary 
components identified from urine, unconjugated metabolites can also be observed. 
Conjugation can also occur in the absence of phase I metabolism if metabolism is 
hindered, or if the compound already possesses suitable functionality 47.  
 
In vitro equine steroid metabolism 
Since anti-doping analysis requires knowledge of the metabolites that indicate 
steroid misuse, the metabolism of each steroid must be studied in order to 
determine which metabolites(s) may be the most suitable markers for detection. In 
vivo administration is a staple method for the study of steroid metabolism, 
however in vitro methods are gaining popularity 46. Additionally, the Association of 
Official Racing Chemists (AORC) criteria currently allow for the use of in vitro-
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derived materials as standards for confirmatory analysis 51, providing additional 
motivation for developing in vitro systems to model equine steroid metabolism. 
The key concern regarding the use of in vitro methods is how accurately they 
reflect the metabolism observed in vivo and for this reason they typically 
accompany administration studies to allow comparison between in vivo and in 
vitro systems.  
 
In order to model the liver, which is the principle organ involved in detoxification 
and metabolism of exogenous substances, preparations involving liver metabolic 
enzymes are amongst the most commonly used in vitro methods 37,52–58. Equine 
liver microsomes and S9 fraction are most commonly used to model equine 
metabolism due to their ease of use and commercial availability. These enzymes 
are typically supplemented with a number of biological co-factors, including 
nicotinamide adenine dinucleotide (NADH), or nicotinamide adenine dinucleotide 
phosphate (NADPH) in order to promote the metabolic reactions. Most systems 
use an excess of these reagents 52,56, although systems have been developed which 
employ co-factor regeneration, in which a NADH/NADPH-generating reaction is 
coupled to the NADH/NADPH-dependant metabolic reactions. Typically, the 
reaction of glucose-6-phosphate (G6P) with a glucose-6-phosphate dehydrogenase 
(G6PDH) enzyme is used, which regenerates NADH/NADPH as a by-product of 
oxidation. This allows for the use of a catalytic amount of these co-factors in the 
metabolism reaction 37,53,54,59. Recent reports have also demonstrated the 
practicality of using homogenised whole liver tissue to perform in vitro studies, in 
an effort to closely replicate in vivo metabolism 59–61. These studies have even 
demonstrated the ability to generate phase II metabolites without the use of 
expensive phase II co-factors such as UDPGA or PAPS 61. The limitations of this 
approach are reflected in the sample preparation of the whole liver extracts, as 
well as potential variations in the metabolic profile due to the their use of 
individual tissue donors. Other approaches to model equine metabolism involve 
microbial systems which are typically based on equine faecal bacteria, and 
although these are currently largely unimportant for modelling equine steroid 
metabolism in an anti-doping context, they may be important in other areas 62–65.  
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Anti-doping screening for designer anabolic steroids 
Historically, steroid metabolites have been detected in analytical samples by thin 
layer chromatography coupled to ultra-violet detection (TLC-UV) 66. This was 
largely superseded by the development of high performance liquid 
chromatography-ultraviolet detection (HPLC-UV) which was popular until the 
1980-1990’s, although still finds use in specialised anti-doping applications 46. 
With the development of gas-chromatography coupled to mass spectrometry (GC-
MS), these instruments became the method of choice in anti-doping laboratories 11. 
In recent years a range of other techniques have become available and occasionally 
find use in anti-doping laboratories alongside existing methods. Biological assays 
11,67–70 can be used to detect doping directly from samples. For example, if a sample 
gave a positive result from an androgen receptor assay, it may indicate that 
anabolic agent(s) are present in the sample which would warrant further testing. 
In most cases, these bioassay techniques can be sufficiently general to allow for 
detection of certain steroid classes or highly specific for certain steroid 
compounds, although they often do not provide an opportunity to confirm the 
identity of any detected compounds 69. Building on this idea, metabolomics 
approaches are also gaining popularity as they allow for the high-throughput 
detection of minor variations of a very large number of biomarkers in response to 
drug administration 71, making it extremely difficult to hide instances of steroid 
misuse. Nuclear magnetic resonance spectroscopy (NMR) occasionally finds use in 
anti-doping laboratories as it can be used to unequivocally determine metabolite 
structure, however is severely limited in most cases as it requires extensive sample 
purification and large sample volumes to be effective 46.  
 
Whilst GC-MS has been the mainstay for analytical laboratories, in recent years 
there has been a movement towards liquid-chromatography coupled to mass 
spectrometry (LC-MS) which offers several advantages over GC-MS analysis 11. GC-
MS requires often laborious sample preparation including purification, hydrolysis 
of the phase II urinary conjugates, and chemical derivatisation to a more volatile 
species prior to analysis. Trimethylsilyl (TMS) ethers or other silyl derivatives are 
among the derivatives most widely used in laboratories due to their stability, ease 
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of preparation, and characteristic fragmentation patterns 72. In contrast, LC-MS 
analysis has the advantage of not requiring these preparatory steps allowing much 
higher throughput in sample analysis. Additionally, LC-MS allows the direct 
detection of intact phase II conjugates, which may offer advantages in the detection 
of some steroid compounds which are primarily excreted as these conjugates and 
may otherwise only be detected indirectly by GC-MS methods after hydrolysis and 
derivatisation 11,54,73. LC-MS is not a complete replacement for GC-MS however, as 
the analysis of some compounds is difficult with LC-MS, including the study of 
saturated steroids and steroid diols, which ionise poorly under the electrospray 
ionisation (ESI) and atmospheric-pressure chemical ionisation (APCI) conditions 
common to LC-MS systems 11,46. Additionally, the characteristic fragmentation 
patterns observed using electron ionisation (EI) common to GC-MS systems may 
often provide more diagnostic information about metabolite structure compared 
to the softer ionisation techniques common to LC-MS 11. 
 
Recent advances in modern instrumentation which allow tandem MS experiments 
(MSn) afford a greater ability to detect and identify metabolites. This is due to the 
ability of these systems to perform a multitude of scan types including: full scan 
MS, multiple reaction monitoring (MRM), product-ion or precursor-ion MS, or 
neutral loss experiments. This is in contrast to older technologies which often rely 
on full-scan and single-ion monitoring (SIM) techniques in order to achieve the 
required sensitivity for detection. Additionally, the recent development of 
affordable liquid-chromatography high resolution accurate mass spectrometry 
(LC-HRAM) technologies has greatly assisted anti-doping laboratories. Data 
obtained with these systems is of very high quality and at sufficient mass 
resolution that minute differences in molecular composition can be detected 74. 
The increase in sensitivity is afforded through the use of a much narrower mass 
window (±10-15 ppm) for mass detection compared to standard triple quadrupole 
detection (±1 Da). As a result, this can allow laboratories to undertake 
retrospective analysis of newly-identified compounds in historically acquired data, 
allowing detection of previously unidentified compounds. 
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The most recent advances in anti-doping research come from new developments 
in “untargeted” or “open” screening methods. Such methods typically attempt to 
screen for characteristic fragments, or fragmentation modes (such as characteristic 
neutral losses) of steroid compounds, rather than the steroid compound itself 75–78. 
This would prevent minor structural changes to a molecule which results in a 
change of the molecular mass from rendering a compound undetectable, and 
highlight the need for follow-up testing to identify the new target compound. 
Another promising advancement is the Equine Biological Passport (EBP) 79, which 
mirrors the Athlete Biological Passport (ABP) maintained by WADA for human 
athletes 80. The EBP would longitudinally monitor the concentration of certain 
biological compounds in the horse, and allow for the detection of changes in these 
levels in response to anabolic steroid misuse. Such an approach would assist 
greatly in establishing relevant threshold levels for endogenous compounds, as 
well as assisting in the detection of designer anabolic steroids. Although there are a 
number of technical and administrative hurdles to overcome before this can be 
fully realised, such as identification of the relevant equine biomarkers and 
harmonisation of the testing protocols and data analysis between racing 
jurisdictions, this approach has the potential to effectively combat the misuse of 
drugs in equine sports. Such methods are likely to be essential to combat the rapid 
increase of designer steroids, and other unknown compounds into the future. 
 
Equine metabolism of designer steroids 
Anabolic steroids are amongst the largest class of substances used to enhance 
performance in competitive equine sports and as a consequence the majority of 
the attention has been directed towards developing methods to detect these 
compounds in equine systems. Such methods typically rely on screening for known 
metabolites and markers of steroid misuse 46 and as such, understanding the 
metabolism of these compounds in equine systems is vital to developing methods 
for the detection of these compounds. The metabolism of all anabolic androgenic 
steroid compounds in horses is far beyond the scope of this review, however a 
substantial summary can be found in several reviews by Scarth et al 81 
(endogenous anabolic steroids in horses and other animals), Teale et al 82 and 
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Houghton et al 83 (phase I and II metabolism studies of some common synthetic 
steroids marketed as pharmaceuticals), and Scarth et al 46 (a comprehensive 
review of drug metabolism in horses). Instead the purpose of this review is to 
explore recent advances in the study of designer anabolic steroids as well as other 
anabolic steroids present in many of the dietary supplements available online, 
which have not been covered in previous reviews. A summary of the metabolism of 
these compounds in equine systems in presented below. The designer steroids 
desoxyvinyltestosterone 84, and estra-4,9-diene-3,17-dione 85 have been studied in 
equine systems as detailed by Scarth et al 46, and are not included in the present 
review. 
Table 1: Summary of the equine metabolism of designer steroids 
Steroid Phase I and Phase II metabolites Comments 
11-Adrenosterone 
(Ref 
52
) 
Predominately C3/C11/C17 
mono/di/trireduced. 
Minor hydroxylated metabolites. 
Phase II metabolism not studied. 
Recommended analyte(s): 
Reduced 11-adrenosterone, 
11β-hydroxyandrosterone 
threshold of greater than 10 
µg/mL, or a 11β-
hydroxyandrosterone:11β-
hydroxyetiocholanolone 
ratio of greater than 20:1 
have been suggested based 
on human studies. 
In vitro metabolism only. 
11-Adrenosterone and its 
metabolites are potentially 
endogenous, may require 
threshold for detection. 
ATD 
(Ref 
52,59
) 
Predominately C17-reduced. 
Minor C16-hydroxylated and 
mono/direduced metabolites. 
C17β-sulfate and C17α-glucuronide 
metabolites. 
Mixture of both sulfate and glucuronide 
minor metabolites. 
Recommended analyte(s): 
17β-hydroxyandrosta-1,4,6-
trien-3-one, and 17β-
hydroxyandrosta-4,6-dien-
3-one. 
Elevated testosterone 
observed in vivo, suggesting 
aromatase inhibition 
Boldenone observed as an in 
vivo metabolite. 
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3α-Chloro-17α-
methyl-5α-androstan-
17β-ol 
(Ref 
37
) 
3α-Chloro-17α-methyl-5α-androstan-
16α,17β-diol identified as the sole equine 
metabolite. 
Phase II metabolism not studied. 
Recommended analyte(s): 
3α-Chloro-17α-methyl-5α-
androstane-16α,17β-diol, 
and 17α-methyl-5α-
androstane-3α,17β-diol. 
 
In vitro metabolism only. 
Potential elimination of C3-
chloride to form madol. 
Halodrol 
(Ref 
52
) 
Turinabol observed as the major 
metabolite. 
Minor C3-oxidised and hydroxylated 
metabolites. 
Phase II metabolism not studied. 
Recommended analyte(s): 
Turinabol (4-chloro-17β-
hydroxy-17α-
methylandrosta-1,4-diene-
3-one). 
 
In vitro metabolism only. 
20-Hydroxyecdysone 
(Ref 
52
) 
No phase I metabolism observed. 
Phase II metabolism not studied. 
Recommended analyte(s): 
20-Hydroxyecdysone. 
 
In vitro metabolism only. 
Phase II metabolism likely 
to predominate in vivo. 
Formestane 
(Ref 
52,53
) 
Predominately C17-reduced, with minor 
C3/C17 direduction. Predominately 
glucuronide conjugated. 
Recommended analyte(s): 
Formestane, and 4,17β-
dihydroxyandrost-4-en-3-
one. 
 
No aromatase inhibition 
observed in vivo. 
Furazadrol 
(Ref 
54
) 
Major in vivo metabolites: furazadrol 
sulfate and furazadrol glucuronide. Minor 
hydroxylated and, oxidised and 
hydroxylated metabolites 
Predominately sulfate conjugated. 
Recommended analyte(s): 
Furazadrol, furazadrol 17-
sulfate, and furazadrol 17-
glucuronide. 
 
Methasterone 
(Ref 
52
) 
Predominately C3-reduced. 
Minor hydroxylated metabolites. 
Phase II metabolism not studied. 
Recommended analyte(s): 
2α,17α-dimethyl-5α-
androstane-3α/β,17β-diol. 
 
In vitro metabolism only. 
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Oxyguno 
(Ref 
55
) 
Predominately C3/C11 mono/direduced. 
Minor C20-hydroxylation and C17-
epimerisation. 
C3 sulfate and glucuronide. C11 
glucuronide only. Proposed C17-epi-
oxyguno sulfate. 
Recommended analyte(s): 
Oxyguno, and 4-chloro-
3,17β-dihydroxy-17α-
methyl-5α-androstan-11-
one. 
 
In vitro metabolism appears 
limited in its ability to 
predict in vivo metabolism. 
Δ1-Testosterone 
(Ref 
86
) 
Range of mono/direduced metabolites. 
Minor hydroxylated and reduced 
metabolites. 
Mixture of sulfate and glucuronide 
conjugates. 
Recommended analyte(s): 
Δ1-Testosterone. 
 
Some metabolites are 
potentially endogenous. 
Tetrahydrogestrinone 
(Ref 
52,56,87
) 
Excreted unmetabolised in vivo. 
Primarily hydroxylated in vitro. 
Hydroxylated glucuronide metabolites 
observed in vitro. 
Recommended analyte(s): 
Tetrahydrogestrinone. 
 
Related steroid 4,9,11-
trienes also studied in vitro 
56
. 
Trestolone 
(Ref 
57
) 
7α-methylestradiol, 7α-methylestrone, and 
two unidentified metabolites. 
Phase II metabolism not studied. 
Recommended analyte(s): 
Trestolone, 
7α-methylestradiol, and 7α-
methylestrone. 
 
In vitro metabolism only. 
Aromatase inhibitor. 
 
11-Adrenosterone (androst-4-ene-3,11,17-trione) 
In humans, 11-adrenosterone is an endogenous steroid 
produced predominately in the adrenal cortex that exerts a 
mild anabolic effect 88. It has been reported as a component 
of dietary supplements such as 11-OXO (ErgoPharm) 88 and 
is marketed as a “selective cortisol modulator” rather than as an anabolic agent. It 
is a known inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1, 
which is required for the formation of cortisol from cortisone 88. Inhibition of 
cortisol biosynthesis may offer athletes a competitive advantage as cortisol itself is 
involved in a range of biological processes including fat and protein metabolism, 
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regulation of the immune system, and responding to stress 88–90. It has been banned 
in competition by both WADA and IFHA 13,91. The endogenous concentrations of 
this compound in the horse is currently unknown, however based on a previously 
reported human in vivo administration 88 it has been suggested that a 11β-
hydroxyandrosterone threshold of greater than 10 µg/mL, or a 11β-
hydroxyandrosterone:11β-hydroxyetiocholanolone ratio of greater than 20:1, or 
the use of GC-IRMS may be indicative of 11-adrenosterone misuse 52. 
 
The equine metabolism of 11-adrenosterone has only been studied by in vitro 
methods 52. Following metabolism with equine liver microsomes and S9 fraction, 
one major reduced metabolite was observed by LC-MS/MS. Minor metabolites 
were also observed including: one minor reduced metabolite, one direduced 
metabolite, one trireduced metabolite, two hydroxylated metabolites, and one 
reduced and hydroxylated metabolite. Metabolites were tentatively assigned 
structures based on analysis of their LC-HRAM product-ion spectra. An additional 
major reduced metabolite was observed by GC-MS/MS. Although the endogenous 
nature of 11-adrenosterone in humans has been established, it is currently unclear 
if this compound is endogenous in horses. An older study has proposed 
11-adrenosterone as a metabolite of cortisol in the synovial fluid of human and 
equine knee joints after cortisol administration 92, however no studies have 
identified it directly. Due to its potential endogenous nature, a threshold approach 
may be required in order to confirm misuse of this compound.  
 
ATD (androsta-1,4,6-triene-3,17-dione) 
ATD is an aromatase inhibitor that has been reported as a 
component of dietary supplements including Attitude (SAN 
Nutrition) 93 and Novedex XT (Gaspari Nutrition) 2,94. 
Aromatase inhibitors irreversibly and covalently bind to the 
active site of the P450 enzyme aromatase, which is essential in the conversion of 
androgens into estrogens in vivo 95,53. Inhibition of this enzyme can be used to limit 
the endogenous conversion of androgens such as testosterone into estrogens, in 
turn increasing the concentration of AAS in the body. Although aromatase 
inhibitors have legitimate therapeutic applications such as in the treatment of 
human breast and ovarian cancers 53,96, they can be exploited to gain muscle mass 
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as they can increase the effects of endogenous or co-administered anabolic 
steroids. They can also potentially alleviate some of the side effects of anabolic 
steroid misuse 53,97. As a result they are banned in competition by both WADA and 
IFHA 13,91. 
 
The equine metabolism of ATD has been studied by in vitro methods 52. Following 
metabolism with equine liver microsomes and S9 fraction, two reduced 
metabolites (tentatively assigned as C17-isomers), and one reduced and 
hydroxylated metabolite (tentatively assigned as C15, or C16-hydroxylated) were 
identified. Minor metabolites including three direduced metabolites, three 
hydroxylated metabolites, five additional reduced and hydroxylated metabolites, 
and three hydroxylated and direduced metabolites were also observed. The 
structures of the major metabolites were tentatively assigned based on their LC-
HRAM product-ion spectra. In addition, one of the direduced metabolites was 
identified as boldenone (17β-hydroxyandrosta-1,4-dien-3-one) by comparison to a 
reference material. The authors recommend analysis by LC-MS over GC-MS due to 
the detection of several C19-nor steroid artefacts that resulted from TMS 
derivatisation prior to GC-MS analysis 52,98, and also due to the higher sensitivity of 
detection by LC-MS. 
 
The metabolism of ATD has also been studied in vivo by a controlled oral 
administration 59. Following phase I metabolism, fourteen metabolites were 
identified by LC-HRAM analysis including: three reduced metabolites (two C17-
reduced and C1-C2 reduced), three direduced metabolites (C1-C2 and C17-
direduced, C1-C2 and C3-direduced, and boldenone), four reduced and 
hydroxylated metabolites, and four direduced and hydroxylated metabolites (two 
C5-C6 and C17 direduced with C16-hydroxylation, and two C1-C2 and C17-
direduced and hydroxylated metabolites). A number of these were matched to 
reference materials. The identities of the phase I metabolites not matched to 
standards were tentatively assigned by analysis of the LC-HRAM product-ion 
spectra. The position of hydroxylation in these metabolites was not assigned 
where standards were not available, although the authors comment on the 
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presence of MS fragments at m/z 149 and 167 being characteristic of D-ring 
hydroxylation which suggests C16-hydroxylation as a major pathway in the 
metabolism of these compounds 46,59. A pair of metabolites resulting from C1-C2 
and C17-direduction and hydroxylation were observed that had not been 
previously detected in human studies 94. Elevated levels of testosterone were also 
observed which were above the threshold levels required for a positive 
testosterone doping result. 
 
Phase II metabolites were observed directly as a mixture of sulfate and 
glucuronide conjugates, and a minority were identified by comparison to the 
products generated from in vitro metabolism with homogenised horse liver 51. 
Phase II metabolites were also identified indirectly by hydrolysis of the 
fractionated glucuronide and sulfate metabolites. Parent ATD was excreted 
primarily unconjugated, whilst one C17-reduced metabolite was identified as the 
sulfate conjugate, and the remaining C17-reduced metabolite as the glucuronide 
conjugate. The authors comment that the C17-glucuronide is likely to be the C17α-
stereochemistry, which agrees with observations reported by many as 
summarised by Scarth et al 46. Sulfate conjugates were also identified for 
boldenone, and for the C1-C2 and C17-direduced metabolite which were 
tentatively assigned C17β-stereochemistry. Glucuronide conjugates were observed 
for the C1-C2 and C3-direduced, and both two C5-C6 and C17 direduced and 
hydroxylated metabolites. The remaining metabolites were observed as mixtures 
of both sulfate and glucuronide conjugates. Some metabolites were identified up to 
77 hr post-administration, and the authors recommend 17β-hydroxyandrosta-
1,4,6-trien-3-one, and 17β-hydroxyandrosta-4,6-dien-3-one as potential target 
analytes for screening due to their long detection windows, and commercial 
availability.  
 
As a part of this study, a comparative phase I in vitro metabolism was performed 
using homogenised equine liver. Twelve of the metabolites observed in vivo were 
identified in vitro in addition to both boldione (androsta-1,4-diene-3,17-dione) and 
epiboldenone (17α-hydroxyandrosta-1,4-dien-3-one) which were identified by 
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comparison to reference materials. Interestingly, elevated levels of testosterone 
were not observed in vitro suggesting that testosterone is not a direct metabolite of 
ATD but rather a result of aromatase inhibition. These results, along with the in 
vivo study agree well with the previously discussed in vitro study by Clarke et al 52. 
 
3α-Chloro-17α-methyl-5α-androstan-17β-ol 
3α-Chloro-17α-methyl-5α-androstan-17β-ol is an anabolic 
steroid containing C3-chlorination, which was identified 
alongside the 3β-chloro isomer (5:2 mixture) in red-and-
black capsules containing white powder seized in 2012 by 
law-enforcement in Queensland, Australia 37. This compound had not been 
previously reported in the literature, and it appears to be the first instance of a C3-
halogenated anabolic steroid intended for doping purposes. It is currently banned 
in competition by both WADA and IFHA, due to structural similarity to known 
anabolic steroid compounds 13,91. 
 
Owing to concerns about its chemical reactivity and potential toxicity, this 
compound was only studied using in vitro systems 37. Yeast, HEK293 and HuH7 
androgen receptor bioassays have found the potency of the major 3α-chloro 
isomer to be similar to testosterone (87-147% potency), whilst the 3β-isomer gave 
much lower potency (2-9%). Acute cellular toxicity was not observed in yeast and 
HEK293 cell lines. In vitro metabolism studies on the 3α-isomer using human and 
equine liver S9 fraction identified differences in metabolism which may be useful 
for doping control. Equine in vitro metabolism afforded 3α-chloro-17α-methyl-5α-
androstane-16α,17β-diol as the sole observed metabolite, the structure of which 
was matched against synthetic reference material. The relative abundance isotope 
pattern of 35Cl and 37Cl (3:1) confirmed retention of C3-chlorination in the equine 
metabolite. The stereochemistry of the C16-hydroxylation was supported by 1H 
NMR, and the failure to form a C16-C17 cis-acetonide derivative, with the C16α-
C17α-isomer used as a control to demonstrate the efficiency of the transformation. 
Human in vitro metabolism afforded 17α-methyl-5α-androstane-3α,17β-diol, 
lacking C3-chlorination, which was not observed in the equine system. This 
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metabolite was confirmed by comparison to both the 3α-hydroxy and 3β-hydroxy 
reference materials, and is a known metabolite of a number of other methylated 
anabolic steroid compounds such as methyltestosterone and mestanolone (17β-
hydroxy-17α-methylandrostan-3-one) 46. As such this metabolite is likely 
detectable by existing methods. The authors recommend laboratories monitor for 
the 3α-chloro-17α-methyl-5α-androstane-16α,17β-diol, and 17α-methyl-5α-
androstane-3α,17β-diol metabolites in routine screening to detect the misuse of 
this compound. 
 
Halodrol (4-chloro-17α-methylandrosta-1,4-diene-3,17β-diol) 
Halodrol is a 4-chloroinated steroid structurally similar to 
clostebol and turinabol 46,52 which has been found a 
variety of dietary supplements such as Halodrol (Gaspari 
Nutrition), Zeus (BioArmor) and Iron Dragon (BioArmor). 
These supplements typically list only the 3β-hydroxy 
isomer on their labelling but typically contain a mixture of both stereoisomers. 
Halodrol alongside its analogues clostebol and turinabol, are banned in 
competition by both WADA and IFHA 13,91. 
 
This equine compound has only been studied using in vitro systems 52. A mixture of 
halodrol isomers (3:2, α:β) was subjected to phase I metabolism using both equine 
liver microsomes and S9 fraction. Metabolism identified the C3-oxidised 
metabolite (turinabol, 4-chloro-17β-hydroxy-17α-methylandrosta-1,4-diene-3-
one) and three oxidised and hydroxylated metabolites as major metabolites. Minor 
metabolites were observed including, two A-ring reduced and C3-oxidised 
metabolites, one hydroxylated metabolite, one A-ring reduced and hydroxylated 
metabolite, two additional oxidised and hydroxylated metabolites, one 
dihydroxylated metabolite, one reduced and dihydroxylated metabolite, one 
direduced and dihydroxylated metabolite, and two oxidised and dihydroxylated 
metabolites. Metabolites were tentatively assigned based on their LC-HRAM, or GC-
MS/MS product-ion spectra. The parent compounds (3α/β,17-diols), and the major 
oxidised and hydroxylated metabolites were reported to ionise poorly under APCI 
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conditions which are commonly used for LC-MS analysis, however ionised well 
under GC-MS (+EI) conditions after TMS derivatisation. There were minor 
differences reported between the two metabolism systems used, with equine liver 
S9 appearing to give more of the major metabolites, which the author suggested 
may highlight the importance of cytosolic enzymes in the metabolism of these 
compounds. The predominate product was the C3-oxidised metabolite, which 
corresponds to the synthetic anabolic steroid turinabol, which has been previously 
studied in vivo in the horse 46,99. A number of the key metabolites of halodrol 
reported in this study match those reported for the metabolism of turinabol. As 
such, the authors recommend that monitoring for turinabol misuse would likely be 
suitable for the detection of halodrol misuse. 
 
20-Hydroxyecdysone 
(2β,3β,14α,20β,22α,25-hexahydroxy-5β-cholest-7-en-6-one) 
20-Hydroxyecdysone is an ecdysteroid 
hormone which is present naturally in 
numerous invertebrate and plant species. It is 
essential for moulting and reproduction in 
many arthropod species, and is also present as 
an insecticide in some plant species where it 
disrupts the development of insect pests that would feed upon them 100. Reports in 
the older steroid literature have suggested that ecdysteroids may exert a small 
anabolic effect in several mammal species 100, although more recent studies offer 
conflicting reports of their anabolic effects 101,102. Nonetheless, 20-
hydroxyecdysone has been found in dietary supplements such as Oxybolin 250 
(High-Tech Pharmaceuticals) and Ecdy-Bolin (Truly Huge Supplements). These 
supplements are often marketed as “natural”, “plant-based”, or “low-testosterone” 
alternatives to other anabolic steroid-containing body-building supplements. 
Whilst it is unclear whether supplements containing 20-hydroxyecdysone would 
offer a competitive advantage, they are currently banned in competition by both 
WADA and IFHA due to their structural similarity to known anabolic steroid 
compounds 13,91. 
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The equine metabolism of 20-hydroxyecdysone has only been studied by in vitro 
methods 52. Only the parent compound was observed after incubation with equine 
liver microsomes and S9 fraction. GC-MS/MS analysis afforded a complex mixture 
of partial derivatisation products and no characteristic fragmentation information, 
likely due to the multiple potential sites for silylation. It is known that complete 
silylation of related ecdysteroid compounds is slow, due to the hindered tertiary 
hydroxyl groups C14 and C20, with optimal silylation occurring only after 
extended reaction times 103. Related ecdysteroid compounds are known to be 
rapidly excreted with only minor metabolic changes in humans 100,103 which could 
explain the lack of phase I metabolism observed in this study. The authors also 
suggest that phase I metabolism was expected to be a minor pathway compared to 
the phase II metabolism that would predominate in vivo and was not investigated 
as a part of this study. They also raise concerns over potential accidental dietary 
consumption through animal feed, as ecdysteroid compounds are known to be 
present in many plant species 100, potentially requiring a threshold approach for 
detection. The authors also observed minor levels of desoxy-, dehydro-, and 
hydroxy-metabolite impurities in their control in vitro incubations, suggesting the 
presence of these minor components in the commercial 20-hydroxyecdysone 
preparation. This could call into question other studies which identify these as 
metabolites 103,104. The authors recommend monitoring for the unconjugated 
parent compound, or its likely phase II conjugates for the detection of 20-
hydroxyecdysone misuse. 
 
Formestane (4-hydroxyandrost-4-ene-3,17-dione) 
Formestane is a pharmaceutical aromatase inhibitor which 
irreversibly and covalently binds to the active site of the 
P450 enzyme aromatase 53. After an adverse analytical 
finding in 2011, the endogenous nature of formestane in 
horses was investigated after concerns were raised that it 
could potentially be a metabolite of androst-4-ene-3,17-dione, an intermediate in 
testosterone biosynthesis 53,81. Additionally, it is a potential metabolite of 4,17β-
dihydroxyandrost-4-en-3-one, an anabolic steroid banned in competition by 
WADA and IFHA 13,91. Analysis of the data obtained during routine screening for 
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269 equine urine samples showed that formestane was not present endogenously. 
Following this, an in vivo controlled oral administration study of formestane was 
undertaken 53. 
 
After phase I metabolism, the parent compound as well as seven metabolites were 
identified as follows: one reduced metabolite (4,17β-dihydroxyandrost-4-en-3-
one) which was matched to a reference material, two direduced metabolites 
(proposed as androst-4-ene-3α,4,17β-triol, and androst-4-ene-3β,4,17β-triol) 
which were matched to the products derived from partial reduction of formestane 
with sodium borohydride, and an additional four direduced metabolites (four of 
the possible 3,4-dihydroxy-5-androstan-17-one metabolites) which were 
tentatively identified by comparison to literature data 97,105. Elevated levels of 
testosterone or other androgens not considered to be metabolites of formestane 
were not identified in this study. The structures of the phase II metabolites were 
determined through hydrolysis of the fractionated glucuronide and sulfate 
metabolites to their corresponding phase I metabolites. Formestane, 4,17β-
dihydroxyandrost-4-en-3-one, and three of the 3,4-dihydroxy-5-androstan-17-one 
metabolites were excreted primarily as glucuronide conjugates, whilst androst-4-
ene-3α,4,17β-triol, androst-4-ene-3β,4,17β-triol, and the remaining 3,4-dihydroxy-
5-androstan-17-one metabolite were excreted as a mixture of glucuronide and 
sulfate metabolites. In addition to identifying the key metabolites, the excretion 
profiles of formestane and 4,17β-dihydroxyandrost-4-en-3-one were studied. Peak 
excretions of 40-44 µg/mL and 7-11 µg/mL respectively were observed at 5.6-6.3 
hr post-administration, falling to below the limits of detection at 29 hr and 34 hr 
post-administration respectively. In addition, formestane was observed in plasma 
peaking at 6-10 hr post-administration, and falling below the limits of detection 34 
hr post-administration. No other formestane metabolites were observed in equine 
plasma. As a part of this study, a comparative in vitro study was also undertaken. 
Phase I metabolism using equine liver microsomes prepared from whole liver 
tissue afforded the parent compound and seven metabolites, identified as follows: 
4,17β-dihydroxyandrost-4-en-3-one, five direduced metabolites (androst-4-ene-
3α,4,17β-triol, androst-4-ene-3β,4,17β-triol, and three of the possible 3,4-
dihydroxy-5-androstan-17-one metabolites), and one trireduced metabolite. The 
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majority of the metabolites observed in vitro matched those observed in vivo after 
hydrolysis of the phase II conjugates.  
 
A separate in vitro study has also been performed by Clarke et al 52, who identified 
a similar metabolite profile. LC-HRAM and GC-MS/MS analysis observed several 
hydroxylated metabolites, in addition to metabolites similar to those reported 
above. Metabolites were not identified by comparison to reference materials in this 
study, but instead were tentatively assigned by analysis of their MS data. Based on 
observations from both studies, the authors recommend monitoring for the parent 
compound, and 4,17β-dihydroxyandrost-4-en-3-one, to detect formestane misuse. 
 
Furazadrol ([1',2’]isoxazolo[4’,5’:2,3]-5α-androstan-17β-ol) 
Furazadrol is a derivative of dihydrotestosterone 
containing an isoxazole ring fused to the steroid A-ring. It 
has been reported as a component of dietary 
supplements such as Orastan-A (Gaspari Nutrition) 40 and 
Furazadrol (Axis Labs) 41 predominately as the tetrahydropyranyl ether. In both 
cases, these supplements had incorrect labelling of the content information 40,41. 
Furazadrol has been reported to exert anabolic activity in the older literature 29,106, 
and also in more recent yeast and human HuH7 androgen bioassays 41. Related 
isoxazole-containing anabolic steroids, including the structurally similar Danazol 
are banned in competition by both WADA and IFHA 13,91. 
 
Following an equine in vivo controlled oral administration 54, furazadrol was 
excreted primarily as the sulfate and glucuronide conjugates without phase I 
metabolism, which were detectable up to 24 hr post-administration by LC-HRAM 
analysis. Additional minor metabolites were also observed including a 
hydroxylated sulfate metabolite, two oxidised and hydroxylated sulfate 
metabolites, epifurazadrol glucuronide, and an oxidised and hydroxylated 
glucuronide metabolite. No unconjugated furazadrol metabolites were observed. 
The identity of furazadrol 17-sulfate, furazadrol 17-glucuronide, and epifurazadrol 
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17-glucuronide was confirmed by comparison to synthetic reference materials 
107,108, and the identity of the other metabolites was tentatively assigned through 
analysis of the LC-HRAM product-ion spectra. The sites of hydroxylation for minor 
metabolites were not identified in this study. Further structural confirmation was 
performed through enzymatic hydrolysis of the fractionated sulfate and 
glucuronide metabolites, with analysis of the corresponding phase I metabolites as 
above. Hydrolysis of the sulfate fraction was achieved through use of Pseudomonas 
aeruginosa arylsulfatase, which is a purified enzyme with sulfatase activity and no 
alternative activities as are commonly found in commercial sulfatase preparations 
109. This enzyme was observed to completely hydrolyse all the in vivo steroid 
sulfate metabolites identified in this study. The major urinary metabolites 
(furazadrol 17-sulfate and furazadrol 17-glucuronide) were quantified in equine 
urine, to determine the detection window and limits of detection for these 
analytes. The authors recommend monitoring for these analytes or their 
hydrolysed phase I counterpart furazadrol for the detection of furazadrol misuse.  
 
As a part of this study, a comparative in vitro phase I metabolism study was also 
undertaken using equine liver S9 fraction. A number of the metabolites identified 
were reported to match those observed from the in vivo profile obtained after 
hydrolysis of the urinary sulfate and glucuronide conjugates. The major phase I 
markers were observed in this study, although the authors comment that the in 
vitro study was limited in its ability to fully replicate metabolism in vivo. Phase I 
metabolism identified a number of metabolites including epifurazadrol, oxidised 
furazadrol, eight hydroxylated metabolites, an oxidised and hydroxylated 
metabolite, and two dihydroxylated metabolites, which were confirmed by 
comparison to synthetic reference materials where available, or tentatively 
assigned through analysis of the LC-HRAM product-ion spectra. 
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Methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one) 
Methasterone is a dimethylated analogue of 
dihydrotestosterone, and the C17-methylated analogue of 
drostanolone. It has been reported in the older steroid 
literature to exert a strong anabolic effect in rats 110,111, and 
predicted to be a potent anabolic agent in a more recent computational study 112. It 
has been reported as a component of the dietary supplements Superdrol (Anabolic 
Xtreme) 42, S-drol (Black China Labs) 113, and Methasterone (Legal Gear) 2. 
Methylated steroids such as these typically have the advantage of being orally 
bioavailable at the cost of higher toxicity to the liver and kidneys 46. As a 
dimethylated steroid, methasterone has additional risks and has been reported to 
be involved in a number of serious health complications including cases of severe 
jaundice, and immunoglobulin A nephropathy 42,114,115. As a consequence, it is 
banned in competition by both WADA and IFHA 13,91. 
 
The equine metabolism of methasterone has only been studied using in vitro 
methods 52. Following metabolism with equine liver microsomes and S9 fraction, 
two C3-reduced metabolites were the predominate metabolites identified. 
Additionally, two minor hydroxylated metabolites and six minor reduced and 
hydroxylated metabolites were also observed. Metabolites were tentatively 
assigned based on their GC-MS/MS product-ion spectra as LC-MS/MS analysis 
afforded poor sensitivity for the target analytes. The authors consider the use of 
GC-MS/MS essential for the detection of the two reduced metabolites (2α,17α-
dimethyl-5α-androstane-3α/β,17β-diol) which may indicate methasterone misuse. 
 
Oxyguno (4-chloro-17β-hydroxy-17α-methylandrost-4-ene-3,11-dione) 
Oxyguno is an analogue of clostebol and 11-adrenosterone, 
and contains C17-methylation typical of orally bioavailable 
anabolic steroids 46. It has been reported as a constituent of 
the dietary supplement Oxyguno (Spectra Force Research) 
41,55,74 and has been reported in the older steroid literature 
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to exert significant anabolic activity 116, as well as more recently in yeast, human 
HEK293, and human HuH7 androgen bioassays 41. Related 4-chloroandrost-4-ene 
compounds including clostebol and turinabol are banned in competition by both 
WADA and IFHA 13,91. 
 
Following an equine in vivo controlled oral administration 55, oxyguno has been 
reported to be excreted as a range of unconjugated, sulfate-conjugated and 
glucuronide-conjugated metabolites which were detectable up to 12 hr post-
administration. After phase I metabolism, the parent compound as well five novel 
metabolites were identified as follows: two C11-reduced metabolites, a C3 and C4-
direduced metabolite, a C20-hydroxylated metabolite with C3, C4 or C11-
direduction, and C17-epi-oxyguno. The identities of these metabolites were 
tentatively assigned by analysis of their GC-MS/MS product ion spectra. The two 
C11-reduced metabolites and the hydroxylated and direduced metabolite were 
observed as glucuronide conjugates, whilst the C3 and C4-direduced metabolite 
was observed as both glucuronide and sulfate conjugates. The C17-epi-oxyguno 
metabolite was observed to arise from the sulfate conjugate. Epimerisation at the 
tertiary centre is a known metabolic pathway in C17-methylated steroids, and 
occurs via hydrolysis of a tertiary sulfate metabolite 117–119. The tentative identities 
of these metabolites were established by LC-HRAM analysis of the intact 
conjugates, with further structural confirmation afforded by GC-MS/MS analysis of 
the enol-TMS ether derivatives obtained from the hydrolysis of the fractionated 
glucuronide and sulfate metabolites. The excretion of free oxyguno was also 
quantified to establish an elimination profile of the drug and determine a suitable 
detection window. Excretion peaked at 1-3 h and 2 h in blood and urine 
respectively, and fell below the limit of detection (LOD) at 7 h and 12 h 
respectively. The authors recommend monitoring for the parent compound, or the 
direduced metabolite 4-chloro-3,17β-dihydroxy-17α-methyl-5α-androstan-11-one 
for the detection of oxyguno misuse. 
 
As a part of this study, a comparative in vitro study was also undertaken. Phase I 
metabolism using equine liver microsomes prepared from whole liver tissue 
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afforded four primary metabolites including two C11-reduced metabolites, a C20-
hydroxylated metabolite, and a C20-hydroxylated metabolite with C11-reducion. 
The tentative identities of these metabolites were established by analysis of the 
GC-MS product-ion spectra of the enol-TMS ether derivatives of the in vitro 
metabolites. The major C11-reduced metabolites were reported to be identical to 
the C11-reduced metabolites observed after hydrolysis of the in vivo samples. The 
metabolic profile generated by in vitro techniques did not agree well with the in 
vivo profile. Only two of the five in vivo metabolites were identified, and the 
recommended screening marker 4-chloro-3,17β-dihydroxy-17α-methyl-5α-
androstan-11-one was not observed, suggesting this in vitro method may be 
limited in its ability to predict in vivo results.  
 
Δ1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one) 
Δ1-Testosterone is a synthetic anabolic steroid which 
closely resembles the structure of testosterone, 
substituting the C4-C5 double bond for a C1-C2 double 
bond. It can also be viewed as a 5α-reduced form of 
boldenone, another anabolic steroid which is well-known for its abuse in sports 46. 
It has been reported to be a component of dietary supplements such as 1-
androsterone (Advanced Muscle Science) and 1-AD (ErgoPharm) which typically 
contain Δ1-testosterone in addition to one or more of the following compounds: 
5α-androst-1-ene-3,17-dione, 5α-androst-1-ene-3,17-diol, or 3β-hydroxy-5α-
androst-1-en-17-one, all of which are metabolised to Δ1-testosterone in vivo 120,121. 
Δ1-Testosterone as well as the steroids listed above are all banned in competition 
by both WADA and IFHA 13,91. 
 
Following an equine in vivo controlled oral administration 86, Δ1-testosterone has 
been reported to be excreted as a range of unconjugated, sulfate-conjugated and 
glucuronide-conjugated metabolites which were detectable up to 72 hr post-
administration. After phase I metabolism, the parent compound as well as eight 
metabolites were identified as follows: four reduced metabolites (5α-androst-1-
ene-3α,17β-diol, 5α-androst-1-ene-3β,17α-diol, 5α-androst-1-ene-3β,17β-diol, and 
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epiandrosterone (3β-hydroxy-5α-androstan-17-one)), three doubly reduced 
metabolites (5α-androstane-3β,17β-diol, 5α-androstane-3α,17α-diol, and 5α-
androstane-3β,17α-diol), and one hydroxylated metabolite. The parent compound, 
5α-androst-1-ene-3α,17β-diol, and the hydroxylated metabolite were found to be 
excreted primarily as sulfate conjugates, whilst 5α-androst-1-ene-3β,17α-diol and 
5α-androst-1-ene-3β,17β-diol were excreted primarily as glucuronide conjugates. 
The remaining metabolites were observed as a mixture of both sulfate and 
glucuronide conjugates. The identities of the phase I metabolites were confirmed 
by comparison to synthetic reference materials where available, and the NIST 
spectral database, or tentatively assigned through a combination of their MS 
behaviour and relative elution order. Hydroxylation at C16 is a common pathway 
for steroid metabolism 46, and the authors rationalise the observed hydroxylated 
metabolite on this basis. The metabolites of Δ1-androgens are also known to have 
similar mass spectra, which may complicate analysis 122. The identity of the phase 
II metabolites was further confirmed through the hydrolysis of the fractionated 
glucuronide and sulfate metabolites to their corresponding phase I metabolites 
and their identities assigned as stated above. A number of the observed 
metabolites were identified up to 72 hr post-administration, however the authors 
comment that these are also potential in vivo metabolites for endogenous steroid 
compounds such as testosterone 81. The metabolites containing the C1-C2 double 
bond are characteristic of administration of Δ1-testosterone, but were observed 
only 2-6 hr post-administration. The authors recommend monitoring for the 
parent compound, which can be detected at low levels (5-9 ng/mL) up to 30 hr 
post-administration. Additionally, longer term detection may be possible by 
adopting thresholds for the endogenous metabolites, or using longitudinal 
monitoring of the steroid profile. 
 
As a part of this study, a comparative in vitro study was also undertaken. Phase I 
metabolism using equine liver microsomes prepared from whole liver tissue 
afforded six metabolites: three reduced metabolites (5a-androst-1-ene-3α,17β-
diol, 5a-androstane-3β,17β-diol, and epiandrosterone), two hydroxylated 
metabolites, and one oxidised metabolite (5α-androst-1-ene-3,17-dione). The 
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majority of the observed in vitro metabolites appear to correlate with the phase I 
metabolites observed after hydrolysis of the phase II metabolites observed in vivo.  
 
Tetrahydrogestrinone 
(18β-homo-17β-hydroxy-19-nor-17α-pregna-4,9,11-trien-3-one) 
Tetrahydrogestrinone (THG) was the second “designer” 
steroid ever reported and was identified during the 
analysis of a spent syringe containing an allegedly 
undetectable anabolic steroid which was provided 
anonymously to USADA in 2004 35–37. It can be produced chemically via a one-step 
reduction of gestrinone, which is a legally available progestin, and was originally 
produced with the express intention of bypassing current screening protocols 35. 
Since its initial discovery, it has been reported in several studies to exert strong 
activity in yeast 36,70,123,124 and mammalian AR CALUX 68 androgen bioassays. After 
its discovery, it was specifically banned in competition by WADA rather than 
relying on the phrasing “…and other substances with a similar chemical structure or 
biological effect(s).” 91 as it represented a whole new class of threat to anti-doping 
analysis. It is also banned by IFHA 13.  
 
Following an equine in vivo controlled oral administration 87, THG has been 
reported to be excreted unmetabolised. An excretion profile was established for 
both plasma and urinary excretion. In plasma, concentrations peaked between 1-2 
hr post-administration and were below the limit of detection at 24 hr post-
administration. In urine, concentrations peaked at 3-6 hr post-administration and 
were below the limit of detection 48 hr post-administration.  
 
In a separate in vitro study using equine liver microsomes and S9 fraction 52, it has 
been reported that metabolism of THG favours formation of hydroxylated 
metabolites. In this study, two major hydroxylated metabolites were observed, 
alongside one oxidised and hydroxylated metabolite. Additional minor metabolites 
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were observed including a reduced metabolite, a reduced and hydroxylated 
metabolite, a dihydroxylated and direduced metabolite, a dihydroxylated and 
oxidised metabolite, two dihydroxylated and reduced metabolites, and two 
dihydroxylated and direduced metabolites. The sites of hydroxylation, oxidation, 
and reduction were not identified in this study. There appears to be little 
difference in the metabolites observed from incubation with equine liver 
microsomes or S9 fraction. The minor metabolites have relative ion abundances up 
to three orders of magnitude less than the primary metabolites. GC-MS analysis 
was complicated by the presence of numerous artefactual products resulting from 
enol-TMS ether derivatisation. Alternate derivatisation conditions for the 
formation of the enol-TMS derivatives, or the use of alternate derivatives such as 
TMS ether or methyloxime-TMS ether (MOX-TMS) may alleviate some of the 
problems associated with derivatising conjugated enone systems 72. Alternatively, 
the authors recommend LC-MS as being most suitable for the detection of THG and 
many of its metabolites. 
 
In another in vitro metabolism study using equine liver microsomes and S9 
fraction 56, the phase I metabolism and phase II glucuronylation of THG was 
reported. Following phase II metabolism, two hydroxylated metabolites were 
observed, alongside THG glucuronide, and two hydroxylated glucuronide 
metabolites. Metabolites were identified by analysis of the LC-MS/MS spectra. 
Glucuronylation of the tertiary alcohol was observed only at low levels, 
presumably reflecting the sterically hindered nature of this position. The positions 
of hydroxylation or glucuronylation were not identified in this study. Additionally, 
the in vitro metabolism of several related steroid 4,9,11-trienes were reported in 
this study. The metabolism of gestrinone (18β-homo-17β-hydroxy-19-nor-17α-
pregna-4,9,11-trien-20-yn-3-one), trenbolone (17β-hydroxyestra-4,9,11-trien-3-
one), and altrenogest (17β-hydroxy-17α-(prop-2-enyl)estra-4,9,11-trien-3-one, 
allyltrenbolone) was reported but have been covered in previous reviews and are 
subject to routine screening in equine anti-doping laboratories 46,58,125,126. The 
equine metabolism of dihydrogestrinone (18β-homo-17β-hydroxy-19-nor-17α-
pregna-4,9,11,20-tetraen-3-one) has not been previously reported and following in 
vitro metabolism, a reduced and hydroxylated metabolite was observed alongside 
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dihydrogestrinone glucuronide. Although reduction could occur at a number of 
positions, it presumably occurs at the terminal alkene to afford hydroxylated THG, 
as the extended conjugation in the A-C rings typically resists metabolism 46. This 
compound is likely to be encountered as an impurity in preparations containing 
THG resulting from the incomplete the hydrogenation of gestrinone 35. The equine 
metabolism of propyltrenbolone (17β-hydroxy-17α-propylestra-4,9,11-trien-3-
one) has also not been previously reported and following in vitro metabolism, 
three hydroxylated metabolites were observed alongside propyltrenbolone 
glucuronide, and three hydroxylated glucuronide metabolites.  
 
Trestolone (17β-hydroxy-7α-methylestr-4-en-3-one) 
Trestolone is a C7-methylated analogue of nandrolone, 
which itself is a C19-norsteroid analogue of testosterone. 
Owing to the lack of the C19-methyl substituent, this 
compound is more resistant to metabolism by aromatase 
enzymes 127, increasing its potential half-life in the body. Dietary supplements 
labelled to contain trestolone such as TR3ST (Olympus Labs) and 7-MENT Alpha 
(Wyked Labs) have become available in recent years. It has been shown in 
bioassays with HeLa cells transfected with the human androgen receptor 128, 
human AR CALUX bioassays 129,130 and in vivo rat models 130–132 to be a potent 
androgen, as well as exhibit strong binding to the human progesterone receptor 128. 
Trestolone has also been recently explored for use as a human male contraceptive 
as it has been shown to inhibit spermatogenesis without inducing androgen 
deficiency 131,133. It has also been shown to inhibit equine and human steroid 
aromatase enzymes 57. This compound is banned in competition by both WADA 
and IFHA 13,91. 
 
The equine metabolism of trestolone has only been studied by in vitro methods 57. 
Following incubation of tritium labelled trestolone with equine placental 
microsomes, four metabolites were detected. Two of the detected metabolites 
were determined to be estrogenic as they were extracted in a phenolic extraction 
assay. Additionally, they matched TLC retention factors and GC-MS fragmentation 
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with reference standards for 7α-methylestradiol, and 7α-methylestrone. The 
identities of the two remaining metabolites were not determined, although they 
were hypothesised to be intermediate compounds in androgen aromatisation, such 
as 1-hydroxytrestolone. These metabolites were not identified in control 
experiments utilising 4-hydroxyandrostenedione, a known aromatase enzyme 
inhibitor 57. Additional kinetic experiments also showed that trestolone 
competitively inhibited the aromatisation of androstenedione and testosterone, 
suggesting that it may also function as an aromatase inhibitor. As a part of this 
study, incubations were also performed using a purified equine testicular P450 
aromatase enzyme. After metabolism, these experiments also showed the presence 
of 7α-methylestradiol, as well as the two intermediates identified above, which 
were matched to the previous experiment. The authors recommend monitoring for 
the parent compound, alongside 7α-methylestradiol, and 7α-methylestrone for the 
detection of trestolone misuse. Additionally, alteration of the endogenous steroid 
profile due to aromatase inhibition could likely be detected through a threshold 
approach, or longitudinal monitoring of the equine steroid profile. 
 
Future Directions 
As laboratories respond to new threats, the directions of equine anti-doping 
research will shift, and will vary into the future. The importance of alternate 
testing matrices is gaining attention, with many jurisdictions incorporating these 
samples into routine testing. Hair has been reported to be a potentially long-term 
marker of steroid misuse 44,46 and these samples are easily acquired and processed 
in the laboratory. Blood is also becoming a more common sample matrix, and it has 
been suggested that the levels of drug compounds in the bloodstream may indicate 
the potential for pharmacological effects in vivo 46. Additionally, since the 
administered drugs can often be directly detected unmetabolised in blood 134 or 
hair 44, the need to conduct equine metabolism studies is reduced. Urine is still 
likely to remain a valuable analytical matrix as it is routinely used in the majority 
of currently available methods, and many of the important analytical thresholds 
for endogenous substances have only been determined in urine. 
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The rapid increase in the prevalence of designer anabolic steroids, present in 
“dietary” and “nutritional” supplements available online containing untested and 
unapproved anabolic agents, is likely to pose a significant threat to the integrity of 
the industry if left unchecked. Due to ethical concerns over the potential 
detrimental effects to the health and welfare of animal subjects, in vitro techniques 
are rapidly gaining attention as tools to study the metabolism of these compounds. 
These techniques, as highlighted by multiple examples throughout this review, are 
rapidly improving, and can more faithfully generate a metabolic profile 
representative of in vivo systems which will greatly assist anti-doping analysis 53–
55,59,86. Currently, AORC criteria allow for the use of in vitro-derived materials as 
standards for confirmatory analysis 51, and improvements to in vitro techniques 
may allow for the direct detection and confirmation of in vivo phase II metabolites 
by LC-MS/MS methods 46. 
 
Recent improvements in untargeted and open screening methods show that these 
methods are also gaining popularity. These methods screen for characteristic 
fragments, or fragmentation modes of metabolite families rather than targeting 
individual drug metabolites, and they have been demonstrated to be suitable for 
the detection of unknown compounds in analytical samples 75–78. The recent 
advancements made in affordable LC-HRAM and MSn technologies also have 
greatly assisted the translation of these methods into routine screening as they 
allow for the acquisition of high-quality data which may be retrospectively 
analysed once new compounds are identified or new methods are developed. The 
development of more powerful computational packages provided by 
manufacturers also has the potential to make metabolomics approaches practical 
enough to be undertaken routinely in laboratories.  
 
The final promising advancement is the development of the Equine Biological 
Passport 79, which mirrors the Athlete Biological Passport maintained by WADA for 
human athletes 80. This approach would build a baseline profile from the routine 
sample analysis of all samples from an individual competing horse. Any future 
instances of doping would then be detected by abnormal changes between the 
41 
baseline and a subsequent sample. Although there are a number of technical and 
administrative hurdles to overcome before this can be realised, this approach has 
the potential to effectively combat the misuse of anabolic steroids, and other 
doping agents in equine sports now and into the future. 
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In the period between when this thesis was submitted (September 2016) and the 
corrections to this thesis were made (May 2017), this review was accepted for 
publication in the journal Drug Testing and Analysis. The full citation for this work 
is as follows: 
 
Waller, C. C.; McLeod, M. D, Drug Testing and Analysis 2016, A review of designer 
anabolic steroids in equine sports, DOI: 10.1002/dta.2112 
 
A copy of the full text article has been reproduced in Appendix A, with permission 
of John Wiley and Sons via Rightslink (License Number: 3994540395974). 
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1.3 Project Aims 
In light of the problems designer steroids are presenting to anti-doping analysis in 
equine sports, this project will be focused on the development of new strategies to 
detect designer steroids in thoroughbred horse racing. Designer steroid 
compounds will be selected amongst those perceived as having a significant 
potential for abuse due to novel structural motifs, or due to their significant 
availability to athletes and trainers. 
 
Specifically, this project aims to undertake: 
 
1) Synthesis of designer steroid reference materials and their phase I and 
phase II metabolites, such as hydroxylated derivatives of the parent 
compound, and their corresponding glucuronide and sulfate conjugates. 
General method development towards these classes of compounds will also 
be developed throughout this project. 
 
2) In vivo equine metabolism studies of selected high priority designer steroid 
targets in thoroughbred horses, subject to ethics approval. 
 
3) Comparative in vitro steroid metabolism studies of designer steroids in 
equine systems with an aim to develop tools to replicate in vivo results. 
 
4) Identification of the key equine metabolites of designer steroid compounds 
and determining their structures by comparison to synthesised reference 
materials, or tentative assignment through thorough analysis of their mass 
spectrometry behaviour. 
 
5) Development of suitable GC-MS, LC-MS, or other assays for the rapid 
analysis of designer steroids in race-day samples. 
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CHAPTER TWO 
 
 
Steroid sulfates 
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Publication: 
Waller, C. C., McLeod, M. D. Steroids 2014, 92, 74-80,  
DOI: 10.1016/j.steroids.2014.09.006 
 
2.1 Foreword 
The following manuscript has been published in the journal “Steroids” and details 
simple protocols for the rapid synthesis and purification of steroid sulfates that are 
suitable for adoption by analytical laboratories. Permission has been granted by 
Elsevier via RightsLink for the reproduction of this publication within this thesis 
(License Number: 3887450060394). This publication and supporting information 
(112 pages containing experimental procedures, characterisation data and copies 
of NMR and MS spectra) was authored by Mr Christopher Waller and Associate 
Professor Malcolm McLeod. All experimental work was undertaken by C. Waller, 
alongside preparation of the initial draft of the manuscript and supporting 
information. Assoc. Prof. McLeod initially conceived of the project, and assisted in 
revising the manuscript prior to submission. A small portion of this work involving 
the chemical synthesis of steroid sulfates with SO3.NEt3, or SO3.py with purification 
by recrystallisation (manuscript section 2.3.3), as well as some characterisation 
data for these compounds has been previously reported by C. Waller in an honours 
thesis entitled “Enzyme preparations for the efficient hydrolysis of steroid sulfates” 
(ANU, 2012). 
 
Scheme 2.1: Small-scale sulfation of a steroid with purification by solid-phase 
extraction (SPE) 
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Steroid sulfates are an important class of phase II steroid metabolites that are of 
growing importance to anti-doping laboratories. This is driven in part by 
improvements in LC-MS technologies that allow for the direct detection of phase II 
conjugates. In anti-doping laboratories, the analysis of phase II steroid sulfate 
metabolites can afford greater retrospectivity for the detection of anabolic steroid 
misuse, and can be used to distinguish between steroids of endogenous and 
exogenous origin. Although there are a range of reliable methods to analyse for 
phase II conjugates in both humans and animals, the range of steroid sulfate 
reference materials is incomplete, meaning that significant steroid sulfate markers 
cannot be identified or confirmed in analytical samples.  
 
In this chapter, tools have been developed which allow synthetic access to a wide 
range of steroid sulfate metabolites for use in anti-doping laboratories. A simple 
method for the preparation of steroid sulfates has been developed which utilises 
SPE, a technique routinely used in anti-doping laboratories, in the key purification 
step. This methodology has been applied to a library of sixteen steroid compounds 
which encompass a representative range of steroid substitution patterns and 
configurations. The scope of this approach was highlighted through the sulfation of 
1 µg testosterone in high yield as determined by LC-MS. This method is suitable for 
use in analytical laboratories and should serve to expand the availability of steroid 
sulfate reference materials for a range of analytical applications.  
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2.2 A simple method for the small scale 
synthesis and solid-phase extraction 
purification of steroid sulfates 
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Due to copyright restrictions from the publisher, the journal article presented in 
section 2.2 has been removed from the online version of this thesis. The full text 
article can be obtained via the ANU Library, or directly from the publisher using 
the link below: 
 
http://www.sciencedirect.com/science/article/pii/S0039128X14002499 
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In response to feedback received from the examiners of this thesis, the following 
comments have been made. 
 
The use of steroid sulfate standards, as described in Chapter 2.1, are suitable for 
use as reference materials for a range of analytical applications. However, to serve 
as reference standards for quantitative analysis purposes in anti-doping 
laboratories around the world, these materials often require certification so the 
absolute concentrations of these materials can be obtained. 
 
The use of quantitative NMR (qNMR) allows for the determination of impurities 
present in organic compounds, which would be required to certify these 
compounds for use in quantitative applications in anti-doping laboratories. 
Although the purity of the compounds prepared in Chapter 2.1 was determined to 
be >98% by analysis of the obtained NMR data, no strictly quantitative analysis 
was undertaken. The absence of peaks which could not be attributed to the steroid 
sulfate molecule was determined to be sufficient evidence of purity of these 
compounds. The presence of impurities not observable through NMR, such as 
inorganic salts, can be determined through alternate analytical methods, such as 
elemental composition analysis. Future work to quantify these standards through 
the use of a suitable qNMR standard would be highly recommended, and is 
currently being undertaken in the McLeod group (May 2017). 
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In addition to the published work presented in Chapter 2.2, the following section 
presents related unpublished work which is the subject of a manuscript currently 
in preparation. Supporting information relevant to this chapter is presented 
electronically alongside this thesis. 
 
2.3 Steroid bis-sulfates 
2.3.1 Introduction 
According to 2014 anti-doping statistics published by WADA 1, the detection of the 
misuse of endogenous anabolic steroids (EAAS) is one of the major challenges to 
anti-doping laboratories. Whilst the detection of high levels of EAAS may be 
indicative of doping, in other cases it may simply be a result of the metabolite 
profile of the individual athlete. As such, there is a need for methods which allow 
anti-doping laboratories to take this inter-individual variation into account and 
still be able to detect instances of misuse. Traditionally threshold levels have been 
used for the detection of EAAS misuse, however these often have to be set at high 
levels to account for athletes with naturally high levels of EAAS. It has been 
recognised however that EAAS levels in the athlete remain relatively stable over 
time but change significantly in response to steroid administration. Therefore, the 
use of exogenously administered EAAS can be detected by looking for the levels 
and differences in the ratio of various compounds in the body of the athlete over 
time 2–4. These ratios form the basis of the Athlete’s Biological Passport (ABP) 
Steroidal Module maintained by WADA, which currently monitors seven 
parameters: the biological concentrations of testosterone, epitestosterone, 
androsterone, etiocholanolone, 5α-androstane-3α,17β-diol, and 5β-androstane-
3α,17β-diol, and the testosterone/epitestosterone ratio, together with the specific 
gravity of the athlete’s urine sample 5. Whilst these seven markers are quite 
comprehensive, it has also been shown that monitoring for additional EAAS may 
improve the sensitivity of screening methods in some cases 6. 
 
Even with these thresholds and ratios in place, some instances of EAAS misuse may 
still go undetected. It has been shown that some endogenous compounds such as 
3α,6β-dihydroxy-5α-androstan-17-one 3-glucuronide, and 3α,6β-dihydroxy-5β-
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androstan-17-one 3-glucuronide are resistant to the enzymatic β-glucuronidase 
hydrolysis routinely used in anti-doping laboratories and therefore cannot be 
subsequently identified by GC-MS analysis 7. Additionally, EAAS sulfate metabolites 
are currently undetectable by many routine methods as these are also resistant to 
β-glucuronidase hydrolysis, and alternative methods such as acid hydrolysis are 
typically not used as they can cause a range of complications, such as increased 
interference from the biological matrix, or degradation of the desired analytes, 
which can result in lowered sensitivity 8,9. Although sulfate metabolites represent a 
significant proportion of steroid metabolism in some individuals 8, early studies of 
their usefulness to anti-doping laboratories has so far been shown to be limited 10. 
Nonetheless, with the growth of LC-MS analysis in anti-doping laboratories, the 
direct detection of phase II conjugates is becoming more important and 
commonplace. Monitoring for intact endogenous steroid glucuronide and sulfate 
metabolites may improve the sensitivity of screening methods or provide 
additional criteria to confirm instances of EAAS misuse 10. In particular, steroid bis-
conjugates may benefit greatly from this technology as they are difficult to study 
by existing GC-MS methods. The role of steroid bis-conjugates in vivo has been 
explored, and steroid bis-glucuronides 11,12, bis-sulfates 13,14, and bis-sulfate 
glucuronides 15,16 have been found to be involved in a variety of biological 
processes. Their importance to anti-doping laboratories however remains unclear 
as to date there has not been any study of the role of steroid bis-conjugates in 
sports doping.  
 
Scheme 2.2: Potential long-term bis-sulfate metabolites of 
17α-methyltestosterone 
 
 
A previous study of the in vivo human metabolism of the exogenous anabolic 
steroid 17α-methyltestosterone identified 17β-methyl-5α-androstane-3α,17α-diol 
3-sulfate as a long-term marker of abuse, with 2-3 times the retrospectivity of 
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previously observed markers (Scheme 2.2) 17. Although not observed in this study, 
this finding implicated the existence of 17α-methyl-5α-androstane-3α,17β-diol 
3,17-bis-sulfate as a metabolite of 17α-methyltestosterone. Tertiary steroid 
sulfates are known to hydrolyse with inversion of configuration 18–20, which 
suggested the presence of steroid bis-sulfates as a potential source of the observed 
long-term metabolite. In light of these observations, this work aimed to explore the 
applicability of steroid bis-sulfates to anti-doping analysis through the synthesis, 
and mass spectrometry analysis of a representative library of steroid bis-sulfate 
compounds. 
 
2.3.2 Experimental 
2.3.2.1 Materials 
Chemicals and solvents including sulfur trioxide pyridine complex (SO3.py), 
estradiol (estra-1,3,5(10)-triene-3,17β-diol) and 1,4-dioxane (dioxane) were 
purchased from Sigma–Aldrich (Castle Hill, Australia) and were used as supplied 
unless otherwise stated. Androsterone (3α-hydroxy-5α-androstan-17-one), 
epiandrosterone (3β-hydroxy-5α-androstan-17-one), etiocholanolone (3α-
hydroxy-5β-androstan-17-one), 11β-hydroxyepiandrosterone (3β,11β-dihydroxy-
5α-androstan-17-one), 11β-hydroxyandrosterone (3α,11β-dihydroxy-5α-
androstan-17-one), 11β-hydroxyetiocholanolone (3α,11β-dihydroxy-5β-
androstan-17-one), androst-5-ene-3β,17β-diol, 16α-hydroxyandrosterone 
(3α,16α-dihydroxy-5α-androstan-17-one) and 16α-hydroxytestosterone 
(16α,17β-dihydroxyandrost-4-en-3-one) were purchased from Steraloids 
(Newport RI, USA). 3α-Hydroxytibolone (7α-methyl-19-nor-17α-pregn-5(10)-en-
20-yne-3α,17β-diol) and 3β-hydroxytibolone (7α-methyl-19-nor-17α-pregn-
5(10)-en-20-yne-3β,17β-diol) were purchased from Toronto Research Chemicals 
(Toronto, Canada). MilliQ water was used in all aqueous solutions. N,N-
Dimethylformamide (DMF) and aqueous ammonia solution were purchased from 
Chem-Supply (Gillman, Australia). Formic acid was purchased from Ajax Chemicals 
(Auburn, Australia). Solid-phase extraction (SPE) was performed using Waters 
(Rydalmere, Australia) Oasis weak anion exchange (WAX) 6cc cartridges (PN 
186004647). 
65 
2.3.2.2 Instruments 
Melting points were determined using a SRS Optimelt MPA 100 melting point 
apparatus and are uncorrected. 1H and 13C nuclear magnetic resonance (NMR) 
spectra were recorded using either Bruker Avance 400 MHz or Bruker Ascend 800 
MHz spectrometers at 298 K using deuterated methanol solvent. Data is reported 
in parts per million (ppm), referenced to residual protons or 13C in deuterated 
methanol solvent (CD3OD: 1H 3.31 ppm, 13C 49.00 ppm) unless otherwise specified, 
with multiplicity assigned as follows: br = broad, s = singlet, d = doublet, dd = 
doublet of doublets, ddd = doublet of doublet of doublets, t = triplet, q = quartet, 
m = multiplet. Coupling constants J are reported in Hertz. Low-resolution mass 
spectrometry (LRMS) and high-resolution mass spectrometry (HRMS) were 
performed using positive electron ionisation (+EI) on a Micromass VG Autospec 
mass spectrometer or negative electrospray ionization (–ESI) on a Micromass ZMD 
ESI-Quad, or a Waters LCT Premier XE mass spectrometer. Reactions were 
monitored by analytical thin layer chromatography (TLC) using Merck Silica gel 60 
TLC plates (7:2:1 ethyl acetate: methanol: water, unless otherwise specified) and 
were visualised by staining with a solution of potassium permanganate [KMnO4 (3 
g), K2CO3 (20 g), NaOH (0.25 g), in H2O (305 mL)] or concentrated sulfuric acid in 
methanol (5% v/v), with heating as required.  
 
2.3.2.3 Synthetic methods 
2.3.2.3.1 General method for the small scale steroid sulfation reaction with 
purification by SPE 
Sulfation was performed according to literature methods 9. A solution of SO3.py 
(10.0 mg, 62.8 mmol) in DMF (100 µL) was added to a solution of steroid (1.0 mg) 
in dioxane (100 µL) and the resulting solution was then stirred in a capped vial at 
room temperature for 4 h. The reaction was then quenched with water (1.5 mL) 
and subjected to purification by SPE. An Oasis WAX SPE cartridge (6 cc) was pre-
conditioned with methanol (5 mL) followed by water (15 mL). The reaction 
mixture (1.7 mL) was then loaded onto the cartridge and eluted under a positive 
pressure of nitrogen at a flow rate of approximately 2 mL/min with the following 
solutions: formic acid in water (2% v/v, 15 mL), water (15 mL), methanol (15 mL) 
and saturated aqueous ammonia solution in methanol (5% v/v, 15 mL). The 
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methanolic ammonia fraction was concentrated in vacuo to yield the desired 
steroid bis-sulfate as the corresponding ammonium salt.  
 
2.3.2.3.2 General method for the small scale steroid sulfation reaction with 
conversion determined by 1H NMR analysis 
A steroid sulfation reaction was performed as per 2.3.2.3.1 above 9. A modified 
WAX SPE protocol eluting with only formic acid in water (2% v/v, 15 mL), water 
(15 mL) and saturated aqueous ammonia solution in methanol (5% v/v, 15 mL), 
followed by concentration of the methanolic ammonia fraction yielded a mixture 
containing both the starting steroid and the corresponding steroid sulfates as the 
ammonium salts. A 400 MHz 1H NMR spectrum was obtained and integration of a 
suitable signal (typically C3-H, and C17-H) of both steroid and steroid sulfate 
provided a ratio of the two compounds which was used to determine the percent 
conversion of the sulfation reaction. The mixture was then subjected to a second 
SPE purification as per 2.3.2.3.1 above to yield the desired steroid bis-sulfate in 
pure form as the corresponding ammonium salt. 
 
2.3.2.3.3 General method for the small scale steroid reduction reaction with 
purification by SPE 
A solution of steroid (5.0 mg) in methanol (100 µL) was added to a vial containing 
sodium borohydride (5 mg, 132 µmol). After the vigorous reaction subsided, the 
reaction was stirred for 4 h. The reaction was then quenched with aqueous 
hydrochloric acid solution (0.1 M, 1.5 mL) and subjected to purification by WAX 
SPE. A modified SPE protocol eluting with formic acid in water (2% v/v, 15 mL), 
water (15 mL) and methanol (5% v/v, 15 mL), followed by concentration of the 
methanol fraction afforded the desired steroid diol in pure form. 
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2.3.2.4 Chemical synthesis of steroid bis-sulfates 
2.3.2.4.1 Androst-5-ene-3β,17β-diol 3,17-bis-sulfate, ammonium salt (1)  
A solution of androst-5-ene-3β,17β-diol (5 mg, 17.2 
µmol) in dioxane (500 µL) was treated with a 
solution of sulfur trioxide-pyridine complex (50 mg, 
314 µmol, 18.2 eq) in DMF (500 µL) and purified by 
SPE as per 2.3.2.3.1 to yield the title compound 1 as a 
white solid. Performing the sulfation reaction as per 2.3.2.3.2 showed >98% 
conversion. Rf 0.23; δH (400 MHz): 5.40 (br s, 1H, C6-H), 4.23 (t, J 8.4 Hz, 1H, C17-
H), 4.13 (m, 1H, C3-H), 2.56-0.91 (m, 19H), 1.05 (s, 3H, C18-H3), 0.82 (s, 3H, C19-
H3); c (100 MHz): 141.7 (C5), 123.0 (C6), 88.2 (C17), 79.8 (C3), 52.1, 51.7, 43.7, 
40.4, 38.4, 37.8, 37.7, 33.1, 32.6, 30.0, 29.2, 24.4, 21.7, 19.8 (C19), 12.0 (C18); 
LRMS (-ESI): m/z 449 (5%, [C19H29O8S2]-), 351 (30%), 224 (15%, [C19H28O8S2]2-), 
110 (15%), 97 (100%, [HSO4]-); HRMS (-ESI): found 449.1297, [C19H29O8S2]- 
requires 449.1304. 
 
2.3.2.4.2 5α-androstane-3β,17β-diol (2) 21  
A solution of epiandrosterone (5 mg, 17.2 µmol) in 
methanol (100 µL) was treated with sodium borohydride 
(5 mg, 132 µmol, 7.7 eq) and purified by SPE as per 
2.3.2.3.3 to yield the title compound 2 as a white solid. Rf 
0.59 (71% EtOAc/hexanes); mp 155-160 oC (lit 21 161-163 oC); δH (400 MHz): 3.55 
(t, 8.6 Hz, 1H, C17-H), 3.51 (m, 1H, C3-H), 2.01-0.62 (m, 22H), 0.85 (s, 3H, C18-H3), 
0.73 (s, 3H, C19-H3); c (100 MHz): 82.5 (C17), 71.8 (C3), 56.1, 52.4, 46.3, 44.1, 
38.9, 38.3, 38.1, 37.0, 32.9, 32.2, 30.7, 29.9, 24.3, 22.0, 12.8 (C18), 11.7 (C19), one 
carbon overlapping or obscured; LRMS (+EI): m/z 293 (20%), 292 (100%, 
[C19H32O2]+
●), 277 (40%), 233 (85%), 217 (70%), 215 (90%), 166 (50%), 165 
(70%), 149 (55%), 123 (40%), 121 (50%), 107 (90%), 95 (60%), 93 (70%), 81 
(70%), 79 (60%), 67 (70%), 55 (80%); HRMS (+EI): found 292.2401, [C19H32O2]+
● 
requires 292.2402. 
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2.3.2.4.3 5α-androstane-3β,17β-diol 3,17-bis-sulfate, ammonium salt (3) 
A solution of 5α-androstane-3β,17β-diol 2 (derived 
from epiandrosterone, 5 mg, 17.2 µmol) in dioxane 
(500 µL) was treated with a solution of sulfur 
trioxide-pyridine complex (50 mg, 314 µmol, 18.2 eq) 
in DMF (500 µL) and purified by SPE as per 2.3.2.3.1 
to yield the title compound 3 as a white solid. Performing the sulfation reaction as 
per 2.3.2.3.2 showed >98% conversion. Rf 0.23; δH (400 MHz): 4.25 (m, 1H, C3-H), 
4.21 (t, J 8.6 Hz, 1H, C17-H), 2.20-0.69 (m, 22H), 0.86 (s, 3H, C18-H3), 0.80 (s, 3H, 
C19-H3); c (100 MHz): 88.2 (C17), 79.7 (C3), 55.8, 51.8, 46.3, 44.0, 38.2, 38.0, 36.7, 
36.6, 36.4, 32.8, 29.8, 29.2, 24.4, 21.8, 12.7 (C19), 12.2 (C18), one carbon 
overlapping or obscured; LRMS (-ESI): m/z 451 (5%, [C19H31O8S2]-), 353 (20%), 
225 (45%, [C19H30O8S2]2-), 97 (100%, [HSO4]-); HRMS (-ESI): found 451.1460, 
[C19H31O8S2]- requires 451.1460. 
 
2.3.2.4.4 5α-androstane-3α,17β-diol (4) 22,23  
A solution of androsterone (5 mg, 17.2 µmol) in methanol 
(100 µL) was treated with sodium borohydride (5 mg, 
132 µmol, 7.7 eq) and purified by SPE as per 2.3.2.3.3 to 
yield the title compound 4 as a white solid. Rf 0.59 (71% 
EtOAc/hexanes); mp 217-220 oC (lit 22 223-224 oC); δH (400 MHz): 3.96 (br s, 1H, 
C3-H), 3.56 (t, J 8.6 Hz, 1H, C17-H), 2.01-0.63 (m, 22H), 0.83 (s, 3H, C18-H3), 0.73 
(s, 3H, C19-H3); c (100 MHz): 82.6 (C17), 67.2 (C3), 56.1, 52.5, 44.1, 40.4, 38.1, 
37.2, 37.0, 36.8, 33.5, 32.9, 30.7, 29.7, 29.6, 24.3, 21.5, 11.7 (2 C, C18 and C19); 
LRMS (+EI): m/z 293 (10%), 292 (25%, [C19H32O2]+
●), 277 (10%), 233 (15%), 217 
(15%), 215 (20%), 166 (10%), 165 (15%), 148 (10%), 145 (20%), 121 (10%), 119 
(15%), 118 (35%), 103 (80%), 91 (25%), 90 (50%), 77 (30%), 76 (100%), 67 
(15%), 59 (40%); HRMS (+EI): found 292.2404, [C19H32O2]+
● requires 292.2402. 
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2.3.2.4.5 5α-androstane-3α,17β-diol 3,17-bis-sulfate, ammonium salt (5) 
A solution of 5α-androstane-3α,17β-diol 4 (derived 
from androsterone, 5 mg, 17.2 µmol) in dioxane (500 
µL) was treated with a solution of sulfur trioxide-
pyridine complex (50 mg, 314 µmol, 18.2 eq) in DMF 
(500 µL) and purified by SPE as per 2.3.2.3.1 to yield 
the title compound 5 as a white solid. Performing the sulfation reaction as per 
2.3.2.3.2 showed >98% conversion. Rf 0.26; δH (400 MHz): 4.59 (br s, 1H, C3-H), 
4.21 (t, J 8.5 Hz, 1H, C17-H), 2.20-0.73 (m, 22H), 0.84 (s, 3H, C18-H3), 0.80 (s, 3H, 
C19-H3); c (100 MHz): 88.3 (C17), 76.4 (C3), 55.9, 51.9, 44.0, 40.8, 38.1, 36.8 (2 C), 
34.7, 33.9, 32.8, 29.5, 29.2, 27.9, 24.4, 21.4, 12.2 (C19), 11.9 (C18); LRMS (-ESI): 
m/z 451 (10%, [C19H31O8S2]-), 353 (40%), 225 (40%, [C19H30O8S2]2-), 110 (60%), 
97 (100%, [HSO4]-); HRMS (-ESI): found 451.1460, [C19H31O8S2]- requires 
451.1460. 
 
2.3.2.4.6 5β-androstan-3α,17β-diol (6) 24  
A solution of etiocholanolone (5 mg, 17.2 µmol) in 
methanol (100 µL) was treated with sodium borohydride 
(5 mg, 132 µmol, 7.7 eq) and purified by SPE as per 
2.3.2.3.3 to yield the title compound 6 as a white solid. Rf 
0.59 (71% EtOAc/hexanes); mp 155-159 oC (lit 24 162-164 oC); δH (400 MHz): 3.58 
(t, J 8.6 Hz, 1H, C17-H), 3.54 (m, 1H, C3-H), 2.03-0.99 (m, 22H), 0.96 (s, 3H, C18-H3), 
0.72 (s, 3H, C19-H3); c (100 MHz): 83.2 (C17), 72.5 (C3), 54.1, 47.2, 45.9, 45.5, 
43.3, 37.2, 36.3, 36.1, 33.1, 31.7, 30.4, 28.0, 27.5, 27.2 (C19), 24.4, 13.9 (C18), one 
carbon overlapping or obscured; LRMS (+EI): m/z 292 (10%, [C19H32O2]+
●), 274 
(80%), 256 (50%), 241 (30%), 230 (40%), 217 (45%), 215 (100%), 161 (30%), 
147 (40%), 133 (30%), 121 (40%), 119 (40%), 107 (70%), 95 (60%), 93 (75%), 
91 (50%), 81 (70%), 79 (60%), 69 (30%), 67 (70%), 57 (30%), 55 (90%); HRMS 
(+ESI): found 315.2300, [C19H32O2Na]+ requires 315.2300. 
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2.3.2.4.7 5β-androstane-3α,17β-diol 3,17-bis-sulfate, ammonium salt (7) 
A solution of 5β-androstane-3α,17β-diol 6 (derived 
from etiocholanolone, 5 mg, 17.2 µmol) in dioxane 
(500 µL) was treated with a solution of sulfur 
trioxide-pyridine complex (50 mg, 314 µmol, 18.2 eq) 
in DMF (500 µL) and purified by SPE as per 2.3.2.3.1 
to yield the title compound 7 as a white solid. Performing the sulfation reaction as 
per 2.3.2.3.2 showed >98% conversion. Rf 0.23; δH (400 MHz): 4.28 (m, 1H, C3-H), 
4.25 (t, J 8.5 Hz, 1H, C17-H), 2.22-1.00 (m, 22H), 0.96 (s, 3H, C18-H3), 0.79 (s, 3H, 
C19-H3); c (100 MHz): 88.2 (C17), 80.4 (C3), 51.8, 44.1, 43.7, 42.0, 38.1, 37.1, 36.5, 
35.7, 34.6, 29.3, 28.9, 28.2, 27.1 (C19), 24.4, 23.8, 21.4, 12.1 (C18); LRMS (-ESI): 
m/z 451 (5%, [C19H31O8S2]-), 353 (25%), 225 (55%, [C19H30O8S2]2-), 97 (100%, 
[HSO4]-); HRMS (-ESI): found 451.1463, [C19H31O8S2]- requires 451.1460. 
 
2.3.2.4.8 11β-hydroxyepiandrosterone 3,11-bis-sulfate, ammonium salt (8) 
A solution of 11β-hydroxyepiandrosterone (5.0 mg, 16.3 
µmol) in dioxane (500 µL) was treated with a solution of 
sulfur trioxide-pyridine complex (50 mg, 314 µmol, 19.3 
eq) in DMF (500 µL) and purified by SPE as per 2.3.2.3.1 
to yield the title compound 8 as a white solid. Performing 
the sulfation reaction as per 2.3.2.3.2 showed >98% conversion. Rf 0.23; 
δH (400 MHz): 4.93 (br s, 1H, C11-H), 4.25 (m, 1H, C3-H), 2.47 (dd, J 8.4 Hz, 19.2 Hz, 
1H, C16-H), 2.11-0.71 (m, 19H), 1.12 (s, 3H, C18-H3), 1.10 (s, 3H, C19-H3); c (100 
MHz): 222.4 (C17), 79.7 (C3), 79.5 (C11), 59.5, 54.1, 47.3, 37.3, 36.9, 36.7, 36.2, 
35.9, 32.4, 29.5, 29.0, 22.5, 15.9 (C18), 14.9 (C19), two carbons overlapping or 
obscured; LRMS (-ESI): m/z 465 (10%, [C19H29O9S2]-), 383 (30%), 367 (25%), 232 
(40%, [C19H28O9S2]2-), 97 (100%, [HSO4]-); HRMS (-ESI): found 465.1259, 
[C19H29O9S2]- requires 465.1253. 
  
71 
2.3.2.4.9 11β-hydroxyandrosterone 3,11-bis-sulfate, ammonium salt (9) 
A solution of 11β-hydroxyandrosterone (5.0 mg, 16.3 
µmol) in dioxane (500 µL) was treated with a solution of 
sulfur trioxide-pyridine complex (50 mg, 314 µmol, 19.3 
eq) in DMF (500 µL) and purified by SPE as per 2.3.2.3.1 
to yield the title compound 9 as a white solid Performing the sulfation reaction as 
per 2.3.2.3.2 showed >98% conversion. Rf 0.23; δH (400 MHz): 4.97 (br s, 1H, C11-
H), 4.59 (br s, 1H, C3-H), 2.46 (dd, J 8.5, 17.8 Hz, 1H, C16-H), 2.05-0.81 (m, 19H), 
1.13 (s, 3H, C18-H3), 1.09 (s, 3H, C19-H3); c (100 MHz): 222.4 (C17), 76.4 (C3), 
76.2 (C11), 59.7, 54.3, 41.7, 37.0, 36.9, 36.2, 34.1, 32.7, 32.5, 32.3, 28.6, 27.7, 22.5, 
16.0 (C18), 14.0 (C19), one carbon overlapping or obscured; LRMS (-ESI): m/z 465 
(5%, [C19H29O9S2]-), 367 (30%), 232 (15%, [C19H28O9S2]2-), 110 (30%), 97 (100%, 
[HSO4]-); HRMS (-ESI): found 465.1273, [C19H29O9S2]- requires 465.1253. 
 
2.3.2.4.10 11β-hydroxyetiocholanolone 3,11-bis-sulfate, ammonium salt (10) 
A solution of 11β-hydroxyetiocholanolone (5.0 mg, 16.3 
µmol) in dioxane (500 µL) was treated with a solution of 
sulfur trioxide-pyridine complex (50 mg, 314 µmol, 19.3 
eq) in DMF (500 µL) and purified by SPE as per 2.3.2.3.1 
to yield the title compound 10 as a white solid Performing the sulfation reaction as 
per 2.3.2.3.2 showed >98% conversion. Rf 0.23; δH (400 MHz): 4.31 (m, 1H, C3-H), 
2.47 (dd, J 8.7, 18.5 Hz, 1H, C16-H), 2.10-1.05 (m, 19H), 1.22 (s, 3H, C18-H3), 1.12 
(s, 3H, C19-H3), C11-H proton obscured by solvent; c (100 MHz): 222.4 (C17), 80.4 
(C3), 76.2 (C11), 55.1, 54.0, 46.4, 45.7, 37.0, 36.2, 35.8, 35.7, 34.4, 32.7, 29.1, 27.0, 
26.6, 22.6, 15.9, one carbon overlapping or obscured; LRMS (-ESI): m/z 465 (1%, 
[C19H29O9S2]-), 367 (15%), 232 (30%, [C19H28O9S2]2-), 110 (30%), 97 (100%, 
[HSO4]-); HRMS (-ESI): found 465.1252, [C19H29O9S2]- requires 465.1253. 
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2.3.2.4.11 16α-hydroxyandrosterone 3,16-bis-sulfate, ammonium salt (11) 
A solution of 16α-hydroxyandrosterone (5.0 mg, 
16.3 µmol) in dioxane (500 µL) was treated with 
a solution of sulfur trioxide-pyridine complex (50 
mg, 314 µmol, 19.3 eq) in DMF (500 µL) and 
purified by SPE as per 2.3.2.3.1 to yield the title compound 11 as a white solid 
Performing the sulfation reaction as per 2.3.2.3.2 showed >98% conversion. Rf 
0.30; δH (400 MHz): 4.94 (d, J 8.0 Hz, 1H, C16-H), 4.60 (br s, 1H, C3-H), 2.25 (dd, J 
8.0, 16.0 Hz, 1H, C15-H), 2.00-1.07 (m, 19H), 0.96 (s, 3H, C18-H3), 0.86 (s, 3H, C19-
H3); c (100 MHz): 216.3 (C17), 77.7 (C16), 76.3 (C3), 55.7, 50.1, 40.8, 36.9, 36.3, 
34.6, 33.8, 32.8, 31.8, 30.7, 29.2, 27.8, 20.8, 14.6 (C18), 11.8 (C19), one carbon 
overlapping or obscured; LRMS (-ESI): m/z 465 (2%, [C19H29O9S2]-), 427 (20%), 
383 (10%), 369 (20%), 232 (100%, [C19H28O9S2]2-), 110 (10%), 97 (20%, [HSO4]-), 
80 (30%); HRMS (-ESI): found 465.1258, [C19H29O9S2]- requires 465.1253. 
 
2.3.2.4.12 16α-hydroxytestosterone 16,17-bis-sulfate, ammonium salt (12) 
A solution of 16α-hydroxytestosterone (5.0 mg, 
16.4 µmol) in dioxane (500 µL) was treated with a 
solution of sulfur trioxide-pyridine complex (50 
mg, 314 µmol, 19.1 eq) in DMF (500 µL) and 
purified by SPE as per 2.3.2.3.1 to yield the title compound 12 as a white solid 
Performing the sulfation reaction as per 2.3.2.3.2 showed >98% conversion. Rf 
0.31; δH (400 MHz): 5.72 (s, 1H, C4-H), 4.79 (t, J 6.0 Hz, 1H, C16-H), 4.32 (d, J 5.8 Hz, 
1H, C16-H), 2.53-0.99 (m, 17H), 1.00 (s, 3H, C18-H3), 0.92 (s, 3H, C19-H3); c (100 
MHz): 202.4 (C3), 175.1 (C5), 124.2 (C4), 93.2 (C17), 84.5 (C16), 55.1, 43.7, 40.0, 
37.8, 36.7, 36.3, 34.7, 33.8, 32.7, 32.1, 21.3, 17.7 (C19), 12.9 (C18), one carbon 
overlapping or obscured; LRMS (-ESI): m/z 463 (5%, [C19H27O9S2]-), 383 (10%), 
365 (10%), 231 (100%, [C19H26O9S2]2-), 97 (20%, [HSO4]-); HRMS (-ESI): found 
463.1100, [C19H27O9S2]- requires 463.1097. 
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2.3.2.4.13 17β-estradiol 3,17-bis-sulfate, ammonium salt (13) 25 
A solution of 17β-estradiol (5.0 mg, 18.4 µmol) in 
dioxane (500 µL) was treated with a solution of 
sulfur trioxide-pyridine complex (50 mg, 314 µmol, 
17.1 eq) in DMF (500 µL) and purified by SPE as per 
2.3.2.3.1 to yield the title compound 13 as a white 
solid Performing the sulfation reaction as per 2.3.2.3.2 showed >98% conversion. 
Rf 0.23, δH (400 MHz): 7.23 (d, J 8.4 Hz, 1H, C1-H), 7.08–6.98 (m, 2H, C2-H and C4-
H), 4.31 (t, J 8.0 Hz, 1H, C17-H), 2.89–2.83 (m, 2H, C6-H2), 2.40–1.15 (m, 13H), 0.78 
(s, 3H, C18-H3); δc (100 MHz): 151.8, 138.8, 137.6, 127.0, 122.5, 119.8, 88.8 (C17), 
51.7, 49.5, 45.5, 39.6, 36.7, 32.8, 30.5, 27.6, 27.0, 22.5, 14.3 (C18); LRMS (-ESI): m/z 
431 (10%, [C18H23O8S2]-), 351 (30%), 333 (5%), 215 (20%, [C18H22O8S2]2-), 175 
(20%), 110 (30%), 97 (60%), 80 (100%); HRMS (-ESI): found 431.0840, 
[C18H23O8S2]- requires 431.0834. 
 
2.3.2.4.14 3α-hydroxytibolone 3,17-bis-sulfate, ammonium salt (14) 
A solution of 3α-hydroxytibolone (1.0 mg, 3.18 
µmol) in dioxane (100 µL) was treated with a 
solution of sulfur trioxide-pyridine complex (10 
mg, 62.8 µmol, 19.7 eq) in DMF (100 µL) and 
purified by SPE as per 2.3.2.3.1 to yield the title 
compound 14 as a white solid Performing the sulfation reaction as per 2.3.2.3.2 
showed 96% conversion. Rf 0.25; H (400 MHz): 4.43 (m, 1H, C3-H), 2.95 (s, 1H, 
C21-H), 2.62-1.15 (m, 20H), 0.94 (s, 3H, C18), 0.79 (d, J 7.0 Hz, 3H, C19-H3); c (100 
MHz): 129.8 (C10) , 125.2 (C5), 87.9 (C20), 85.4 (C17), 77.0 (C21), 76.8 (C3), 50.2, 
45.6, 42.9, 41.2, 39.7, 38.8, 37.0, 34.4, 30.9, 28.6, 27.7, 26.5, 23.3, 14.5 (C18), 13.1 
(C22); LRMS (-ESI): m/z 473 (5%, [C21H29O8S2]-), 393 (5%, C21H29O5S]-), 375 
(30%), 236 (100%, [C21H28O8S2]2-), 97 (95%, [HSO4]-); HRMS (-ESI): found 
473.1307, [C21H29O8S2]- requires 473.1304. 
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2.3.2.4.15 3β-hydroxytibolone 3,17-bis-sulfate, ammonium salt (15) 
A solution of 3β-hydroxytibolone (3.0 mg, 9.54 
µmol) in dioxane (500 µL) was treated with a 
solution of sulfur trioxide-pyridine complex (50 
mg, 314 µmol, 32.9 eq) in DMF (500 µL) and 
purified by SPE as per 2.3.2.3.1 to yield the title 
compound 15 as a white solid Performing the sulfation reaction as per 2.3.2.3.2 
showed 93% conversion. Rf 0.46; δH (800 MHz): 4.68 (m, 1H, C3-H), 2.94 (s, 1H, 
C21-H), 2.62 (ddd, J 4.1 Hz, 12.2 Hz, 15.4 Hz, 1H, C16-H), 2.45 (ddd, J 5.6 Hz, 9.7 Hz, 
14.7 Hz, 1H, C16-H), 2.33 (m, 1H, C1-H), 2.27 (dd, J 4.2 Hz, 16.5 Hz, 1H, C6ax-H), 
2.23-2.16 (m, 2H, C4-H2), 2.06-1.98 (m, 2H, C2eq-H and C11-H), 1.89-1.79 (m, 4H, 
C1-H, C7-H, C12-H and C14-H), 1.72-1.63 (m, 4H, C2ax-H, C9-H, C12-H and C15-H), 
1.56 (dd, J 1.6 Hz, 16.8 Hz, 1H, C6eq-H), 1.48 (ddd, J 2.6 Hz, 11.2 Hz, 13.4 Hz, 1H, C8-
H), 1.38 (m, 1H, C15-H), 1.19 (ddd, J 3.6 Hz, 13.0 Hz, 16.6 Hz, 1H, C11-H), 0.94 (s, 
3H, C18), 0.79 (d, J 6.9Hz, 3H, C19-H3); c (200 MHz): 129.9 (C5 or C10), 123.7 (C5 
or C10), 87.9 (C17), 85.5 (C20), 76.9 (C21), 75.1 (C3), 50.1 (C13), 45.7 (C14), 42.9 
(C8), 41.1 (C9), 40.0 (C6), 37.8 (C1, C2 or C4), 37.0 (C16), 34.4 (C12), 28.9 (C7), 
28.6 (C1, C2 or C4), 26.3 (C11), 23.8 (C1, C2 or C4), 23.3 (C15), 14.0 (C18), 13.3 
(C19); LRMS (-ESI): m/z 473 (5%, [C21H29O8S2]-), 393 (5%, C21H29O5S]-), 375 
(30%), 236 (90%, [C21H28O8S2]2-), 97 (100%, [HSO4]-), 80 (20%); HRMS (-ESI): 
found 473.1305, [C21H29O8S2]- requires 473.1304. 
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2.3.3 Results and Discussion 
2.3.3.1 Synthesis of steroid bis-sulfates 
The chemical synthesis of steroid bis-sulfate compounds was achieved using 
previously reported methodology 9. The treatment of the steroid diol with an 
excess of sulfur trioxide-pyridine (SO3.py) cleanly afforded the desired steroid bis-
sulfate in high conversion (93 to >98%) after purification by WAX SPE. These 
reaction conditions have proved to be quite general, and have afforded a library of 
twelve steroid bis-sulfates, as highlighted below (Scheme 2.3, and Table 2.1). 
 
Scheme 2.3: Small-scale sulfation and purification of steroid bis-sulfates 
 
 
The synthesis of bis-sulfates 1, 3, 5, and 7-12 which contain only secondary 
alcohols proceeded smoothly to afford the desired bis-sulfates as the sole observed 
products. Conducting the sulfation reaction of androst-5-ene-3β,17β-diol in the 
presence of limiting (1 eq) SO3.py provided a mixture of C3-mono sulfated, and 
C17-mono sulfated products suggesting no discernible difference between the 
reactivity at the C3 and C17 positions. Based on these observations it was expected 
that the C11, and C16 positions would display similar reactivity. Of interest was the 
reaction of 16α-hydroxytestosterone which proceeded smoothly to afford the 
desired 16,17-bis-sulfate 12 in high conversion (>98%) which was expected to be 
problematic due to the steric hindrance resulting from sulfation at the two 
adjacent reaction sites. 
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Table 2.1: Synthesis of steroid bis-sulfates with purification by SPE 
Entry Steroid bis-sulfate Conversion 
(%) A 
Entry Steroid bis-sulfate Conversion 
(%) A 
 
1 
 
 
 
>98 
 
10 
 
 
 
>98 
 
3 
 
 
 
>98 
 
11 
 
 
>98 
 
5 
 
 
 
>98 
 
12 
 
 
>98 
 
7 
 
 
 
>98 
 
13 
 
 
 
>98 
 
8 
 
 
 
>98 
 
14 
 
 
96% 
 
9 
 
 
 
>98 
 
15 
 
 
93% 
AConversion based on 400 MHz 1H NMR integration 
  
77 
2.3.3.2 Synthesis of estradiol 3,17-bis-sulfate 
The sulfation of estradiol proceeded smoothly to afford bis-sulfate 13 in >98% 
conversion, which is in contrast to previous observations 9. Sulfation at the 
aromatic position was expected to be reduced (based on electronic 
considerations), due to the reduced reactivity of the phenolic hydroxyl groups over 
alkyl hydroxyl groups. The study described in Chapter 2.2 9 required the use of 
chlorosulfonic acid to achieve sulfation at the C3 position of estrone, while the 
present study achieved sulfation under much milder conditions. The sulfation of 
estrone and estradiol has also been reported under similar mild conditions 25,26. It 
has been hypothesised that wet or impure sources of SO3.py may be the culprit in 
the earlier reactions 9, as the effects from poor quality reagents may be amplified 
on the milligram-scale. The reaction of estradiol (5 mg) under standard conditions 
as per section 2.3.2.3.1, with the addition of water (100 µL) at the start of the 
reaction, resulted in a mixture of estradiol 17-sulfate, and estradiol 3,17-bis-
sulfate. The decomposition of SO3.py in the presence of water would likely yield a 
solution of dilute sulfuric acid and pyridine, which could be implicated in these 
observations. It is currently unknown if the earlier observed product distribution 
occurred as a result of the hydrolysis of the phenolic sulfate after the sulfation 
reaction had taken place, or as a result of an incomplete reaction due to 
decomposition of the reagent before the sulfation reaction could occur 9. 
 
2.3.3.3 Synthesis of tertiary steroid bis-sulfates 
The sulfation of 3α/β-hydroxytibolone to give bis-sulfates 14 and 15 was expected 
to be more difficult as both of these compounds possess a tertiary alcohol. 
Previous results have shown that tertiary hydroxyl groups remain untouched 
under these reaction conditions 9, although this may have been in part to the same 
problems that have been discussed immediately above in section 2.3.3.2. 
Additionally, C17-tertiary steroid sulfates have been observed to decompose under 
mildly acidic conditions, rearranging to give 17,17-dimethylandrost-13-enes, as 
well as C17-epimerisation, which have also been observed as steroid metabolites 
in vivo 18–20 (Scheme 2.4).  
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Scheme 2.4: Possible decomposition products of 17α-methyltestosterone 
17-sulfate 18 
 
 
Whilst tertiary steroid sulfates have been previously used to access C17-epimers of 
existing steroid compounds 20, attempts to isolate 17α-methyltestosterone 17-
sulfate were met with success only when care was taken to avoid exposure to 
excess air or moisture. This was achieved through the use of dry, distilled solvents, 
and a nitrogen atmosphere throughout the reaction. These conditions were then 
applied to the synthesis of bis-sulfates 14 and 15. Owing to the steric congestion 
afforded by the adjacent alkynyl substituent, the reaction afforded a mixture of C3-
mono and C3,C17-bis sulfated products, although the bis-sulfates were still 
observed in high conversions of 96% and 93% respectively. There was no evidence 
to suggest epimerisation at C17, or elimination to the corresponding 7α,17β-
dimethyl-18,19-dinor-17α-pregn-5(10),13-dien-20-yn-3-ol 3-sulfates. This was 
surprising, as the propargylic cation that would result from sulfate elimination was 
expected to be highly stable 18, however the stability of these tertiary sulfates may 
reflect the differences in the steric demand of a smaller C17-alkyne substituent 
over a C17-methyl substituent, or other unknown factors. 
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2.3.3.4 NMR analysis of steroid bis-sulfates 
During this study we found that the majority of the bis-sulfate compounds 
prepared had little to no characterisation data present in the literature and as a 
result they were characterised by 1H and 13C NMR after their preparation. NMR 
analysis was simplified due to their similarity to data previously reported for 
related steroid mono-sulfates 9. For the secondary alcohols subjected to sulfation, 
we observed a strong downfield shift of the protons at the reaction site. A shift of 
0.63-0.84 ppm was observed for the C3 protons, a shift of 0.63 ppm was observed 
for the C11 protons, a shift of 0.64-0.77 ppm was observed for the C16 protons, 
and a shift of 0.65-0.93 ppm was observed for the C17 protons. The proximity of 
the two sulfate groups to each other had an effect on the magnitude of the 
downfield shift observed, as expected due to electronic considerations. The 
smallest downfield shifts were observed when the sulfate groups were far apart 
such as for 3,17 bis-sulfates (0.63, and 0.65 ppm for C3, and C17 respectively), 
whilst the largest downfield shifts was observed for 16α-hydroxytestosterone 
16,17-bis-sulfate (0.77 ppm, and 0.93 ppm for C16, and C17 respectively) which 
contain sulfate groups on adjacent carbons. For the sulfation of estradiol to give 
bis-sulfate 13, a strong downfield shift of 0.51-0.54 ppm for the ortho C2, and C4 
protons was observed alongside a smaller shift of 0.20 ppm for the C1 proton. 
These observations were broadly consistent with previously reported 
observations 9. The sulfation of 3α/β-hydroxytibolone to give bis-sulfates 14 and 
15 proceeded with a downfield shift of 0.69 ppm for the C3 proton, and a very 
small shift of 0.06 ppm for the C21 alkyne proton.  
 
2.3.3.5 Full scan mass spectrometry behaviour of steroid bis-
sulfates 
In addition to the synthesis of bis-sulfates 1, 3, 5, and 7-15, the mass spectrometry 
behaviour of these compounds was investigated in full-scan with -ESI. In the 
example spectrum below (Figure 2.1), the mass spectrum of bis-sulfate 1 displays 
in-source fragmentation and peaks at mass-to-charge ratio (m/z) 449 (5%, [M-H]-), 
351 (30%, [M-2H-HSO4]-), 224 (15%, [M-2H]2-), and 97 (100%, [HSO4]-), where M 
refers to the neutral compound, C19H30O8S2. Additional fragmentations observed in 
some cases include loss of [SO3]-
● (m/z 80), and loss of [HSO3]- (m/z 81). For the 
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majority of these bis-sulfate compounds, the major peak associated with the intact 
molecule in full scan was the di-anion [M-2H]2-, while the mono-anion [M-H]-
normally ranged between 5-45%. The exception to this was bis-sulfate 12 which 
ionised preferentially as the mono-anion. This preference presumably arises from 
the charge repulsion that results from the two negatively-charged sulfate groups 
being in close proximity, which decreases the stability of the di-anion. Bis-sulfates 
1, 3, 5, 7-11, and 13-15 where the sulfate groups were further apart had a lower 
proportion of the mono-anion in their full scan spectra, and ionised preferentially 
as the di-anion. 
 
Figure 2.1: Full scan (-ESI) mass spectrometry behaviour of androst-5-ene-
3β,17β-diol 3,17-bis-sulfate (1) 
 
 
2.3.3.6 MS/MS behaviour of steroid bis-sulfates 
In addition to the full scan studies undertaken at the ANU, the MS/MS behaviour of 
bis-sulfates 1, 3, 5, 7, 9-12, and 15 was also studied on a triple quadrupole 
instrument (Table 2.2). This work was undertaken by Ms Argitxu Esquivel, Ms 
[M-H]- 
[M-2H-HSO4]- 
[M-2H]2- 
[HSO4]- 
[M-2H-HSO3]- 
[SO3]-
● 
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Georgina Balcells, and Dr Óscar Pozo at the Institut Hospital del Mar 
d'Investigacions Mèdiques (IMIM, Barcelona, Spain). After selecting the di-anion as 
the precursor ion, the resulting MS/MS product ion spectra of the above 
compounds were dominated by the presence of two major ions. The base peak in 
most cases corresponded to [HSO4]- (m/z 97), alongside a fragment ion [M-2H-
HSO4]-, which was generated from the loss of the [HSO4]- anion, and depended on 
the molecular mass of the bis-sulfate under study. This resulted in an increase of 
m/z of the observed fragment, and appeared to be general to most bis-sulfate 
compounds. A general mechanism for this fragmentation pathway is proposed 
below (Scheme  2.5). 
 
Table 2.2: MS/MS product ion behaviour of bis-sulfates 1, 3, 5, 7, 9-12, and 
15, at 20 eV collision energy 
Bis-sulfate Product ion scan selecting [M-2H]2- as the precursor ion 
 Base peak (m/z) [M-2H-HSO4]- (m/z) Other ions (>10%) (m/z) 
1 97 (100%) 351 (25%) 335 (18%) 
3 97 (100%) 353 (27%) 337 (10%) 
5 97 (100%) 353 (81%) 80 (20%) 
7 97 (100%) 353 (40%) - 
9 97 (100%) 367 (27%) - 
10 97 (100%) 367 (24%) - 
11 97 (100%) 367 (2%) 80 (48%), 81 (25%), 369 (48%) 
12 97 (100%) 365 (58%) 80 (45%), 285 (17%) 
15 97 (100%) 375 (9%) 80 (53%) 
 
Scheme 2.5: Proposed fragmentation pathway of androst-5-ene-3β,17β-diol 
3,17-bis-sulfate (1), based on observed MS/MS behaviour. 
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Although these two peaks were the most prominent ions, a significant fragment ion 
corresponding to [SO3]-
● (m/z 80) was also observed for bis-sulfates 5, 11, 12, and 
15 (20-53% abundance, Table 2.2). This ion has been previously observed for 
some steroid mono-sulfate compounds, most commonly for compounds containing 
a phenolic, or tertiary sulfate group 9,27. Additionally, for bis-sulfate 11 which has a 
sulfate group adjacent to a carbonyl group at C17, a prominent ion was observed 
corresponding to the consecutive loss of [SO3]-
● and [CH3]
●. A feasible pathway for 
this fragmentation is shown below (Scheme 2.6). 
 
Scheme 2.6: Proposed fragmentation pathway for the consecutive losses of 
[SO3]-
● and [CH3]
● for 16α-hydroxyandrosterone 3,16-bis-sulfate (11). 
 
The observed ion fragmentation patterns were used to develop an open screening 
protocol for the untargeted detection of steroid bis-sulfate compounds. Two 
approaches were considered for the detection of bis-sulfate compounds: a 
precursor ion scan method selecting m/z 97 as the product ion, and a constant ion 
loss (CIL) method based on the constant loss of the [HSO4]- anion. The precursor 
ion scan method was easily employed by common MS/MS software packages, and 
allowed for selection of m/z 97 in the second quadrupole, with scanning for 
precursor ions in the first quadrupole. The detection of sulfate metabolites by 
precursor ion methods has been previously reported 27–29. 
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The CIL method was more difficult to employ as the product ion m/z depended 
upon the m/z of the precursor ion, as described below.  
 
𝑃𝑟𝑒𝑐𝑢𝑟𝑠𝑜𝑟 𝑖𝑜𝑛 (𝑚/𝑧) = 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝑖𝑜𝑛 (𝑚′/𝑧′ ) + 𝐶𝐼𝐿 (𝑚"/𝑧")   
 
As a result, the mass of the product ion for a given CIL, was given as shown below: 
 
𝑚′/𝑧′ =  
[(𝑚/𝑧) × 𝑧] − [(𝑚"/𝑧") × 𝑧"]
𝑧 − 𝑧"
 
 
The change in m/z (Δm/z) observed during the CIL was given as shown below: 
 
Δ𝑚/𝑧 =  
𝑧" ×  [(𝑚/𝑧) − (𝑚"/𝑧")]
𝑧 − 𝑧"
 
 
In the current application the CIL is [HSO4]- (m”/z” 97), z”=1, and the precursor ion 
is [M-2H]2-, z=2. The theory predicted a positive m/z (ie. an increase in m/z) for 
any CIL where the m/z of the precursor ion is greater than the constant ion. This 
agreed with experimental observations. 
 
Although the m/z of the product ion could be calculated, a software tool was not 
available to perform the CIL method on currently available instrumentation. As 
such, a MRM method was developed which included a calculated SRM transition 
for each precursor ion/product ion pair arising from CIL. Based on the known 
molecular masses of endogenous steroid compounds and their metabolites (250-
400 Da), the bis-sulfate SRM transitions selected were restricted to the range m/z 
199 to m/z 274. A MRM method containing 75 transitions in this range was then 
used for the untargeted detection of steroid bis-sulfates in human urine. Although 
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the transitions selected were predetermined, this approach was considered 
untargeted as the MRM method covered the entire expected mass range of 
endogenous steroid bis-sulfates 
 
In order to test the suitability of this method to detect steroid bis-sulfates, the 
method was applied to human urine samples spiked with bis-sulfates 1, 3, 5, 8, 9, 
and 11-13. The extraction recovery of these compounds was determined by 
comparing the bis-sulfate responses in urine samples spiked with bis-sulfate both 
before and after sample processing. Additional experiments were also performed 
to identify the limits of detection of these analytes by the precursor ion, and CIL 
methods. Urine samples spiked with various concentrations of bis-sulfates were 
analysed by both analytical methods, and the lowest concentration with a signal-
to-noise (S/N) ratio greater than 3 was selected as the limit of detection (LOD). 
These results are shown in Table 2.3. Extraction recovery from human urine was 
44-85%, with a relative standard deviation of 4-20%. Limits of detection were 2-
20 ng/mL for the CIL method, compared to 10-50 ng/mL for the precursor ion 
method. In general, the CIL strategy showed a lower LOD than the precursor ion 
scan approach. The increase in sensitivity can be explained by the higher 
specificity of the transitions selected. The use of transitions involving increases of 
m/z have been reported to be more specific in the detection of other multiply 
charged analytes such as peptides 30. 
 
Table 2.3: Extraction recoveries and LODs obtained for the bis-sulfates 
reference materials 1, 3, 5, 8, 9, 11-13 (PI: precursor ion). 
Bis-sulfate Extraction CIL PI scan 
 Recovery 
(%) 
RSD (%) Precursor 
ion (m/z) 
Product ion 
(m/z) 
LOD 
(ng/mL) 
LOD 
(ng/mL) 
1 55 7 224 351 2 10 
3 53 25 225 353 5 20 
5 56 20 225 353 5 20 
8 83 4 232 367 2 10 
9 85 11 232 367 5 10 
11 56 16 232 367 10 10 
12 84 11 231 365 10 50 
13 44 10 215 333 20 20 
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The endogenous bis-sulfate profile was evaluated by analysis of the urine samples 
collected from healthy volunteers. Ethical approval for this study was granted by 
the Comité Ètic d’Investigació Clínica (CEIC, Parc de Salut Mar, Barcelona, Spain, 
and all subjects participating in the study gave their written informed consent 
prior to inclusion. In the majority of the samples, several peaks were detected by 
the CIL method. Peaks were observed at the theoretical m/z for several classes of 
endogenous compounds including: estrogens like estriol bis-sulfate (m/z 223  
m/z 349) and estradiol bis-sulfate (m/z 215  333); androgens like 
androstanediol bis-sulfate (m/z 225 m/z 353) and androstenediol bis-sulfate 
(m/z 224 m/z 351); progestogens like pregnanediol bis-sulfate (m/z 239  m/z 
381) and pregnenediol bis-sulfate (m/z 238  m/z 379); and corticosteroids like 
tetrahydrocortisol (m/z 262  m/z 427). For many transitions multiple peaks 
were identified, suggesting the presence of regio-, stereo-, or constitutional 
isomers. The observation of bis-sulfate metabolites belonging to several classes of 
steroid metabolites suggests that bis-sulfation is a common metabolic pathway for 
steroid compounds. The identity of some of the detected bis-sulfates was 
confirmed by comparison of the urine samples to reference materials. Bis-sulfate 1 
was observed to match an endogenous metabolite by comparison of both retention 
time and relative abundances of the selected ion transitions, by both analytical 
methods. Additionally, endogenous metabolites were confirmed by comparison to 
16-hydroxydehydroepiandrosterone bis-sulfate, and 5-pregnenediol bis-sulfate 
reference materials available at the IMIM laboratories. 
 
2.3.4 Conclusions  
Utilising a small-scale sulfation protocol with purification by solid-phase 
extraction, twelve steroid bis-sulfate compounds have been prepared for study. 
These compounds have not been previously prepared, and have been 
characterised by 1H NMR, 13C NMR, and mass spectrometry studies. These 
compounds were determined to be suitable for use as reference materials in 
analytical laboratories. A unique mode of fragmentation, corresponding to anion 
loss of [HSO4]- (m/z 97) which results in an increase of m/z has been identified, 
and formed the basis of a constant ion loss scan method for the untargeted 
detection of bis-sulfate metabolites of anabolic steroids. This methodology could 
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also potentially be used for the detection of bis-sulfate metabolites of other drug 
classes. This method proved more sensitive for steroid bis-sulfate metabolites over 
the alternative precursor ion method, which also detects steroid mono-sulfate 
metabolites. The developed CIL approach allowed for the untargeted detection of 
endogenous bis-sulfates at the low ng/mL range. The detection of endogenous bis-
sulfate metabolites confirms that this metabolic pathway is common to all classes 
of endogenous steroid compounds. This method will hopefully be suitable for the 
detection of all classes of steroid bis-conjugates such as bis-glucuronides, mixed 
bis-sulfate-glucuronides, or other multiply-charged metabolites, broadening the 
utility of this method for use in anti-doping laboratories. It is hoped in future that 
this methodology can be applied to study the endogenous steroid profile and how 
it changes in response to EAAS misuse, and to study the formation of steroid bis-
sulfates that result from the administration of synthetic anabolic steroids, 
including designer steroids. 
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corrections to this thesis were made (May 2017), this work was accepted for 
publication in the journal Analytical Chemistry. The full citation for this work is as 
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McLeod M. D., Waller, C. C, Esquivel, A., Balcells, G., Ventura, R., Segura, J., Pozo, Ó. J.; 
Anal. Chem. 2017 89 (3), 1602-1609, DOI: 10.1021/acs.analchem.6b03671 
 
A copy of the full text article has been reproduced in Appendix A. Reprinted with 
permission. Copyright 2017 American Chemical Society.  
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CHAPTER THREE 
 
 
3α/β-chloro-17α-methyl-5α-androstan-17β-ol 
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Publication: 
Cawley, A. T.; Blakey, K.; Waller, C. C.; McLeod, M. D.; Boyd, S.; Heather, 
A.; McGrath, K. C.; Handelsman, D. J.; Willis, A. C. Drug Test. Anal. 2016, 
8 (7), 621–632, DOI: 10.1002/dta.1832 
 
3.1 Foreword 
The following manuscript has been published in the journal “Drug Testing and 
Analysis” and details the discovery of a novel anabolic agent intended for doping 
purposes in samples seized by law-enforcement, and the subsequent investigations 
to elucidate its structure, identify the primary human and equine metabolites, and 
to incorporate these into routine anti-doping screening protocols. Permission has 
been granted by John Wiley and Sons via RightsLink for the reproduction of this 
publication within this thesis (License Number: 3887470777611). This publication 
and supporting information (15 pages containing experimental procedures, and 
characterisation data) was authored by Dr Adam Cawley, Dr Karen Blakey, Mr 
Christopher Waller, Associate Professor Malcolm McLeod, Dr Sue Boyd, Dr Alison 
Heather, Dr Kristine McGrath, Professor David Handelsman, and Dr Anthony Willis. 
This collaboration resulted through the contribution of all authors, and was 
coordinated by Dr Cawley. The specific contributions of C. Waller are listed below: 
 
 The synthesis of 3α-chloro-17α-methyl-5α-androstan-17β-ol, 3β-chloro-
17α-methyl-5α-androstan-17β-ol, 3α-chloro-17β-methyl-5α-androsta-
16α,17α-diol, and 3α-chloro-17α-methyl-5α-androsta-16α,17β-diol 
reference materials. 
 Full characterisation of all reference materials and intermediates produced. 
 Human and equine in vitro metabolism studies, including the identification 
and confirmation of the major metabolites. 
 Preparation of pages 9-15 of the supporting information, which contains 
experimental procedures, and characterisation data. 
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The detection of novel anabolic agents intended for doping purposes remains a 
significant problem in both human and equine sports. These “designer” steroids 
frequently contain chemical modifications which may prevent their identification 
by both law-enforcement and anti-doping laboratories. The greatest hurdle to 
responding effectively is often obtaining intelligence regarding the availability of 
new designer steroids, and therefore identifying the most likely candidates for 
misuse.  
 
In this chapter, a suite of tools has been deployed to assist anti-doping laboratories 
in responding to the threat of designer steroids. The manuscript presented 
describes a study in which an unknown sample was seized by law-enforcement, 
and after extensive structural analysis was determined to contain a 5:2 mixture of 
3α-chloro-17α-methyl-5α-androstan-17β-ol, and 3β-chloro-17α-methyl-5α-
androstan-17β-ol. Although new to science, the proposed structures were 
confirmed through the individual chemical synthesis of both isomers present in 
the mixture, which then allowed for subsequent investigations using androgen 
bioassays and in vitro metabolism. The data obtained from these studies was then 
used in order to develop and evaluate routine anti-doping screening protocols to 
allow for detection of these compounds in human and equine urine. 
 
This study highlights a workflow suitable for adoption by anti-doping laboratories 
that allows for the development of screening protocols in the event that new 
designer steroids are identified. 
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3.2 Detection and metabolic investigations of 
a novel designer steroid: 3-chloro-17α-
methyl-5α-androstan-17β-ol 
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Due to copyright restrictions from the publisher, the journal article presented in 
section 3.2 has been removed from the online version of this thesis. The full text 
article can be obtained via the ANU Library, or directly from the publisher using 
the link below: 
 
http://onlinelibrary.wiley.com/doi/10.1002/dta.1832/abstract 
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CHAPTER FOUR 
 
 
Furazadrol 
[1’,2’]isoxazolo[4’,5’:2,3]-5α-androstan-17β-ol  
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Publication: 
Waller, C. C.; Cawley, A. T.; Suann, C. J.; Ma, P.; McLeod, M. D. Journal of 
Pharmaceutical and Biomedical Analysis 2016, 124, 198–206, DOI: 
10.1016/j.jpba.2016.02.031 
 
4.1 Foreword 
The following manuscript has been published in the “Journal of Pharmaceutical and 
Biomedical Analysis” and details an investigation into the in vivo and in vitro 
metabolism of the designer steroid furazadrol in thoroughbred racehorses, with an 
aim to identify metabolites relevant to anti-doping laboratories. Permission has 
been granted by Elsevier via RightsLink for the reproduction of this publication 
within this thesis (License Number: 3887470374721). This publication and 
supporting information (58 pages containing experimental procedures, 
characterisation data and copies of NMR and MS spectra) was authored by Mr 
Christopher Waller, Dr Adam Cawley, Dr Craig Suann, Mr Paul Ma, and Associate 
Professor Malcolm McLeod. All experimental work with the exception of the in vivo 
administration was undertaken by C. Waller, alongside preparation of the initial 
draft of the manuscript. Dr Suann performed the in vivo administration and 
collected the biological samples. P. Ma expressed and purified the Escherichia coli 
β-glucuronylsynthase enzyme, and prepared the α-D-glucuronyl fluoride which 
were used to prepare the glucuronide reference materials. Dr Cawley, and Assoc. 
Prof. McLeod initially conceived of the project, assisted with interpretation of the 
LC-MS/MS data, and assisted in revising the manuscript prior to submission. 
 
The detection of designer anabolic steroids remains a problem for anti-doping 
laboratories, and understanding the metabolism of these compounds is essential in 
order to develop methods which can identify them in biological samples. The 
designer steroid furazadrol ([1’,2’]isoxazolo[4’,5’:2,3]-5α-androstan-17β-ol), which 
is the focus for this chapter, is found in many “dietary” or “nutritional” 
supplements available online. The presence of an isoxazole ring fused to the 
steroid core changes how this compound is metabolised in vivo compared to 
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traditional anabolic steroids, and understanding the metabolism of this compound 
would provide information useful to anti-doping laboratories. 
 
In this chapter the equine metabolism of furazadrol was explored with an aim to 
provide information regarding the metabolism of this compound for use by anti-
doping laboratories. Synthetic furazadrol was administered to a thoroughbred 
racehorse, and the key urinary metabolites were identified in post-administration 
samples. 
Figure 4.1: The major urinary metabolites observed following furazadrol 
administration 
 
The major metabolites observed after furazadrol administration (furazadrol 17-
sulfate, and furazadrol 17-glucuronide) were identified by comparison to 
synthetically prepared reference materials, and quantified to establish an 
excretion profile and determine suitable limits of detection. Epifurazadrol 
glucuronide was also identified, alongside minor metabolites including 
hydroxylated furazadrol, and hydroxylated and oxidised furazadrol, present as the 
sulfate and glucuronide conjugates. The phase II metabolites were subjected to 
enzymatic hydrolysis by E. coli β-glucuronidase and P. aeruginosa arylsulfatase to 
further confirm the identity of the corresponding phase I metabolites. A 
comparative in vitro study was also undertaken, which identified all but two of the 
minor in vivo phase I metabolites. These investigations have identified the key 
urinary metabolites of furazadrol following oral administration, which can be 
incorporated into anti-doping screening and confirmation procedures. 
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4.2 In vivo and in vitro metabolism of the 
designer anabolic steroid furazadrol in 
thoroughbred racehorses 
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Due to copyright restrictions from the publisher, the journal article presented in 
section 4.2 has been removed from the online version of this thesis. The full text 
article can be obtained via the ANU Library, or directly from the publisher using 
the link below: 
 
http://www.sciencedirect.com/science/article/pii/S0731708516300930 
 
 
 
  
110 
  
111 
  
112 
  
113 
  
114 
  
115 
  
116 
  
117 
  
118 
In addition to the published work presented in Chapter 4.2, the following related 
unpublished work is also presented. Supporting information relevant to this 
chapter is presented electronically alongside this thesis. 
 
4.3 In vitro phase II metabolism  
4.3.1 Introduction 
As has been highlighted throughout this thesis so far, one of the primary problems 
with developing methods for the detection of designer steroids in horses is a lack 
of data detailing how these compounds are metabolised in equine systems. In 
order to successfully develop methods that allow for the detection of these 
compounds, metabolites of the parent drug must usually be targeted, and these 
have to be determined experimentally. These metabolites have been traditionally 
identified though in vivo studies, although the use of in vitro technologies is rapidly 
gaining acceptance in anti-doping laboratories. In vitro experiments have the 
advantage of being technically simpler to perform, as well as mitigating many of 
the ethical concerns regarding animal health and safety 1,2. These concerns are 
particularly important in the case of designer steroids since a large number of 
these compounds are brought to market in a clandestine fashion, and the majority 
of these compounds do not have any available data regarding their purity, safety, 
or efficacy. As a result, in vivo studies are often hard to justify on ethical grounds. 
Although phase I steroid metabolism has been studied extensively by in vitro 
methods, the same cannot be said for the study of phase II metabolism. This is 
problematic as phase II metabolism is an important aspect of steroid metabolism. 
The conjugation of polar sulfate or glucuronic acid donor groups to the 
hydrophobic steroid backbone increases their aqueous solubility, and facilitates 
their excretion from the body via the urine. These phase II metabolites are 
important markers for drug detection, and monitoring directly for these 
metabolites can offer advantages such as reduced sample preparation, and 
increased detection windows for some analytes 3. Although in vitro systems are 
sometimes able to predict the major metabolites of steroid metabolism, there is a 
need for systems which can faithfully replicate in vivo metabolism as the accuracy 
of these systems is often questioned, and can limit how these methods are used to 
study steroid metabolism. This is particularly important in equine sports, as 
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current AORC criteria allow for the use of in vitro-derived materials as reference 
materials in confirmatory analysis 4, so systems that can better replicate in vivo 
metabolism can be used to detect instances of steroid misuse. 
 
In vitro technologies typically make use of enzymatic products derived from liver 
tissue, as the liver is the primary organ involved in detoxification of xenobiotic 
compounds 2,5–11. Equine liver microsomes and S9 fraction are among the most 
popular choices; however, they often require supplementation with expensive 
uridine diphosphate glucuronic acid (UDPGA), and 3'-phosphoadenosine-5'-
phosphosulfate (PAPS) co-factors in order to study phase II metabolism, and as a 
result studies are typically limited to phase I metabolism. There have been some 
reports detailing the study of phase II steroid metabolism using in vitro systems 
9,12, but to date these have not been widely adopted by laboratories.  
 
Although phase II metabolites can be generated in vitro through the use of the co-
factors UDPGA and PAPS, these reagents have a number of limitations that 
frequently prohibit their usage. The use of UDPGA (AU$100 for 25 mg, Sigma 
Aldrich 13), and PAPS (AU$2790 for 25 mg, Sigma-Aldrich 14) are limited by their 
chemical instability and prohibitive costs, and as a consequence a number of 
systems have been developed which allow for the study of phase II metabolism 
using alternative methods. 
 
One of the primary methods used to overcome the prohibitive cost of PAPS is to 
use it in a catalytic quantity in conjugation with a PAPS-regeneration system. 
These systems regenerate PAPS in situ through use of various enzymatic cascades 
15–17. Since PAPS is an essential co-factor required for phase II sulfation in vivo, a 
number of the PAPS-regeneration systems mimic its biosynthesis, as shown in 
Scheme 4.1. It is known that PAPS is generated in vivo in two enzymatic steps from 
adenosine triphosphate (ATP); the enzyme ATP sulfurylase first catalyses the 
sulfation of ATP to generate adenosine-5’-phosphosulfate (APS), and APS is 
subsequently phosphorylated by APS kinase to generate PAPS 18. During the 
transfer of sulfate to the target molecule, sulfotransferase enzymes liberate 3'-
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phosphoadenosine-5'-phosphate (PAP) which is then dephosphorylated by PAP-
nucleotidase to generate adenosine 5’-phosphate (AMP). This is then converted 
back to ATP, allowing the cycle to begin again 15. A number of enzymatic and 
whole-cell systems have been developed which include these enzymes to 
regenerate PAPS as it is consumed during the reaction 15–17. 
 
Scheme 4.1: In vivo regeneration of PAPS 
 
 
Since PAPS is generated in vivo from ATP, it was reasoned that the enzymes 
required to generate PAPS may already be present in the liver S9 fraction, and 
could be used to generate PAPS in vitro in the presence of ATP and a suitable 
sulfate source. This would allow for phase II sulfation using vastly cheaper 
reagents (ATP AU$79 for 1000 mg, Sigma Aldrich 19). Optimal conditions for in 
vitro phase II steroid sulfation were previously developed by Ms Ling Fam during 
an undergraduate research project in the McLeod Group 20, and were achieved 
when using ATP (16 mM), Na2SO4 (8 mM), and MgCl2 (16 mM) in place of PAPS 
(80 µM) with a reaction time of 16-24 h. With these conditions in hand, we aimed 
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to investigate the in vitro phase II metabolism of the designer steroids furazadrol, 
and superdrol. 
 
4.3.2 Experimental 
4.3.2.1 Materials 
Chemicals and solvents including lithium tri-sec-butylborohydride (L-Selectride®) 
solution in anhydrous tetrahydrofuran (THF), anhydrous N,N-dimethylformamide 
(DMF), magnesium chloride, sulfur-trioxide pyridine complex (SO3.py), tertiary-
butanol (t-BuOH), glucose-6-phosphate (G6P), NAD-dependant glucose-6-
phosphate dehydrogenase (G6PDH) from Leuconostoc mesenteroides, adenosine 
triphosphate (ATP), 3'-phosphoadenosine-5'-phosphosulfate (PAPS), nicotinamide 
adenine dinucleotide phosphate (NADP), and uridine diphosphate glucuronic acid 
(UDPGA) were purchased from Sigma–Aldrich (Castle Hill, Australia), and were 
used as supplied unless otherwise stated. Nicotinamide adenine dinucleotide 
(NAD) was purchased from Amresco (Solon, USA). Formic acid was purchased 
from Ajax Chemicals (Auburn, Australia). 1,4-Dioxane (dioxane) was purchased 
from Merck (Darmstadt, Germany). Superdrol (methasterone, 17β-hydroxy-
2α,17α-dimethyl-5α-androstan-3-one) was purchased from the National 
Measurement Institute (North Ryde, Australia). Equine liver S9 fraction was 
purchased from XenoTech (Kansas City, USA). Solid-phase extraction (SPE) was 
performed using Waters (Rydalmere, Australia) Oasis WAX 6cc cartridges (PN 
186004647), or Waters Sep-Pak C18 (3 cc, 500 mg) cartridges (PN WAT020805) 
as specified. Escherichia coli glucuronylsynthase, and α-D-glucuronyl fluoride were 
prepared according to literature methods 21. NADP-dependant G6PDH was 
recombinantly expressed from E. coli according to a previously reported method 22. 
 
4.3.2.2 Furazadrol reference materials 
A range of furazadrol reference materials were employed to aid the identification 
of phase I and phase II metabolites. These were furazadrol 
([1’,2’]isoxazolo[4’,5’:2,3]-5α-androstan-17β-ol) F, isofurazadrol ([1’,2’]isoxazolo-
[4’,3’:2,3]-5α-androstan-17β-ol) IF, epifurazadrol ([1’,2’]isoxazolo[4’,5’:2,3]-5α-
androstan-17α-ol) EF, oxidised furazadrol ([1’,2’]isoxazolo[4’,5’:2,3]-5α-androstan-
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17-one) OF, oxidised isofurazadrol ([1’,2’]isoxazolo[4’,3’:2,3]-5α-androstan-17-one) 
OIF, furazadrol 17-sulfate FS, isofurazadrol 17-sulfate IFS, epifurazadrol 17-sulfate 
EFS, furazadrol 17-glucuronide FG, isofurazadrol 17-glucuronide IFG, and 
epifurazadrol 17-glucuronide EFG. These were prepared as previously reported 
2,23. 
 
4.3.2.3 Superdrol reference materials  
A range of superdrol reference materials were employed to aid the identification of 
phase I and phase II metabolites. Superdrol S was sourced commercially, however 
the remaining materials were prepared synthetically, including: 2α,17α-dimethyl-
5α-androstane-3α,17β-diol 16, 2α,17α-dimethyl-5α-androstane-3β,17β-diol 17, 
2α,17α-dimethyl-5α-androstane-3α,17β-diol 3-sulfate 3α-RSS, 2α,17α-dimethyl-5α-
androstane-3β,17β-diol 3-sulfate 3β-RSS, and 2α,17α-dimethyl-5α-androstane-
3β,17β-diol 3-glucuronide 3β-RSG. These were prepared as outlined below. Copies 
of the 1H NMR, 13C NMR, and +EI LRMS or -ESI LRMS where appropriate are 
included electronically in the supporting information for this chapter. 
 
4.3.2.3.1 2α,17α-Dimethyl-5α-androstane-3α,17β-diol (16)  
A solution of superdrol (1.0 mg, 3.14 µmol) in methanol 
(80 µL) was treated with a solution of L-Selectride® in 
anhydrous THF (1.0 M, 20 µL, 20 µmol, 6.4 eq), and stirred 
at room temperature for 2 h. The reaction was quenched 
with aqueous hydrochloric acid (2 M, 1 mL) and purified 
by SPE. A C18-SPE cartridge was pre-conditioned with methanol (3 mL) and water 
(3 mL), and the reaction mixture was then loaded. The sample was washed with 
water (2 mL) until neutral, and eluted with methanol (2 mL). Concentration of the 
methanol fraction afforded the title compound 16 in >98% conversion as 
determined by 400 MHz 1H NMR analysis 23. Rf 0.55 (40% EtOAc/hexanes); 
δH (400 MHz, CDCl3): 3.77 (m, 1H, C3-H), 1.82-0.68 (m, 22H), 1.20 (s, 3H, C20-H3), 
0.93 (d, J 6.9 Hz, 3H, C21-H3), 0.84 (s, 3H, C18-H3), 0.80 (s, 3H, C19-H3), 2 x OH not 
observed; c (100 MHz, CDCl3): 81.9 (C17), 70.9 (C3), 54.6, 50.9, 45.7, 41.0, 39.2, 
39.0, 36.7, 36.6, 36.4, 31.9 (2 peaks), 31.8, 28.3, 26.0 (C20), 23.4, 20.1, 18.6 (C21), 
123 
14.2 (C18), 12.4 (C19); LRMS (+EI): m/z 320 (25%, [C21H36O2]+), 305 (45%), 245 
(70%), 231 (85%), 179 (80%), 163 (55%), 135 (45%), 121 (100%), 107 (70%), 95 
(70%), 81 (70%), 79 (40%), 55 (65%); HRMS (+EI): found 320.2715, [C21H36O2]+ 
requires 320.2715. 
 
4.3.2.3.2 2α,17α-Dimethyl-5α-androstane-3β,17β-diol (17)  
A solution of superdrol (1.0 mg, 3.14 µmol) in methanol 
(80 µL) was treated with sodium borohydride (1 mg, 
26.4 µmol, 8.4 eq) and stirred at room temperature for 2 
h. The reaction was quenched with aqueous hydrochloric 
acid (2 M, 1 mL) and purified by SPE as outlined in section 
4.3.2.3.1. Concentration of the methanol fraction afforded a 3:1 mixture containing 
the title compound 17, alongside the 3α-isomer 16 in >98% total conversion as 
determined by 400 MHz 1H NMR analysis 23. Data are reported for the 3β-isomer 
where appropriate. Rf 0.54 (40% EtOAc/hexanes); δH (400 MHz, CDCl3): 3.13 (dt, J 
4.8 Hz, 10.4 Hz, 1H, C3-H), 1.82-0.58 (m, 22H), 1.20 (s, 3H, C20-H3), 0.98 (d, J 6.4 
Hz, 3H, C21-H3), 0.84 (s, 6H, C18-H3, and C19-H3), 2 x OH not observed; c (100 
MHz, CDCl3): 81.9 (C17), 70.9 (C3), 54.6, 50.9, 46.6, 45.7, 45.6, 39.2, 38.2, 36.7, 36.4, 
35.8, 31.9, 31.8, 28.5, 26.0 (C20), 23.4, 21.1, 19.0 (C21), 14.2 (C18), 13.3 (C19); 
LRMS (+EI): m/z 320 (40%, [C21H36O2]+), 305 (60%), 245 (60%), 231 (80%), 179 
(80%), 163 (55%), 135 (50%), 121 (100%), 107 (70%), 95 (70%), 81 (70%), 55 
(70%); HRMS (+EI): found 320.2711, [C21H36O2]+ requires 320.2715. 
 
4.3.2.3.3 2α,17α-Dimethyl-5α-androstane-3α,17β-diol 3-sulfate, ammonium 
salt (3α-RSS) 
Sulfation was performed according to a literature 
method with minor modifications 23. A solution of 
2α,17α-dimethyl-5α-androstane-3α,17β-diol 16 
(derived from 1.0 mg superdrol, assumed 3.14 µmol) 
in DMF (2 mL) was treated with SO3.py (10 mg, 62.8 µmol, 20.0 eq) and stirred at 
room temperature for 4 h. The reaction was quenched by addition of water (5 mL) 
and was subjected to purification by SPE as per Chapter 2.2, manuscript section 
2.3.1), affording the title compound 3α-RSS in >98% total conversion 23. Rf 0.51 
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(7:2:1 EtOAc:MeOH:H2O); δH (400 MHz, CD3OD): 4.41 (m, 1H, C3-H), 2.51-0.68 (m, 
21H), 1.01 (s, 3H), 0.98 (d, J 7.0 Hz, 3H, C21-H3), 0.87 (s, 3H), 0.81 (s, 3H); LRMS (-
ESI): m/z 399 (20%, [C21H35O5S]-), 381 (100%), 110 (55%), 97 (90%); HRMS (-
ESI): found 399.2209, [C21H35O5S]- requires 399.2205. 
 
4.3.2.3.4 2α,17α-Dimethyl-5α-androstane-3β,17β-diol 3-sulfate, ammonium 
salt (3β-RSS) 
A solution of 2α,17α-dimethyl-5α-androstane-3β,17β-
diol 17 (3:1 β:α mixture derived from 1.0 mg 
superdrol, assumed 3.14 µmol) in DMF (500 µL) was 
treated with SO3.py (10 mg, 62.8 µmol, 20.0 eq), 
followed by purification by WAX SPE as outlined in section 4.3.2.3.3, to afford a 3:1 
mixture containing the title compound 3β-RSS, alongside the 3α-isomer 3α-RSS in 
>98% conversion 23. Data are reported for the 3β-isomer where appropriate. Rf 
0.49 (7:2:1 EtOAc:MeOH:H2O); δH (400 MHz, CD3OD): 3.86 (dt, J 4.9 Hz, 10.8 Hz, 1H, 
C3-H), 2.63 (m, 1H), 2.03-0.68 (m, 20H), 1.50 (s, 3H, C20-H3), 1.01 (d, J 6.4 Hz, 3H, 
C21-H3), 0.92 (s, 3H, C18-H3), 0.88 (s, 3H, C19-H3); LRMS (-ESI): m/z 399 (90%), 
381 (100%), 239 (10%), 97 (90 %); HRMS (-ESI): found 399.2221, [C21H35O5S]- 
requires 399.2205. 
 
4.3.2.3.5 2α,17α-Dimethyl-5α-androstane-3β,17β-diol 3-glucuronide, 
ammonium salt (3β-RSG) 
Glucuronylation was performed according to 
literature methods 21. A solution of 2α,17α-
dimethyl-5α-androstane-3β,17β-diol (derived 
from 5.0 mg superdrol, assumed 15.7 µmol) 
in t-BuOH (2.26 mL) was treated with a 
solution of α-D-glucuronyl fluoride (21 mg, 98.5 µmol, 6.3 eq) in sodium phosphate 
buffer (50 mM, pH 7.5, 18.34 mL), followed by a solution of glucuronylsynthase 
(10.2 mg/mL, 450 µL) in aqueous sodium phosphate buffer/glycerol solution 
(50% v/v, 50 mM, pH 7.4). The reaction was incubated for 48 h at 37 oC, and was 
then subjected to purification by WAX SPE as outlined in section 4.3.2.3.3 to afford 
the title compound 3β-RSG in 51% conversion 21. Rf 0.41 (7:2:1 EtOAc:MeOH:H2O); 
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δH (400 MHz, CD3OD): 4.40 (d, J 7.8 Hz, 1H, C22-H), 3.53-3.35 (m, 4H, C3-H, C24-H, 
C25-H, and C26-H), 3.20 (t, J 8.5 Hz, 1H, C23-H), 1.81-0.65 (m, 20H), 1.18 (s, 3H, 
C20-H3), 0.99 (d, J 6.2 Hz, 3H, C21-H3), 0.87 (s, 3H, C18-H3), 0.83 (s, 3H, C19-H3); 
δC (100 MHz, CD3OD): 179.9 (C27), 100.9 (C22), 82.5 (C3, or C17), 82.3 (C3, or 
C17), 78.0 (C24), 76.8 (C26), 75.1 (C23), 73.8 (C25), 55.9, 52.1, 48.1, 46.9, 46.3, 
39.3, 37.6, 37.3, 34.6, 34.5, 33.1, 33.0, 29.7, 26.1 (C20), 24.3, 22.0, 19.6 (C21), 14.7 
(C18), 13.5 (C19); LRMS (-ESI): m/z 495 (100%), 82 (10%), 61 (10%); HRMS 
(-ESI): found 495.2964, [C27H43O8]- requires 495.2963. 
 
4.3.2.4 Analytical methods 
4.3.2.4.1 Furazadrol LC-MS analysis 
LC-MS analysis for furazadrol was performed as previously reported 2. Positive 
mode liquid chromatography-high resolution accurate mass (LC-HRAM) 
spectrometry analysis was undertaken using a Thermo Fisher Scientific (Bremen, 
Germany) Ultimate 3000 HPLC coupled to an Q Exactive Hybrid Quadrupole 
Orbitrap mass spectrometer equipped with a Waters SunFire C18 column (100 x 
2.1 mm, 3.5 um) eluting with a gradient consisting of the following mobile phases, 
A: 0.1% formic acid in water, B: 0.1% formic acid in methanol, gradient: 0-1 min Α-
Β (95:5 v/v), 1-15 min Α-Β (95:5 v/v) to Α-Β (5:95 v/v), 15-19 min Α-Β (5:95 v/v), 
5 min re-equilibration, flow rate 0.4 mL min-1. Unconjugated steroids and steroid 
glucuronides were monitored for the proton adduct ([M+H]+) using HESI in 
positive full scan mode at a resolution of 70,000 (FWHM). Negative mode LC-
HRAM spectrometry analysis was undertaken using a Q Exactive Hybrid 
Quadrupole-Orbitrap mass spectrometer equipped with a Phenomenex (Torrance 
CA, USA) Gemini C18 column (50 mm x 2 mm, 5 µm), eluting with a gradient 
consisting of the following mobile phases, A: aqueous ammonium acetate (0.01 M, 
pH 9.0), B: 0.1% acetic acid in acetonitrile, gradient: 0-2 min Α-Β (99:1 v/v), 2-8.5 
min Α-Β (99:1 v/v) to Α-Β (20:80 v/v), 2.7 min re-equilibration, flow rate 0.5 
mL/min. Steroid glucuronide and sulfate conjugates were monitored for the anion 
([M-H]-) using HESI in negative full-scan or targeted MS/MS mode at a resolution 
of 70,000 (FWHM). 
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4.3.2.4.2 Superdrol LC-MS analysis 
LC-MS analysis for superdrol was performed using an Agilent 1290 Infinity II LC 
system coupled to an Agilent 6545 Q-TOF mass spectrometer equipped with a 
Phenomenex Gemini C18 column (50 mm x 2 mm, 5 µm). Injections were resolved 
using the gradient outlined for negative mode LC-MS analysis in section 4.3.2.4.1.  
 
4.3.2.5 In vitro phase II metabolism 
4.3.2.5.1 In vitro phase II metabolism using PAPS 
In vitro phase II metabolism was performed by modification to a known literature 
method 2. A solution containing steroid (120 µM, 250 µL) in sodium phosphate 
buffer (100 mM, pH 7.4) and methanol (0.4%) was treated in order with the 
following solutions: aqueous magnesium chloride (1.0 M, 2.3 µL), aqueous G6P 
(100 mM, 37.5 µL), aqueous NAD (50 mM, 15 µL), aqueous NADP (50 mM, 15 µL), 
aqueous NAD-dependant G6PDH (40 units/mL, 12.5 µL), aqueous NADP-
dependant G6PDH (40 units/mL, 12.5 µL), aqueous PAPS (1.6 mM, 22.5 µL), 
additional aqueous magnesium chloride in association with PAPS (1.0 M, 2.5 µL), 
aqueous UDPGA (610 µM, 31 µL), water (74 µL), and equine liver S9 fraction 
(20 mg/mL, 25 µL). The final solution (500 µL) was then incubated in an open tube 
with agitation for 16 h at 37 oC. The reaction was quenched with acetonitrile 
(1 mL), centrifuged (2000 rpm, 5 min) to pellet solids, and the supernatant was 
decanted. Concentration of the supernatant under a stream of nitrogen at 60 oC 
afforded a residue which was reconstituted in methanol-water (5:95 v/v, 200 µL) 
and transferred to a sealed vial for subsequent LC-MS analysis as per section 
4.3.2.4. Control experiments excluding PAPS, UDPGA, both UDPGA and PAPS, all 
phase I co-factors, equine liver S9 fraction, and steroid respectively were 
performed alongside the above reaction, with addition of water or buffer as 
required to maintain a constant final reaction volume and buffer concentration. 
 
4.3.2.5.2 In vitro phase II metabolism using ATP and Na2SO4 
In vitro metabolism with ATP and sodium sulfate was performed as per section 
4.3.2.5.1 with the following substitutions: the addition of PAPS solution was 
replaced by addition of aqueous ATP (250 mM, 32 µL), aqueous sodium sulfate 
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(100 mM, 40 µL), and additional aqueous magnesium chloride (1.0 M, 5.5 µL). The 
volume of water added was reduced to maintain a constant final reaction volume 
(500 µL). Control experiments analogous to those reported in section 4.3.2.5.1 
were also performed alongside this reaction. 
 
4.3.4 Results and Discussion 
4.3.4.1 Synthesis of steroid reference materials 
The synthesis of the furazadrol reference materials used in this study has been 
discussed in Chapter 4.2 2. The chemical synthesis of superdrol reference materials 
has not been previously reported, although some of these materials have been 
tentatively identified in previous in vitro metabolism studies 5,24. The reduction of 
superdrol with sodium borohydride gave rise to a mixture of 3α/β-alcohol isomers 
16 and 17, predominately favouring the 3β-isomer 17. Axial addition to 
cyclohexanone systems by small hydride donors is well-known 25, and selectively 
affords the equatorial alcohol. In the case of superdrol however, the adjacent 
equatorial C2α-methyl substituent partially blocks approach of the incoming 
nucleophile on the α-face, and as a result the reduction is less selective, affording a 
3:1 mixture of products. On the other hand, reduction with L-Selectride®, which is 
a bulky reducing agent, exclusively gave rise to the 3α-alcohol isomer 16. The 
addition of hydride occurs exclusively on the β-face as this minimises the steric 
interaction between the reducing agent, and the ring substituents. Performing 
these reactions on the milligram-scale proceeded smoothly but unfortunately did 
not allow these isomers to be readily separated. As a result, the 3β-isomer 17 was 
prepared with a minor 3α-impurity 16 which was carried through subsequent 
reaction steps. The pure 3α-isomer 16 was used as a control to identify the 
presence of products derived from the 3β-isomer 17. 
 
Mono-sulfation of the 3α/β,17β-diols to give 3α-RSS, and mixed 3α-RSS/3β-RSS 
proceeded smoothly, and in high yield, using established methodology 23. 
Surprisingly, there appeared to be no difference in the reactivity of the two 
isomers even in the presence of the bulky C2 methyl substituent. On the other 
hand, enzymatic glucuronylation was problematic as only the 3β-isomer 
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underwent the reaction. This was highlighted by the reaction of a mixture of 3α/β-
hydroxy isomers 16/17, which afforded 2α,17α-dimethyl-5α-androstane-3β,17β-
diol 3-glucuronide 3β-RSG as the sole product after purification by SPE. Unreacted 
16 was isolated from the reaction mixture. The selectivity for the glucuronylation 
of 3β-steroid alcohols using this enzyme has been documented 21, and presumably 
reflects the substrate binding within the enzyme active site. Alternative methods 
for the synthesis of the 3α-hydroxy isomer, 3α-RSG (2α,17α-dimethyl-5α-
androstane-3α,17β-diol 3-glucuronide), such as the chemical Koenigs-Knorr 
method 26, were not attempted for this substrate due to the expense and limited 
availability of 16. 
 
4.3.4.2 In vitro phase II metabolism of superdrol  
In vitro metabolism systems are a useful alternative when in vivo studies are not 
possible due to ethical or financial constraints. One of the key criticisms of in vitro 
methods is their purported inability to adequately reflect the in vivo metabolic 
profile. To investigate these issues, the phase II equine metabolism of the designer 
steroids superdrol, and furazadrol was investigated. Metabolism data were 
examined using mass filters for predicted metabolites formed from up to three 
metabolic transformations including oxidation, reduction and hydroxylation, with 
or without subsequent sulfation or glucuronylation. Metabolite peaks were 
identified where exact masses were observed within ±10 ppm of the predicted 
mass, and by comparison with control experiments. Metabolites were also 
matched against synthesised reference materials where available. The phase II 
equine metabolism of superdrol has not been previously reported, however 
previous studies have reported the phase I metabolism of superdrol using equine 5, 
and human 24 in vitro systems, which will be used for comparison to the present 
study.  
 
Metabolism of superdrol with UDPGA, ATP, Na2SO4, and equine liver S9 fraction as 
per section 4.3.2.5.2 afforded a range of metabolites (Table 4.1). Phase I 
metabolism presumably afforded a number of steroid diol, or triol metabolites 
which are known to poorly ionise under +ESI conditions 1,27, and were 
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subsequently not detected by LC-HRAM analysis. Major phase II metabolites were 
also observed including 3β-RSS, and a reduced superdrol glucuronide metabolite 
G2, the former of which was matched to the corresponding reference material. 
Minor phase II metabolites were observed including two hydroxylated superdrol 
sulfate metabolites (S1, S2), a reduced and hydroxylated superdrol metabolite 
(S3), a superdrol glucuronide (G1), 3β-RSG, and two reduced and hydroxylated 
superdrol metabolites (G3, G4). The phase I metabolism appears to be quite 
simple, and the phase II conjugates observed appear to correlate well with the 
phase I metabolites previously reported for the equine and human in vitro studies 
5,24. Both 3β-RSS and 3β-RSG were confirmed as major and minor metabolites 
respectively by comparison to the corresponding reference materials. 
 
Interestingly however, 3α-RSS was not observed as a metabolite by comparison to 
reference materials. The tendency for C3β-reduction in the horse is well-known, as 
is the preference for sulfation to predominate in phase II, as reflected by 3β-RSS in 
the metabolite profile above. The formation of the C3β-sulfate is known to be 
favoured in horses, compared to the C3α-glucuronide that predominates in human 
metabolism 1. This is reflected in the present in vitro profile where sulfate 
metabolites are among the most intense peaks observed. The observation of G2, 
the presumed 3α-hydroxy isomer, as a major metabolite was unexpected and this 
metabolite is reasoned to form from 16, which is not subject to sulfation. 
 
The metabolism of superdrol appears to be simple however (Figure 4.2), and the 
reduced superdrol phase II metabolites appear to be the most abundant. This also 
mirrors observations made in previous phase I in vitro studies 5,24. As such, these 
metabolites would likely be among the major metabolites observed in vivo. 
Additionally, these compounds are also easily prepared from the parent compound 
superdrol, and so should be available as reference materials to assist in 
confirmation 21,23. As such, it is recommended that anti-doping laboratories 
monitor for 3β-RSS, and 2α,17α-dimethyl-5α-androstane-3α,17β-diol 3-
glucuronide (assumed to correspond to G2), or their phase I counterparts 17, and 
16, until such time as a comparative in vivo study can be undertaken.  
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Figure 4.2: Proposed in vitro equine metabolism of superdrol; AMatched to 
reference material. H, hydroxylation, R, reduction, G, glucuronylation, S, 
sulfation 
 
The use of in vitro methods to study phase II metabolism is currently limited by the 
requirements for expensive phase II co-factors, such as PAPS. This work has 
demonstrated that that ATP/Na2SO4 can be used to generate in vitro sulfate 
metabolites, and can serve as a viable alternative to study phase II metabolism. 
This methodology will now be used to study the phase II metabolism of the 
designer steroid furazadrol, with comparison to the previously reported in vivo 
study described in Chapter 4.2 2.  
131 
Table 4.1: In vitro phase II equine metabolism of superdrol 
Metabolite Precursor ion and MS/MS 
fragments (m/z) (% of base 
peak), [collision energy]A 
RT 
(min) 
A 
Precursor 
ion 
Theoretical 
m/z 
3β-RSS 399.2219 (95%), 96.9607 
(100%), [40 eV] 
5.53 B [M-H]- 399.2211 
hydroxylated superdrol 
sulfate S1 
413.1998 (60%), 96.9599 
(100%), [40 eV] 
5.03 [M-H]- 413.2003 
hydroxylated superdrol 
sulfate S2 
413.1997 (65%), 96.9597 
(100%), [40 eV] 
5.68 [M-H]- 413.2003 
reduced and 
hydroxylated superdrol 
sulfate S3 
415.2170 (100%), 96.9616 
(50%), [40 eV] 
5.03 [M-H]- 415.2160 
superdrol glucuronide 
G1 
493.2789 (40%), 317.2486 
(60%), 175.0272 (20%), 
113.0241 (40%), 85.0292 (90%), 
75.0089 (100%), [40 eV] 
5.11 [M-H]- 493.2807 
3β-RSG 495.2954 (25%), 113.0244 
(55%), 85.0296 (90%), 75.0089 
(100%), [40 eV] 
4.99  
C 
[M-H]- 495.2963 
reduced superdrol 
glucuronide G2 
495.2966 (50%), 113.0247 
(50%), 85.0296 (90%), 75.0090 
(100%), [40 eV] 
5.14 [M-H]- 495.2963 
reduced and 
hydroxylated superdrol 
glucuronide G3 
511.2906 (50%), 335.2587 
(25%), 113.0245 (50%), 85.0293 
(90%), 75.0088 (100%), [40 eV] 
4.90 [M-H]- 511.2913 
reduced and 
hydroxylated superdrol 
glucuronide G4 
511.2904 (95%), 113.0246 
(80%), 85.0293 (100%), 75.0089 
(95%), [40 eV] 
5.28 [M-H]- 511.2913 
AFrom targeted MS/MS data acquisition on the Agilent LC-MS/MS instrument using conditions 
specified for negative mode analysis (section 4.3.2.4.1). BMatched against mixed 3α-RSS and 3β-
RSS reference material. CMatched against 3β-RSG reference material 
 
4.3.4.3 In vitro phase II metabolism of furazadrol with PAPS 
The designer steroid furazadrol was the next compound to be studied. The data 
obtained from this study were compared to the recently reported phase II in vivo, 
and phase I in vitro equine metabolism studies of furazadrol, as described in 
Chapter 4.2 2. The in vitro metabolism of furazadrol using equine liver S9 fraction, 
UDPGA, and PAPS, afforded a range of metabolites, as shown below (Tables 4.2, 
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and 4.3). For reference, the numbering system for the minor metabolites M1-M16 
in this section is different to that reported in Chapter 4.2, but correlations will be 
highlighted where appropriate. 
Table 4.2: In vitro equine metabolism of furazadrol – Phase I 
Metabolite Precursor ion and MS/MS fragments 
(m/z) (% of base peak), [collision energy]A 
RT 
(min) A 
Precursor 
ion 
Theoretical 
m/z 
F 316.2270 (10%), 173.1325 (10%), 
159.1168 (15%), 145.1012 (25%), 
119.0857 (30%), 105.0702 (50%), 84.0048 
(100%), [60 eV] 
14.15 
B, G, H, I, J, 
K 
[M+H]+ 316.2271 
IF 316.2271 (45%), 288.2323 (15%), 
201.1639 (15%), 187.1482 (20%), 
159.1168 (30%), 145.1013 (60%), 
105.0702 (100%), [60 eV] 
13.76 
B, C, G, H, 
I, J, K 
[M+H]+ 316.2271 
EF 316.2272 (15%), 171.1170 (10%), 
143.0856 (30%), 105.0702 (40%), 84.0449 
(100%), [60 eV] 
14.32 
D, H, I, J, K 
[M+H]+ 316.2271 
OF 314.2115 (10%), 197.1325 (10%), 
159.1170 (20%), 145.1013 (45%), 
105.0702 (60%), 84.0449 (100%), [60 eV] 
13.68  
E, I, J, K 
[M+H]+ 314.2115 
OIF 314.2115 (30%), 286.2163 (20%), 
199.1482 (20%), 185.1326 (30%), 
157.1012 (40%), 119.0857 (60%), 
105.0702 (100%), [60 eV] 
13.41  
E, F, I, J, K 
[M+H]+ 314.2115 
hydroxylated 
furazadrol M1 
332.2220 (80%), 197.1328 (10%), 
161.1325 (20%, 145.1012 (35%), 105.0702 
(50%), 84.0448 (100%), [50 eV] 
11.27   
J 
[M+H]+ 332.2220 
hydroxylated 
furazadrol M2 
332.2220 (50%), 197.1327 (10%), 
145.1013 (20%), 105.0702 (30%), 84.0449 
(100%), [50 eV] 
11.48  
I, J, K 
[M+H]+ 332.2220 
hydroxylated 
furazadrol M3 
332.2220 (30%), 201.1639 (5%), 171.1168 
(10%), 145.1013 (20%), 105.0702 (25%), 
84.0449 (100%), [50 eV] 
11.63  
I, J, K 
[M+H]+ 332.2220 
hydroxylated 
furazadrol M4 
332.2220 (90%), 304.2270 (30%), 
185.1326 (10%), 145.1012 (20%), 
108.0811 (100%), [50 eV] 
11.91 
G, I, J, K 
[M+H]+ 332.2220 
hydroxylated 
furazadrol M5 
332.2220 (50%), 211.1484 (10%), 
171.1169 (20%), 145.1013 (40%), 
105.0702 (50%), 84.0448 (100%), [50 eV] 
12.16  
J, K 
[M+H]+ 332.2220 
hydroxylated 
furazadrol M6 
332.2219 (50%), 145.1012 (30%), 
105.0702 (30%), 84.0448 (100%), [50 eV] 
12.28  
K 
[M+H]+ 332.2220 
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hydroxylated 
furazadrol M7 
332.2218 (100%), 304.2270 (15%), 
185.1325 (15%), 145.1011 (25%), 
105.0701 (35%), [50 eV] 
12.47  
K 
[M+H]+ 332.2220 
hydroxylated 
furazadrol M8 
332.2220 (70%), 211.1480 (10%), 
171.1169 (15%), 145.1012 (25%), 
105.0702 (40%), 84.0448 (100%), [60 eV] 
12.81  
I, J, K 
[M+H]+ 332.2220 
hydroxylated 
furazadrol M9 
332.2221 (80%), 215.1432 (10%), 
197.13252 (20%), 145.1013 (30%), 
84.0449 (100%), [60 eV] 
13.12  
J, K 
[M+H]+ 332.2220 
oxidised and 
hydroxylated 
furazadrol 
M10 
330.2063 (100%), 288.1949 (15%), 
199.1484 (25%), 159.1169 (55%), 84.0449 
(65%), [50 eV] 
10.35   
J 
[M+H]+ 330.2064 
oxidised and 
hydroxylated 
furazadrol 
M11 
330.2060 (15%), 300.1957 (75%), 
240.2684 (10%), 201.1273 (15%), 
143.0855 (15%), 105.0702 (25%), 84.0448 
(100%), [50 eV] 
12.03  
K 
[M+H]+ 330.2064 
oxidised and 
hydroxylated 
furazadrol 
M12 
330.2063 (45%), 288.1955 (15%), 
185.1326 (15%), 145.1013 (30%), 84.0448 
(100%), [60 eV] 
12.16  
J, K 
[M+H]+ 330.2064 
dihydroxylated 
furazadrol 
M13 
348.2158 (20%), 183.1165 (5%), 157.1008 
(15%), 112.0392 (25%), 84.0446 (100%), 
[50 eV] 
8.92     
J, K 
[M+H]+ 348.2169 
dihydroxylated 
furazadrol 
M14 
348.2156 (25%), 209.1313 (5%), 159.1165 
(10%), 105.0698 (20%), 84.0446 (100%), 
[50 eV] 
9.75     
J 
[M+H]+ 348.2169 
dihydroxylated 
furazadrol 
M15 
348.2157 (25%), 183.1162 (5%), 145.1007 
(10%), 112.0392 (30%), 84.0446 (100%), 
[50 eV] 
10.24   
J, K 
[M+H]+ 348.2169 
dihydroxylated 
furazadrol 
M16 
348.2159 (20%), 237.1633 (5%), 197.1319 
(10%), 155.0850 (15%), 105.0699 (25%), 
84.0446 (100%), [50 eV] 
10.78   
J, K 
[M+H]+ 348.2169 
AFrom targeted MS/MS data acquisition on the Q Exactive instrument using conditions specified for 
positive mode analysis (section 4.3.2.4.1). BMatched with mixed F and IF reference material. 
CMatched with IF reference material. DMatched with mixed EF and EIF reference material. EMatched 
with mixed OF and OIF reference material. FMatched with OIF reference material. GMatched with 
metabolite identified in in vivo samples after P. aeruginosa arylsulfatase hydrolysis. HMatched with 
metabolite identified in in vivo samples after E. coli β-glucuronidase hydrolysis. IMatched with 
metabolite identified in previously reported phase I in vitro study (Ref 2). JMetabolite observed 
from in vitro metabolism with UDPGA and PAPS. KMetabolite observed from in vitro metabolism 
with UDPGA, ATP, and Na2SO4.   
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Table 4.3: In vitro equine metabolism of furazadrol – Phase II 
Metabolite Precursor ion and MS/MS 
fragments (m/z) (% of base peak), 
[collision energy]A 
RT 
(min) A 
Precursor 
ion 
Theoretical 
m/z 
FS 394.1624 (10%), 96.9573 (100%), 
[60 eV] 
6.27    
B, G, H, I 
[M-H]- 394.1683 
IFS 394.1624 (20%), 96.9573 (100%), 
[60 eV] 
6.13    
B, C, G, H, I 
[M-H]- 394.1683 
hydroxylated 
furazadrol 
sulfate S1 
410.1636 (30%), 330.2068 (30%), 
96.9589 (100%), [40 eV] 
5.07    
H, I 
[M-H]- 410.1632 
hydroxylated 
furazadrol 
sulfate S2 
410.1633 (100%), 364.1584 (40%), 
96.9589 (50%), [40 eV] 
5.13    
G, H, I 
[M-H]- 410.1632 
hydroxylated 
furazadrol 
sulfate S3 
410.1637 (100%), 334.1987 (10%), 
96.9586 (50%), [40 eV] 
5.21    
H, I 
[M-H]- 410.1632 
hydroxylated 
furazadrol 
sulfate S4 
410.1644 (60%), 330.2069 (15%), 
96.9589 (100%), [40 eV] 
5.41    
H, I 
[M-H]- 410.1632 
hydroxylated 
furazadrol 
sulfate S5 
410.1638 (75%), 96.9588 (100%), 
[40 eV] 
5.72    
H, I 
[M-H]- 410.1632 
hydroxylated 
furazadrol 
sulfate S6 
410.1571 (55%), 328.1861 (10%), 
96.9574 (100%), [60 eV] 
5.89    
H, I 
[M-H]- 410.1632 
oxidised and 
hydroxylated 
furazadrol 
sulfate S7 
408.1481 (20%), 328.1907 (25%), 
96.9589 (100%), [40 eV] 
5.41    
H 
[M-H]- 408.1475 
oxidised and 
hydroxylated 
furazadrol 
sulfate S8 
408.1479 (100%), 96.9589 (50%), 
79.9561 (50%), [40 eV] 
5.79    
G, I 
[M-H]- 408.1475 
FG 492.2589 (70%), 316.2269 (90%), 
199.1479 (20%), 141.0181 (35%), 
113.0234 (45%), 84.0447 (100%), 
[40 eV] 
13.96 
D, G, I, J, H, 
I 
[M+H]+ 492.2592 
 
IFG 492.2583 (15%), 316.2266 (70%), 
288.2319 (30%), 187.1480 (20%), 
141.0181 (40%), 113.0234 (55%), 
85.0287 (100%), [50 eV] 
13.46 
D, E, G, H, I 
[M+H]+ 492.2592 
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EFG 492.2588 (50%), 316.2268 (55%), 
298.2160 (100%), 217.0315 (20%), 
159.0285 (10%), [30 eV] 
14.35  
F, G, H, I 
[M+H]+ 492.2592 
 
hydroxylated 
furazadrol 
glucuronide G1 
508.2538 (40%), 332.2220 (20%), 
304.2266 (20%), 199.1476 (10%), 
141.0181 (55%), 84.0448 (100%), 
[40 eV] 
10.57   
H 
[M+H]+ 508.2541 
hydroxylated 
furazadrol 
glucuronide G2 
508.2539 (35%), 332.2217 (70%), 
197.1318 (10%), 136.0617 (100%), 
[40 eV] 
11.16  
H 
[M+H]+ 508.2541 
hydroxylated 
furazadrol 
glucuronide G3 
508.2544 (10%), 332.2216 (100%), 
296.2005 (50%), 197.1324 (20%), 
136.0616 (45%), 84.0448 (80%), 
[40 eV] 
11.37 
H, I 
[M+H]+ 508.2541 
hydroxylated 
furazadrol 
glucuronide G4 
508.2534 (45%), 332.2213 (50%), 
293.2103 (10%), 197.1322 (10%), 
136.0617 (100%), [40 eV] 
12.64  
H 
[M+H]+ 508.2541 
hydroxylated 
furazadrol 
glucuronide G5 
508.2525 (55%), 332.2220 (40%), 
296.2001 (10%), 184.0732 (15%), 
136.0618 (100%), [30 eV] 
13.47   
I 
[M+H]+ 508.2541 
hydroxylated 
furazadrol 
glucuronide G6 
508.2534 (25%), 332.2216 (75%), 
296.2005 (10%), 197.1326 (10%), 
141.0181 (100%), [40 eV] 
13.53   
H 
[M+H]+ 508.2541 
oxidised and 
hydroxylated 
furazadrol 
glucuronide G7 
506.2390 (10%), 136.0618 (100%), 
[30 eV] 
11.29   
I 
[M+H]+ 506.2385  
oxidised and 
hydroxylated 
furazadrol 
glucuronide G8 
506.2386 (35%), 330.2063 (65%), 
294.1851 (30%), 136.0618 (100%), 
[30 eV] 
12.28   
I 
[M+H]+ 506.2385  
oxidised and 
hydroxylated 
furazadrol 
glucuronide G9 
506.2376 (55%), 330.2059 (100%), 
294.1849 (40%), 242.1537 (10%), 
141.0181 (50%), [30 eV] 
12.34   
H 
[M+H]+ 506.2385  
oxidised and 
hydroxylated 
furazadrol 
glucuronide G10 
506.2393 (30%), 330.2058 (55%), 
300.1955 (70%), 201.1275 (20%), 
136.0618 (100%), [40 eV] 
12.47  
H, I 
[M+H]+ 506.2385  
AFrom targeted MS/MS data acquisition on the Q Exactive instrument using conditions specified for 
positive mode or negative mode analysis as specified (section 4.3.2.4.1). BMatched against mixed FS 
and IFS reference material. CMatched against IFS reference material. DMatched against mixed FG 
and IFG reference material. EMatched against IFG reference material. FMatched against mixed EFG 
and epiisofurazadrol 17-glucuronide reference material. GMatched with in vivo metabolite (Ref 2). 
HMetabolite observed from in vitro metabolism with UDPGA and PAPS. IMetabolite observed from 
in vitro metabolism with UDPGA, ATP, and Na2SO4. 
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Major phase I metabolites were observed including F, IF, EF, OF, and OIF which 
were matched to reference materials. Additionally, a number of unidentified minor 
phase I metabolites were observed by positive mode LC-HRAM analysis including 
seven hydroxylated metabolites (M1-M5, M8, M9), two oxidised and hydroxylated 
metabolites (M10, M12), and four dihydroxylated metabolites (M13-M16). Of 
these metabolites, F, IF, EF, OF, OIF, M2-M4, and M8 were identified as matches 
with our previously reported phase I study by comparison of their retention times 
and mass spectrometry behaviour. The extent of phase I metabolism in the present 
study appeared to be greater than the previously reported phase I study 2. The 
present study used a combination of NADH and NADPH co-factors, in contrast to 
the previous study which used only NADH, which could explain the minor increase 
in hydroxylated metabolites identified in the present study. Metabolite M4 was 
also observed to match a phase I metabolite (matches M3 in Chapter 4.2) which 
was observed after P. aeruginosa arylsulfatase hydrolysis of in vivo samples. Major 
phase II metabolites were also observed including FS, IFS, FG, IFG, and EFG which 
were matched to reference materials. EFS was not observed by comparison to 
reference material, which also reflects observations from the in vivo study. 
Additionally, a number of minor unidentified phase II metabolites were observed 
including six hydroxylated furazadrol sulfate metabolites (S1-S6), one oxidised 
and hydroxylated furazadrol sulfate metabolite (S7), five hydroxylated furazadrol 
glucuronide metabolites (G1-G4, G6), and two oxidised and hydroxylated 
furazadrol glucuronide metabolites (G9, G10). The overall number of phase II 
metabolites agreed well with the number of observed phase I metabolites. Of these 
metabolites, FS, IFS, FG, IFG, EFG, and S2 (matches S1 in Chapter 4.2) were 
identified as matches with the previously reported in vivo study.  
 
A comparison of the study previously reported in Chapter 4.2 with the present 
study is outlined below (Table 4.4). Briefly, the major phase I metabolites F, IF, EF, 
OF, and OIF have been identified in both studies. The phase I profile of the minor 
metabolites in these studies also appears to be similar, with only minor differences 
observed. The major phase II metabolites FS, IFS, FG, IFG, and EFG have been 
identified in both studies (Table 4.5), and the lack of EFS is common to both in vivo 
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and in vitro systems. The in vitro studies appear to generate significantly more 
minor phase II metabolites compared to those observed in vivo. 
 
Table 4.4: Comparison of in vivo and in vitro (UDPGA and PAPS) metabolism 
of furazadrol 
Metabolic 
transformation 
Chapter 4.2         
Phase I in vitro 
Chapter 4.3 
Phase I in vitro 
Chapter 4.2 
Phase II in vivo 
Chapter 4.3 
Phase II in vitro 
furazadrol 
(major) 
F, IF, EF F, IF, EF, FS, IFS, FG, IFG, 
EFG 
FS, IFS, FG, IFG, 
EFG 
oxidised 
furazadrol 
(major) 
OF, OIF OF, OIF   
hydroxylated 
furazadrol 
(minor) 
(x 8) (x 7)                 
M1-M5, M8, M9 
sulfate (x 1) sulfate (x 6)          
S1-S6              
glucuronide (x 5) 
G1-G4, G6 
oxidised and 
hydroxylated 
furazadrol 
(minor) 
(x 1) (x 2)                   
M10, M12 
sulfate (x 2) 
glucuronide (x 2) 
sulfate (x 1)                
S7             
glucuronide (x 2) 
G9, G10 
dihydroxylated 
furazadrol 
(minor) 
(x 2) (x 4)                 
M13-M16 
  
 
Table 4.5: Comparison of in vivo and in vitro (UDPGA, ATP, and Na2SO4) 
metabolism of furazadrol 
Metabolic 
transformation 
Chapter 4.2         
Phase I in vitro 
Chapter 4.3 
Phase I in vitro 
Chapter 4.2 
Phase II in vivo 
Chapter 4.3 
Phase II in vitro 
furazadrol 
(major) 
F, IF, EF F, IF, EF, FS, IFS, FG, IFG, 
EFG 
FS, IFS, FG, IFG, 
EFG 
oxidised 
furazadrol 
(major) 
OF, OIF OF, OIF   
hydroxylated 
furazadrol 
(minor) 
(x 8) (x 8)                      
M2-M9 
sulfate (x 1) sulfate (x 6)          
S1-S6              
glucuronide (x 2) 
G3, G5 
oxidised and 
hydroxylated 
furazadrol 
(minor) 
(x 1) (x 2)                   
M11, M12 
sulfate (x 2) 
glucuronide (x 2) 
sulfate (x 1)                
S8             
glucuronide (x 3) 
G7, G8, G10 
dihydroxylated 
furazadrol 
(minor) 
(x 2) (x 3)                
M13, M15, M16 
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4.3.4.4 Comparison of PAPS and ATP/Na2SO4 for the generation of 
phase II in vitro sulfate metabolites 
Due to the high cost to purchase PAPS we elected to investigate conditions which 
would allow for comparable sulfation using more readily available reagents, as 
discussed in the introduction. Optimal conditions for in vitro phase II steroid 
sulfation were previously developed by Ms Ling Fam during an undergraduate 
research project in the McLeod Group 20, and were employed for the phase II in 
vitro metabolism of furazadrol. 
 
The phase II in vitro metabolism of furazadrol using UDPGA, ATP and Na2SO4 
proceeded similarly to metabolism using UDPGA and PAPS (Tables 4.3, and 4.3). 
Major phase I metabolites were observed including F, IF, EF, OF, and OIF, which 
were matched to reference materials. Additional minor phase I metabolites were 
observed, including eight hydroxylated metabolites (M2-M9), two oxidised and 
hydroxylated metabolites (M11, M12), and three dihydroxylated metabolites 
(M13, M15, M16). Of these metabolites, F, IF, EF, OF, OIF, M2-M4, and M8 were 
identified as matches with the phase I study reported in Chapter 4.2 2. Metabolite 
M4 (matches M3 in Chapter 4.2) was also observed to match the phase I 
metabolite which was identified after P. aeruginosa arylsulfatase hydrolysis of the 
in vivo samples. A comparison of the phase I metabolites observed using both 
PAPS, and ATP/Na2SO4 in vitro systems indicated that a majority of the metabolites 
were common. The major phase I metabolites F, IF, EF, OF, and OIF were common 
to both systems. The minor phase I metabolites also appeared to correlate well 
between systems (M2-M5, M8, M9, M12, M13, M15, and M16 were common), 
with a few exceptions. The number of phase I metabolites observed did not appear 
to change significantly in control experiments where phase II co-factors were 
excluded, suggesting that phase II metabolism was occurring after phase I 
metabolism had occurred, and was not altering the phase I profile. 
 
Major phase II metabolites were also observed including FS, IFS, FG, IFG, and EFG 
which were matched to reference materials. EFS was not observed by comparison 
to the reference material. Additionally, minor phase II metabolites were observed 
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including six hydroxylated furazadrol sulfate metabolites (S1-S6), one oxidised 
and hydroxylated furazadrol sulfate metabolite (S8), two hydroxylated furazadrol 
glucuronide metabolites (G3, G5), and three oxidised and hydroxylated furazadrol 
glucuronide metabolites (G7, G8, G10). The overall number of phase II metabolites 
agreed well with the number of observed phase I metabolites. Of these 
metabolites, FS, IFS, FG, IFG, EFG, and S8 (matches S3 in Chapter 4.2) were 
identified as matches with the previously reported in vivo study.  
 
A comparison of the phase II metabolites observed using both PAPS and 
ATP/Na2SO4 in vitro systems (Tables 5, and 6) also indicated that a majority of the 
metabolites were common. The major phase II metabolites FS, IFS, FG, IFG, and 
EFG were common to both systems. In both instances EFS was not observed, which 
agreed with observations from the in vivo study 2. Of particular interest are 
metabolites S2, and S8, which were both observed in the previous in vivo study 
(matches S1, and S3 in Chapter 4.2 respectively). Metabolite S8 was not formed in 
the corresponding in vitro study employing PAPS, in contrast to S2 which was only 
observed with PAPS, suggesting that ATP/Na2SO4 may be a better choice for 
generating some in vivo metabolites. 
 
Although the majority of the sulfate metabolites were also common to both 
systems, the minor phase II metabolites appeared to vary between systems, 
particularly for the glucuronides (S1-S6, G3, G10 were common). The differences 
in the glucuronide profile could potentially be attributed to the different sulfation 
reagents used in these systems, and this issue was not explored in the present 
study. In the experiment utilising PAPS, the co-factors are added at the start of the 
metabolism reaction, and PAPS is then consumed by the reaction, or decays in 
solution over time. This results in in a burst of phase II metabolism towards the 
beginning of the metabolism reaction, which levels off relatively quickly. This is in 
contrast to the experiments utilising ATP/Na2SO4 in which there is an initial lag to 
phase II metabolism as PAPS has to be generated in situ. Once PAPS is generated 
however, there is significantly more phase II metabolism occurring, and the 
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resulting metabolism reaction lasts for a longer period until all the ATP is 
consumed.  
 
It appears that the substitution of PAPS with ATP/Na2SO4 is capable of generating 
comparable in vitro metabolic profiles, and can serve as a cheaper alternative for 
the generation of phase II in vitro sulfate metabolites. The major metabolites FS, 
IFS, FG, IFG, and EFG, which represent the most useful markers for anti-doping 
screening were all detected at much higher levels (ion counts ~107-108) than the 
corresponding minor phase II metabolites in these studies (ion counts ~105-106). 
On the other hand, the minor in vivo metabolites S2, and S8 would likely be 
difficult to distinguish from the other minor phase II metabolites observed in vitro. 
In the absence of in vivo data, the major metabolites would likely be considered the 
most important metabolites and targeted by anti-doping laboratories, however in 
more complicated systems it may be difficult to distinguish between major and 
minor metabolites, and as such limit the ability to predict the predominate in vivo 
metabolites. Although it could be argued from these results that these conditions 
are capable of generating an adequate representation of the in vivo profile, further 
work could be targeted towards refining these conditions, allowing for the 
unambiguous determination of the entire in vivo profile solely from in vitro results. 
This is particularly important as current AORC criteria currently allow for the use 
of in vitro-derived materials as reference materials in confirmatory analysis 4, and 
being able to accurately reflect the in vivo profile using in vitro techniques could 
allow additional instances of anabolic steroid misuse to be confirmed through the 
use of these reference materials. 
 
4.3.5 Conclusions 
In vitro technologies offer an opportunity to study the metabolism of steroid 
compounds that may not otherwise be able to be studied in vivo due to ethical or 
financial constraints. The data gained from these studies may assist anti-doping 
laboratories in developing protocols to allow detection of compounds that may 
otherwise pass undetected through routine screening. The in vitro phase II 
metabolism of the designer steroids furazadrol, and superdrol has been 
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investigated. The observed metabolites of superdrol have been recommended as 
suitable screening markers until a comparative in vivo study can be undertaken. 
The observed metabolites of furazadrol have been shown to correlate well with the 
metabolites observed in a previously reported in vivo study. Alternate conditions 
for in vitro phase II sulfation employing ATP/Na2SO4 in place of the expensive 
phase II co-factor PAPS were also explored, and in the case of the designer steroid 
furazadrol was found to offer comparable metabolism. The ability of these systems 
to replicate in vivo results has been shown through the identification of the major 
equine in vivo metabolites of furazadrol in the phase II in vitro study. Although 
some of the minor in vivo metabolites were also identified in this work, the ability 
of these systems to fully replicate in vivo metabolism for the minor metabolites is 
currently limited, and it is hoped that future work will afford the ability to 
accurately predict the in vivo metabolism of unknown compounds solely from in 
vitro results. 
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CHAPTER FIVE 
 
 
Hemapolin 
2α,3α-epithio-17α-methyl-5α-androstan-17β-ol 
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This chapter presents unpublished work which is the subject of a manuscript 
currently in preparation. Supporting information relevant to this chapter is 
presented electronically alongside this thesis. 
 
5.1 In vivo metabolism of the designer anabolic steroid hemapolin 
in thoroughbred racehorses 
5.1.1 Introduction 
Hemapolin (2α,3α-epithio-17α-methyl-5α-androstan-17β-ol, called H in this work) 
is unique in that it possesses a 2,3-episulfide; a motif that is not often encountered 
by chemists due to its rarity in nature, chemical instability, the unpleasant odour 
often associated with its compounds or decomposition products, as well as a 
general lack of reliable methodology for its synthesis 1. Hemapolin is also a 
designer steroid which has been detected in “dietary” supplements such as those 
marketed by Black China Labs 2, and StarMark Laboratories 3. It is also marketed as 
a component of the supplements EPISTANE™ (Innovative Body Enhancement), and 
P-PLEX™ (Competitive Edge Labs), however a study has reported that these 
supplements labelled to contain H instead contain the related compounds: 2β,3β-
epithio-17α-methyl-5α-androstan-17β-ol, madol (M, desoxymethyltestosterone, 
17α-methyl-5α-androst-2-en-17β-ol), and 17α-methyl-5α-androst-3-en-17β-ol 4. 
Hemapolin has also been reported to exert significant anabolic activity in yeast and 
human HuH7 androgen bioassays 3, as well as predicted activity in recent 
computational QSAR models 5. Hemapolin and related epithio-containing steroids 
are banned in competition by the World Anti-Doping Agency (WADA), and the 
International Federation of Horseracing Authorities (IFHA) as they have similar 
chemical structures and biological effects to other banned AAS 6,7. 
 
The metabolism of H has not been previously reported, highlighting the need for 
this work. To this end, the equine metabolism of this compound was investigated 
through use of an in vivo drug administration study, with major metabolites 
matched against an extensive library of synthetically derived reference materials. 
This metabolic profiling study provides anti-doping laboratories with the 
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information required to establish routine screening methods which allow for the 
detection of H misuse in horses.  
 
5.1.2 Experimental  
5.1.2.1 Materials 
Chemicals and solvents including N-bromosuccinimide (NBS), 
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 4-toluenesulfonyl chloride (TsCl), 
pyridinium chlorochromate (PCC), anhydrous N,N-dimethylformamide (DMF), 
phenyltrimethylammonium tribromide (PTAB), sulfur-trioxide pyridine complex 
(SO3.py), N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA), dithiothreitol 
(DTT), and n-dodecane were purchased from Sigma–Aldrich (Castle Hill, 
Australia), and were used as supplied unless otherwise stated. Aqueous perchloric 
acid solution, formic acid, and pyridine were purchased from Ajax Chemicals 
(Auburn, Australia). 1,4-Dioxane (dioxane), ethyl acetate (EtOAc), methanol 
(MeOH), petroleum spirit (bp 40-60 oC, hexanes), and diisopropyl ether (DIPE), 
were purchased from Merck (Darmstadt, Germany). Aqueous hydrogen peroxide 
solution was purchased from Chem-Supply (Gillman, Australia). Epiandrosterone 
(3β-hydroxy-5α-androstan-17-one), mestanolone (17β-hydroxy-17α-methyl-5α-
androstan-3-one), and 17α-methyltestosterone (17β-hydroxy-17α-methylandrost-
4-en-3-one) were purchased from Steraloids (Newport RI, USA). 16,16,17-d3-
Testosterone, 16,16,17-d3-testosterone 17-glucuronide, and 16,16,17-d3-
testosterone 17-sulfate were purchased from the National Measurement Institute 
(North Ryde, Australia). NBS was recrystallised from water and dried thoroughly 
under vacuum before use. Tetrahydrofuran (THF) was distilled from sodium wire 
before use. TsCl was purified before use according to literature methods 8. 
3,3-Dimethyldioxirane (DMDO) was prepared as a solution in acetone according to 
literature methods and titrated immediately before use 9,10. MilliQ water was used 
in all aqueous solutions. Solid-phase extraction (SPE) was performed using Waters 
(Rydalmere, Australia) Oasis WAX 6cc cartridges (PN 186004647), Waters Oasis 
WAX (60 mg, 3 cc, 30 µm) cartridges (PN 186002490), Waters Sep-Pak C18 (3 cc, 
500 mg) cartridges (PN WAT020805), UCT (Bristol, USA) Xtrackt (200 mg, 3 mL) 
cartridges (PN XRDAH203), or Agilent (Santa Clara, USA) Bond-Elute NEXUS (60 
mg, 3 mL) cartridges (PN 12103101) as specified.  
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5.1.2.2 Instruments 
Melting points were determined using a SRS (Sunnyvale CA, USA) Optimelt MPA 
100 melting point apparatus and are uncorrected. Optical rotations were 
determined using a Perkin-Elmer (Waltham, USA) Model 343 polarimeter (sodium 
D line, 298 K) in the indicated solvents. 1H and 13C nuclear magnetic resonance 
(NMR) spectra were recorded using either Bruker Ascend 400 MHz or Bruker 
Ascend 800 MHz spectrometers at 298 K using deuterated chloroform or 
deuterated methanol solvent. Data is reported in parts per million (ppm), 
referenced to residual protons or 13C in deuterated chloroform (CDCl3: 1H 7.26 
ppm, 13C 77.16 ppm) or methanol (CD3OD: 1H 3.31 ppm, 13C 49.0 ppm) unless 
otherwise specified, with multiplicity assigned as follows: br = broad, s = singlet, 
d = doublet, dd = doublet of doublets, ddd = doublet of doublet of doublets, dt = 
doublet of triplets, t = triplet, q = quartet, m = multiplet. Coupling constants J are 
reported in Hertz. Low-resolution mass spectrometry (LRMS) and high-resolution 
mass spectrometry (HRMS) for reference material characterisation were 
performed using positive electron ionisation (+EI) on a Micromass VG Autospec 
mass spectrometer or negative electrospray ionization (–ESI) on a Micromass ZMD 
ESI-Quad, or a Waters LCT Premier XE mass spectrometer. Reactions were 
monitored by analytical thin layer chromatography (TLC) using Merck Silica gel 60 
TLC plates using solvents as specified and were visualised by staining with a 
solution of concentrated sulfuric acid in methanol (5% v/v), with heating as 
required.  
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5.1.2.3 Hemapolin reference materials 
An extensive range of hemapolin reference materials were employed to aid the 
identification of phase I, and phase II metabolites. These were hemapolin H, madol 
M, 17β-hydroxy-17α-methyl-5α-androst-2-en-1-one E1, 17β-hydroxy-17α-methyl-5α-
androst-3-en-2-one E2, 17β-hydroxy-17α-methyl-5α-androst-1-en-3-one E3, 17β-
hydroxy-17α-methyl-5α-androst-2-en-4-one E4, 17α-methyltestosterone E5, 17α-
methyl-5α-androst-2-ene-1α,17β-diol D1, 17α-methyl-5α-androst-2-ene-1β,17β-diol 
D2, 17α-methyl-5α-androst-3-ene-2α,17β-diol D3, 17α-methyl-5α-androst-3-ene-
2β,17β-diol D4, 17α-methyl-5α-androst-1-ene-3α,17β-diol D5, 17α-methyl-5α-
androst-1-ene-3β,17β-diol D6, 17α-methyl-5α-androst-2-ene-4α,17β-diol D7, 17α-
methyl-5α-androst-2-ene-4β,17β-diol D8, 17α-methylandrost-4-ene-3α,17β-diol D9, 
17α-methylandrost-4-ene-3β,17β-diol D10, hemapolin S-oxide HS, and madol 17-
sulfate MS. The structures of these compounds are outlined in the supporting 
information, together with experimental procedures, characterisation data, and 
copies of the 1H NMR, 13C NMR, and +EI LRMS or -ESI LRMS where appropriate.  
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5.1.2.3.1 Epiandrosterone 3-tosylate (18) 11–13 
A solution of epiandrosterone (10.075 g, 34.7 
mmol) in pyridine (100 mL) was added to a 
flask containing TsCl (10.043 g, 52.7 mmol, 1.5 
eq) and was stirred at room temperature for 16 
h. The reaction was then diluted with water (500 mL) and the solid that formed 
collected by filtration. The crude tosylate was then purified by recrystallisation 
from acetone to afford the title compound 18 (14.202 g, 92%) as small white 
needles. Rf 0.56 (40% EtOAc/hexanes); mp 159-162 oC (lit 12 164-165 oC); [α]25D 
+50 (c 1, CHCl3) (lit 11 [α]25D +46 [CHCl3]); 1H NMR (400 MHz, CDCl3): 7.79 (d, J 8.2 
Hz, 2H, C21-H), 7.32 (d, J 8.2 Hz, 2H, C22-H), 4.41 (m, 1H, C3-H), 2.44 (s, 3H, C24-
H3), 2.43 (dd, J 8.8 Hz, 19.4 Hz, 1H, C16-H), 1.94-0.61 (m, 21H), 0.84 (s, 3H, C18-
H3), 0.80 (s, 3H, C19-H3); 13C NMR (100 MHz, CDCl3): 221.1 (C17), 144.5 (C20), 
134.8 (C23), 129.8 (C21), 127.7 (C22), 82.3 (C3), 54.3, 51.4, 47.8, 44.9, 36.8, 35.9, 
35.5, 35.0, 34.9, 31.6, 30.8, 28.4, 28.2, 21.8, 21.7 (C24), 20.5, 13.9 (C18), 12.2 (C19); 
LRMS (+EI): m/z 444 (15%, [C26H36O4S]+
●), 273 (20%), 272 (100%), 257 (25%), 
218 (95%), 190 (30%), 172 (45%), 161 (25%), 147 (20%), 122 (20%), 108 (45%), 
107 (70%), 93 (35%), 91 (100%), 79 (40%), 67 (25%), 55 (25%); HRMS (+EI): 
found 444.2340, [C26H36O4S]+
● requires 444.2334. 
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5.1.2.3.2 5α-androst-2-en-17-one (19) 14–16 
A solution of epiandrosterone 3-tosylate 18 (4.874 g, 11.0 
mmol) in DBU (25 mL, 167 mmol, 15.2 eq) under a nitrogen 
atmosphere was brought to reflux and stirred for 16 h. The 
reaction was diluted with ethyl acetate (200 mL) and washed 
with a solution of aqueous hydrochloric acid (2 M, 2 x 200 mL). The aqueous phase 
was then re-extracted with additional ethyl acetate (2 x 200 mL). The combined 
organic extract was then washed with water (200 mL), saturated aqueous sodium 
chloride solution (200 mL), dried with anhydrous magnesium sulfate and 
concentrated in vacuo. Purification of the crude residue by column 
chromatography (10% EtOAc/hexanes) afforded the title compound 19 (1.494 g, 
50%) as a 95:5 inseparable mixture of Δ2-3 and Δ3-4 alkene isomers. Data is 
reported for the major isomer where appropriate. Rf 0.74 (40% EtOAc/hexanes); 
mp 96-103 oC (lit 14 92-96 oC); [α]25D +163 (c 0.9, CHCl3) (lit 15 +153 [CHCl3]);1H 
NMR (400 MHz, CDCl3): 5.64-5.55 (m, 2H, C2-H and C3-H), 2.44 (dd, J 9.1 Hz, 18.9 
Hz, 1H, C16-H), 2.11-0.73 (m, 19H), 0.87 (s, 3H, C18-H3), 0.78 (s, 3H, C19-H3); 13C 
NMR (100 MHz, CDCl3): 221.4 (C17), 125.7 (2 peaks, C2 and C3), 54.2, 54.5, 47.7, 
41.4, 39.7, 35.8, 35.1, 34.8, 31.6, 30.7, 30.2, 28.4, 21.8, 20.2, 13.7 (C18), 11.7 (C19); 
LRMS (+EI): 272 (75%, [C19H28O]+
●), 219 (25%), 218 (100%), 190 (40%), 161 
(25%), 147 (15%), 122 (20%), 106 (20%), 93 (20%), 91 (25%), 79 (20%), 67 
(15%), 55 (15%); HRMS (+EI): found 272.2139, [C19H28O]+
● requires 272.2140. 
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5.1.2.3.3 17α-methyl-5α-androst-2-en-17β-ol (madol, M) 17,18 
A solution of 5α-androst-2-en-17-one 19 (1.027 g, 3.77 mmol, 
95:5 inseparable mixture of Δ2-3 and Δ3-4 alkene isomers) in 
dry THF (13 mL) under an atmosphere of nitrogen was treated 
with a solution of methylmagnesium bromide in diethyl ether 
(3.0 M, 7.0 mL, 21.0 mmol, 5.6 eq) and stirred at room temperature 16 h. The 
reaction was diluted with ethyl acetate (100 mL) and washed with saturated 
aqueous ammonium chloride solution (100 mL), water (100 mL), saturated 
aqueous sodium chloride solution (100 mL), dried with anhydrous magnesium 
sulfate and concentrated in vacuo. The crude residue was purified by column 
chromatography (30% EtOAc/hexanes) to afford the title compound M (834 mg, 
77%) as a 95:5 inseparable mixture of Δ2-3 and Δ3-4 alkene isomers. Data is 
reported for the major isomer where appropriate. Rf 0.59 (40% EtOAc/hexanes); 
mp 145-150 oC (lit 17 154-155 oC); [α]25D +53 (c 0.8, CHCl3); 1H NMR (800 MHz, 
CDCl3): 5.60 (m, 1H, C3-H), 5.58 (m, 1H, C2-H), 1.94 (m, 1H, C1-H), 1.86 (m, 1H, C4-
H), 1.80 (ddd, J 3.1 Hz, 11.6, Hz, 12.8 Hz, 1H, C16-H), 1.74-1.65 (m, 4H, C1-H, C4-H, 
C16-H, and C7 -H), 1.59-1.52 (m, 2H, C15-H, and C11-H), 1.48 (m, 1H, C12-H), 1.42 
(m, 1H, C6-H), 1.39-1.33 (m, 3H, C5-H, C8-H, and C11-H), 1.28-1.23 (m, 2H, C15-H, 
and C12-H), 1.21 (s, 3H, C20-H3), 1.18-1.10 (m, 2H, C14-H, and C6-H), 0.86 (m, 1H, 
C7-H), 0.85 (s, 3H, C18-H3), 0.77 (s, 3H, C19-H3), 0.68 (m, 1H, C9-H), OH not 
observed; 13C NMR (200 MHz, CDCl3): 126.0 (2 peaks, C2 and C3), 81.9 (C17), 54.3 
(C9), 50.8 (C14), 45.7 (C13), 41.7 (C5), 40.0 (C1), 39.1 (C16), 36.7 (C8), 34.9 (C10), 
31.8 (C12), 31.7 (C7), 34.5 (C4), 28.8 (C6), 25.9 (C20), 23.4 (C15), 20.7 (C11), 14.1 
(C18), 11.9 (C19); LRMS (+EI): 288 (55%, [C20H32O]+
●), 270 (30%), 255 (30%), 234 
(65%), 230 (100%), 216 (75%), 215 (60%), 201 (25%), 176 (70%), 161 (55%), 
147 (55%), 135 (30%), 108 (40%), 107 (40%), 106 (75%); HRMS (+EI): found 
288.2455, [C20H32O]+
● requires 288.2453. 
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5.1.2.3.4 17α-methyl-5α-androstan-3β,17β-diol (20) 19–21 
A solution of epiandrosterone (2.020 g, 6.95 mmol) in dry 
THF (58 mL) under an atmosphere of nitrogen was 
treated slowly with a solution of methylmagnesium 
bromide in diethyl ether (3.0 M, 10.0 mL, 30.0 mmol, 4.3 
eq) and stirred at room temperature for 18 h. The reaction was diluted with ethyl 
acetate (100 mL), washed with saturated aqueous ammonium chloride solution 
(100 ml), water (100 mL), saturated aqueous sodium chloride solution (100 mL), 
dried with anhydrous magnesium sulfate and concentrated in vacuo. The crude 
residue was purified by column chromatography (40% EtOAc/hexanes) to afford 
the title compound 20 (1.738 g, 82%) as a white solid. Rf 0.57 (40% 
EtOAc/hexanes), mp 164-167 oC (lit 19 165-168 oC); [α]25D +20 (c 0.7, CHCl3) (lit 19 
[α]25D +20 [CHCl3]); 1H NMR (400 MHz, CDCl3): 3.59 (m, 1H, C3-H), 1.82-0.61 (m, 
22H), 1.21 (s, 3H, C20-H3), 0.85 (s, 3H, C18-H3), 0.83 (s, 3H, C19-H3), 2 x OH not 
observed; 13C NMR (100 MHz, CDCl3): 81.9 (C20), 71.5 (C3), 54.6, 50.8, 45.1, 39.2, 
38.3, 37.2, 36.5, 35.7, 32.0, 31.8, 31.7, 28.8, 25.9 (C20), 23.4, 21.0, 14.1 (C18), 12.5 
(C19), one carbon overlapping or obscured; LRMS (+EI): m/z 306 (35%, 
[C20H34O2]+
●), 291 (75%), 273 (100%), 255 (45%), 233 (50%), 215 (50%), 201 
(10%), 165 (45%), 147 (40%), 121 (40%), 107 (65%), 93 (50%), 81 (45%), 67 
(35%), 55 (30%); HRMS (+EI): found 306.2556, [C20H32O2]+
● requires 306.2559. 
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5.1.2.3.5 17β-hydroxy-17α-methyl-5α-androstan-3-one (mestanolone, 21) 
21,22 
A solution of 17α-methyl-5α-androstan-3β,17β-diol 20 
(1.738 g, 5.67 mmol) in chloroform (60 mL) was added to a 
flask containing PCC (6.137 g, 28.5 mmol, 5.0 eq) and silica 
gel (6.334 g) and the resulting slurry was stirred at room 
temperature for 18 h. The reaction was filtered and the solid residue washed 
thoroughly with diethyl ether (10 x 25 mL). The combined organic extract was 
then washed with aqueous hydrochloric acid solution (2 M, 2 x 200 mL), water (2 x 
200 mL), saturated aqueous sodium chloride solution (200 mL), dried with 
anhydrous magnesium sulfate and concentrated in vacuo. The crude residue was 
purified by column chromatography (40% EtOAc/hexanes) to afford the title 
compound 21 (1.228 g, 71%) as a pale yellow solid. Rf 0.65 (40% EtOAc/hexanes); 
mp 189-191 oC (lit 22 190-192 oC); [α]25D +24 (c 0.7, CHCl3) (lit 22 [α]25D +10.5 
[CHCl3]); 1H NMR (400 MHz, CDCl3): 2.44-0.61 (m, 21H), 1.21 (s, 3H, C20-H3), 0.88 
(s, 3H, C18-H3), 0.69 (s, 3H, C19-H3), OH not observed; 13C NMR (100 MHz, CDCl3): 
212.1 (C3), 81.8 (C17), 54.0, 50.7, 47.0, 45.7, 44.9, 39.1, 38.8, 38.3, 36.5, 35.9, 31.8, 
31.6, 29.0, 26.0 (C20), 23.4, 21.3, 14.2 (C18), 11.7 (C19); LRMS (+EI): m/z 304 
(30%, [C20H32O2]+
●), 289 (70%), 271 (100%), 247 (65%), 231 (65%), 215 (30%), 
175 (30%), 163 (50%), 123 (40%), 107 (35%), 93 (35%), 81 (35%), 67 (35%), 55 
(35%); HRMS (+EI): found 304.2408, [C20H32O2]+
● requires 304.2402. 
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5.1.2.3.6 17β-hydroxy-17α-methyl-5α-androst-1-en-3-one (E3) 21–23 
A solution of 17β-hydroxy-17α-methyl-5α-androstan-3-one 
21 (994 mg, 3.26 mmol) in THF (30 mL) was treated with 
phenyltrimethylammonium tribromide (1.329 g, 3.56 
mmol, 1.1 eq) and stirred at room temperature for 60 min. 
The reaction was diluted with ethyl acetate (100 mL) and the organic extract 
washed with saturated aqueous sodium bicarbonate solution (100 mL), water 
(100 mL), saturated aqueous sodium chloride solution (100 mL), dried with 
anhydrous magnesium sulfate and concentrated in vacuo to afford 2α-bromo-17β-
hydroxy-17α-methyl-5α-androstan-3-one which was used without further 
purification. Rf 0.46 (40% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3): 4.75 (dd, J 
6.3 Hz, 13.4 Hz, 1H, C2-H), 2.65 (dd, J 6.4 Hz, 12.8 Hz, 1H, C4-H), 2.44-0.74 (m, 
19H), 1.21 (s, 3H, C20-H3), 1.11 (s, 3H, C19-H3), 0.87 (s, 3H, C18-H3), OH not 
observed. The crude product (1.292 g, assumed 3.37 mmol) was then dissolved in 
DMF (35 mL) and the solution was transferred to a dry flask containing lithium 
bromide (473 mg. 5.45 mmol, 1.6 eq) and lithium carbonate (438 mg, 5.93 mmol, 
1.8 eq) under a nitrogen atmosphere. The solution was then brought to reflux and 
stirred for 18 h. After cooling to room temperature, the reaction was diluted with 
ethyl acetate (200 mL) and the organic extract was washed with aqueous 
hydrochloric acid solution (2 M, 2 x 200 mL), water (2 x 200 mL), saturated 
aqueous sodium chloride solution (200 mL), dried with anhydrous magnesium 
sulfate and concentrated in vacuo. The crude residue was purified by column 
chromatography (40% EtOAc/hexanes) to afford the title compound E3 (423 mg, 
41 % over two steps) as a pale yellow solid. Rf 0.36 (40% EtOAc/hexanes); mp 
150-153 oC (lit 22 154-155 oC); [α]25D +31 (c 0.6, CHCl3) (lit 22 [α]25D +30 [CHCl3]); 
1H NMR (800 MHz, CDCl3): 7.14 (d, J 10.2 Hz, 1H, C1-H), 5.85 (d, J 10.2 Hz, 1H, C2-
H), 2.37 (dd, J 14.3 Hz, 17.7 Hz, 1H, C4-H), 2.22 (dd, J 4.0 Hz, 17.7 Hz, 1H, C4-H), 
1.92 (m, 1H, C5-H), 1.84-1.80 (m, 2H, C12-H, and C16-H), 1.76-1.71 (m, 2H, C7-H, 
and C16-H), 1.59-1.55 (m, 2H, C11-H, and C15-H), 1.53 (ddd, J 4.0 Hz, 10.4 Hz, 11.1 
Hz, 1H, C8-H), 1.49-1.38 (m, 3H, C6-H2, and C12-H), 1.33 (ddd, J 4.1 Hz, 12.7 Hz, 
12.7 Hz, 1H, C11-H), 1.30-1.23 (m, 2H, C14-H, and C15-H), 1.22 (s, 3H, C20-H3), 
1.03 (s, 3H, C19-H3), 0.99-0.91 (m, 2H, C7-H, and C9-H), 0.89 (s, 3H, C18-H3), OH 
not observed; 13C NMR (200 MHz, CDCl3): 200.3 (C3), 158.5 (C1), 127.6 (C2), 81.7 
(C17), 50.8 (C14), 50.2 (C9), 45.8 (C13), 44.6 (C5), 41.1 (C4), 39.2 (C10), 39.1 
154 
(C16), 36.7 (C8), 31.7 (C11), 31.2 (C7), 27.7 (C6), 26.0 (C20), 23.3 (C15), 21.1 
(C12), 14.3 (C18), 13.2 (C19); LRMS (+EI): m/z 302 (30%, [C20H30O2]+
●), 284 
(10%), 269 (85%), 245 (30%), 200 (10%), 163 (45%), 149 (35%), 134 (35%), 122 
(100%), 107 (60%), 91 (50%), 79 (45%), 67 (25%), 55 (25%); HRMS (+EI): found 
302.2242, [C20H30O2]+
● requires 302.2246. 
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5.1.2.3.7 1α,2α-epoxy-17β-hydroxy-17α-methyl-5α-androstan-3-one (22) 
21,23,24 
A solution of 17β-hydroxy-17α-methyl-5α-androst-1-en-3-
one E3 (238 mg, 786.9 µmol) in methanol (4 mL) was 
cooled to 0 oC (ice-water bath) and treated with a solution 
of aqueous sodium hydroxide (5.0 M, 240 µl, 1.20 mmol, 1.5 
eq) followed by a solution of aqueous hydrogen peroxide (30% w/v, 900 µL, 7.94 
mmol, 10.1 eq) and stirred at 0 oC for 2h, then at room temperature for 3 h. The 
reaction was diluted with water (50 mL) and extracted with chloroform (3 x 50 
mL). The combined organic extract was dried with anhydrous magnesium sulfate 
and concentrated in vacuo. The crude residue was purified by column 
chromatography (40% EtOAc/hexanes) to afford the title compound 22 (30 mg, 
12%) as an off-white solid. Rf 0.40 (40% EtOAc/hexanes); mp 145-150 oC (lit 24 
138-142 oC); [α]25D +67 (c 0.3, CHCl3) (lit 24 [α]25D +37 [CHCl3]); 1H NMR (400 MHz, 
CDCl3): 3.52 (d, J 4.1 Hz, 1H, C2-H), 3.23 (d, J 4.1 Hz, 1H, C1-H), 2.27 (dd, J 4.6 Hz, 
18.6 Hz, 1H, C4-H), 2.10-0.88 (m, 17H), 1.23 (s, 3H, C20-H3), 0.91 (s, 3H, C19-H3), 
0.88 (s, 3H, C18-H3), OH not observed; 13C NMR (100 MHz, CDCl3): 206.0 (C3), 81.8 
(C17), 61.2 (C1), 56.2 (C2), 50.6, 49.0, 45.7, 40.3, 39.0, 36.9, 36.5, 34.4, 31.6, 31.0, 
27.3, 26.0 (C20), 23.4, 21.4, 14.2 (C18), 11.3 (C19); LRMS (+EI): m/z 318 (5%, 
[C20H30O3]+
●), 303 (55%), 285 (100%), 261 (60%), 245 (40%), 215 (15), 201 
(15%), 187 (15%), 173 (20%), 163 (25%), 147 (25%), 133 (20%), 121 (30%), 107 
(40%), 91 (50%), 79 (40%), 67 (30%), 55 (25%); HRMS (+EI): found 318.2204, 
[C20H30O3]+
● requires 318.2195. 
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5.1.2.3.8 17α-methyl-5α-androst-2-en-1α,17β-diol (D1) 21 
A solution of 1α,2α-epoxy-17β-hydroxy-17α-methyl-5α-
androstan-3-one 22 (27 mg, 84.9 µmol) in hydrazine 
monohydrate (1.0 mL, 20.6 mmol, 242 eq) was stirred at room 
temperature for 90 min. The reaction was diluted with water 
(10 mL) and extracted with chloroform (3 x 10 mL). The combined organic extract 
was dried with anhydrous magnesium sulfate and concentrated in vacuo. The 
crude residue was purified by column chromatography (40% EtOAc/hexanes) to 
afford the title compound D1 (20 mg, 77%) as a yellow-brown solid. Rf 0.39 (40% 
EtOAc/hexanes); mp 101-104 oC; 1H NMR (400 MHz, CDCl3): 5.87-5.78 (m, 2H, C2-
H and C3-H), 3.71 (d, J 4.4 Hz, 1H, C1-H), 2.41-0.89 (m, 18H), 1.21 (s, 3H, C20-H3), 
0.86 (s, 3H, C18-H3), 0.73 (s, 3H, C19-H3), 2 x OH not observed; 13C NMR (100 MHz, 
CDCl3): 130.7 (C2 or C3), 127.8 (C2 or C3), 81.8 (C17), 69.8 (C1), 50.6, 46.2, 45.4, 
39.0, 38.9, 36.4, 34.8, 31.5, 32.2, 30.7, 28.5, 25.9 (C20), 23.3, 20.3, 13.9 (C18), 11.4 
(C19); LRMS (+EI): m/z 304 (10%, [C20H32O2]+
●), 286 (25%), 271 (25%), 246 
(30%), 234 (25%), 201 (15%), 176 (40%), 161 (40%), 147 (25%), 135 (15%), 119 
(15%), 105 (45%), 91 (45%), 79 (25%), 70 (15%), 55 (10%);HRMS (+EI): found 
304.2402, [C20H32O2]+
● requires 304.2402. 
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5.1.2.3.9 17β-hydroxy-17α-methyl-5α-androst-2-en-1-one (E1) 21 
A solution of 17α-methyl-5α-androst-2-en-1α,17β-diol D1 (15 
mg, 49.3 µmol) in chloroform (500 µL) was added to a flask 
containing PCC (55 mg, 255 µmol, 5.2 eq) and silica gel (53 
mg) and the resulting slurry was stirred at room temperature 
for 18 h. The reaction was diluted with diethyl ether (10 mL), filtered and the solid 
residue washed thoroughly with additional diethyl ether (10 x 5 mL). The 
combined organic extract was then washed with aqueous hydrochloric acid 
solution (2 M, 2 x 50 mL), water (2 x 50 mL), saturated aqueous sodium chloride 
solution (50 mL), dried with anhydrous magnesium sulfate and concentrated in 
vacuo. The crude residue was purified by column chromatography (40% 
EtOAc/hexanes) to afford the title compound E1 (10 mg, 67%) as a pale yellow 
solid. Rf 0.48 (40% EtOAc/hexanes); mp 148-153 oC; 1H NMR (400 MHz, CDCl3): 
6.65 (dt, J 3.9 Hz, 10.0 Hz, 1H, C3-H), 5.80 (dt, J 2.1 Hz, 10.1 Hz, 1H, C2-H), 2.44 (m, 
1H, C4-H), 2.17-2.13 (m, 2H, C4-H and C5-H), 1.87-0.79 (m, 15H), 1.23 (s, 3H, C20-
H3), 1.08 (s, 3H, C19-H3), 0.88 (s, 3H, C18-H3), OH not observed; 13C NMR (100 
MHz, CDCl3): 206.6 (C1), 145.2 (C3), 129.0 (C2), 81.9 (C17), 50.8, 47.6, 47.5, 45.8, 
43.6, 38.9, 37.6, 31.9, 31.4, 30.5, 28.3, 26.1 (C20), 23.5, 23.3, 14.5 (C18), 10.7 (C19); 
LRMS (+EI): m/z 302 (10%, [C20H30O2]+
●), 284 (20%), 269 (100%), 245 (70%), 
201 (10%), 161 (15%), 122 (45%), 109 (40%), 91 (30%), 79 (15%), 55 (10%); 
HRMS (+EI): found 302.2247, [C20H30O2]+
● requires 302.2246. 
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5.1.2.3.10 17β-hydroxy-17α-methyl-5α-androst-3-en-2-one (E2) 
A solution of 17α-methyl-5α-androst-2-en-17β-ol M (989 
mg, 3.43 mmol) in dioxane (20 mL) was treated with a 
solution of NBS (681 mg, 3.82 mmol, 1.1 eq) in water (20 
mL). An aqueous solution of perchloric acid (70% w/w, 540 
µL, 3.87 mmol, 1.1 eq) was then added dropwise and the reaction was stirred at 
room temperature for 18 h. The reaction was diluted with water (100 mL), 
extracted with chloroform (4 x 100 mL) and the organic extract was then dried 
with anhydrous magnesium sulfate and concentrated in vacuo to afford 3α-bromo-
17α-methyl-5α-androstan-2β,17β-diol which was used without further purification. 
Rf 0.55 (40% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3): 4.33 (br s, 1H, C3-H), 
4.22 (br s, 1H, C2-H), 2.20-0.67 (m, 21 H), 1.21 (s, 3H, C20-H3), 1.02 (s, 3H, C19-H3), 
0.84 (s, 3H, C18-H3), 2 x OH not observed. The crude product (1.206 g, assumed 
3.13 mmol) was then dissolved in chloroform (31 mL), treated with PCC (3.375 g, 
15.7 mmol, 5.0 eq) and silica (3.457 g) and stirred at room temperature for 18 h. 
The reaction was then filtered and the solid residue washed with diethyl ether (10 
x 25 mL). The combined organic extract was then washed with aqueous 
hydrochloric acid solution (2 M, 2 x 100 mL), water (2 x 200 mL), saturated 
aqueous sodium chloride solution (200 mL), dried with anhydrous magnesium 
sulfate and concentrated in vacuo to afford 3α-bromo-17β-hydroxy-17α-methyl-5α-
androstan-2-one which was used without further purification. Rf 0.58 (40% 
EtOAc/hexanes);1H NMR (400 MHz, CDCl3): 4.29 (br s, 1H, C3-H), 2.83 (d, J 13.5 Hz, 
1H, C1-H), 2.30 (d, J 13.5 Hz, 1H, C1-H), 2.14-0.75 (m, 18 H), 1.21 (s, 3H, C20-H3), 
0.84 (s, 3H, C19-H3), 0.75 (s, 3H, C18-H3), OH not observed. The crude product 
(962 mg, assumed 2.51 mmol) was then dissolved in DMF (25 mL) and the solution 
was transferred to a dry flask containing lithium bromide (335 mg. 3.85 mmol, 1.5 
eq) and lithium carbonate (272 mg, 3.68 mmol, 1.5 eq) under a nitrogen 
atmosphere. The solution was then brought to reflux and stirred for 18 h. After 
cooling to room temperature, the reaction was diluted with ethyl acetate (200 mL) 
and the organic extract was washed with aqueous hydrochloric acid solution (2 M, 
2 x 200 mL), water (2 x 200 mL), saturated aqueous sodium chloride solution (200 
mL), dried with anhydrous magnesium sulfate and concentrated in vacuo. The 
crude residue was purified by column chromatography (40% EtOAc/hexanes) to 
afford an 83:17 mixture containing the title compound E2 and E3 (381 mg, 37% 
159 
over three steps) as a pale yellow solid. Data is reported for the major isomer 
where appropriate. Rf 0.37 (40% EtOAc/hexanes); [α]25D +70 (c 0.7, CHCl3); 1H 
NMR (400 MHz, CDCl3): 6.56 (d, J 9.9 Hz, 1H, C4-H), 5.96 (d, J 9.8 Hz, 1H, C3-H), 
2.56 (d, J 16.0 Hz, 1H, C1-H), 2.06 (d, J 18.2 Hz, 1H, C1-H), 2.64-0.67 (m, 16H), 1.21 
(s, 3H, C20-H3), 0.89 (s, 3H, C19-H3), 0.85 (s, 3H, C18-H3), OH not observed; 13C 
NMR (100 MHz, CDCl3): 200.3 (C2), 154.2 (C4), 128.7 (C3), 81.7 (C17), 53.6, 52.2, 
50.6, 47.2, 45.8, 41.1, 39.0, 35.6, 31.8, 31.6, 26.6, 26.0 (C20), 23.3, 20.7, 14.2 (C18), 
12.9 (C19); LRMS (+EI): m/z 302 (65%, [C20H30O2]+
●), 284 (45%), 269 (100%), 245 
(45%), 229 (45%), 161 (35%), 147 (25%), 121 (55%), 107 (55%), 91 (45%), 79 
(45%), 55 (30%); HRMS (+EI): found 302.2242, [C20H30O2]+
● requires 302.2246.  
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5.1.2.3.11 3α,4α-epoxy-17β-hydroxy-17α-methyl-5α-androstan-2-one (23) 
A solution of 17β-hydroxy-17α-methyl-5α-androst-3-en-2-
one E2 (381 mg, 1.26 mmol, 83:17 mixture containing E2 
and E3) in methanol (6 mL) was cooled to 0 oC (ice-water 
bath) and treated with a solution of aqueous sodium 
hydroxide (5.0 M, 380 µl, 1.90 mmol, 1.5 eq) followed by a solution of aqueous 
hydrogen peroxide (30% w/v, 1.4 mL, 9.79 mmol, 9.8 eq) and stirred at 0 oC for 2h, 
then at room temperature for 3 h. The reaction was diluted with water (50 mL) 
and extracted with chloroform (3 x 50 mL). The combined organic extract was 
dried with anhydrous magnesium sulfate and concentrated in vacuo. The crude 
residue was purified by column chromatography (40% EtOAc/hexanes) to afford 
the title compound 23 (141 mg, 36%) as a white solid. Rf 0.41 (40% 
EtOAc/hexanes); mp 98-103 oC; [α]25D +53 (c 0.7, CHCl3); 1H NMR (400 MHz, 
CDCl3): 3.21 (d, J 3.8 Hz, 1H, C3-H), 3.10 (d, J 3.7 Hz, 1H, C4-H), 2.29 (d, J 13.8 Hz, 
1H, C1-H), 2.19 (d, J 13.8 Hz, 1H, C1-H), 1.88-0.76 (m, 16H), 1.21 (s, 3H, C20-H3), 
0.83 (s, 6H, C18-H3 and C19-H3), OH not observed; 13C NMR (100 MHz, CDCl3): 
207.3 (C2), 81.6 (C17), 61.3 (C4), 54.9 (C3), 52.6, 50.4, 48.5, 47.4, 45.8, 43.1, 39.0, 
35.6, 31.5, 31.4, 26.0 (C20), 25.6, 23.3, 21.0, 14.9 (C19), 14.2 (C18); LRMS (+EI): 
m/z 318 (40%, [C20H30O3]+
●), 303 (100%), 285 (100%), 260 (50%), 245 (65%), 
215 (20%), 201 (20%), 175 (35%), 161 (25%), 147 (30%), 133 (30%), 121 (30%), 
105 (35%), 91 (45%), 81 (35%), 71 (50%), 55 (30%); HRMS (+EI): found 
318.2191, [C20H30O3]+
● requires 318.2195. 
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5.1.2.3.12 17α-methyl-5α-androst-2-en-4α,17β-diol (D7) 21 
A solution of 3α,4α-epoxy-17β-hydroxy-17α-methyl-5α-
androstan-2-one 22 (119 mg, 373.7 µmol) in hydrazine 
monohydrate (4.0 mL, 82.2 mmol, 220 eq) was stirred at room 
temperature for 90 min. The reaction was diluted with water 
(50 mL) and extracted with chloroform (3 x 50 mL). The 
combined organic extract was dried with anhydrous magnesium sulfate and 
concentrated in vacuo. The crude residue was purified by column chromatography 
(40% EtOAc/hexanes) to afford the title compound D7 (43 mg, 38%) as an off-
white solid. Rf 0.47 (40% EtOAc/hexanes); mp 99-102 oC; 1H NMR (400 MHz, 
CDCl3): 5.72-5.60 (m, 2H, C2-H and C3-H), 3.78 (m, 1H, C4-H), 2.02-0.70 (m, 18H), 
1.21 (s, 3H, C20-H3), 0.85 (s, 3H, C19-H3), 0.83 (s, 3H, C18-H3), 2 x OH not 
observed; 13C NMR (100 MHz, CDCl3): 129.2 (C2 or C3), 127.7 (C2 or C3), 81.7 
(C17), 70.8 (C4), 53.9, 50.6, 50.5, 45.4, 39.6, 39.0, 36.6, 36.2, 31.6, 31.1, 25.8 (C20), 
24.3, 23.2, 20.3, 13.9 (C18), 12.7 (C19); LRMS (+EI): m/z 304 (40%, [C20H32O2]+
●), 
286 (40%), 268 (30%), 253 (30%), 228 (30%), 213 (25%), 176 (15%), 161 (40%), 
147 (40%), 133 (30%), 119 (40%), 105 (90%), 91 (100%), 79 (50%), 67 (35%), 
55 (40%); HRMS (+EI): found 304.2404, [C20H32O2]+
● requires 304.2402. 
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5.1.2.3.13 17β-hydroxy-17α-methyl-5α-androst-2-en-4-one (E4) 21 
A solution of 17α-methyl-5α-androst-2-en-4α,17β-diol D7 (22 
mg, 72.2 µmol) in chloroform (700 µL) was added to a flask 
containing PCC (79 mg, 366.5 µmol, 5.1 eq) and silica gel (93 
mg) and the resulting slurry was stirred at room temperature 
for 18 h. The reaction was diluted with diethyl ether (10 mL), 
filtered and the solid residue washed thoroughly with additional diethyl ether (10 
x 5 mL). The combined organic extract was then washed with aqueous 
hydrochloric acid solution (2 M, 2 x 50 mL), water (2 x 50 mL), saturated aqueous 
sodium chloride solution (50 mL), dried with anhydrous magnesium sulfate and 
concentrated in vacuo. The crude residue was purified by column chromatography 
(40% EtOAc/hexanes) to afford the title compound E4 (15 mg, 69%) as an off-
white solid. Rf 0.50 (40% EtOAc/hexanes); mp 130-133 oC; 1H NMR (400 MHz, 
CDCl3): 6.79 (ddd, J 2.3 Hz, 6.0 Hz, 10.1 Hz, 1H, C2-H), 5.98 (dd, J 3.0 Hz, 10.1 Hz, 
1H, C3-H); 2.49-0.79 (m, 18H), 1.21 (s, 3H, C20-H3), 0.87 (s, 3H, C19-H3), 0.85 (s, 
3H, C18-H3), OH not observed; 13C NMR (100 MHz, CDCl3): 201.3 (C4), 146.6 (C2), 
128.8 (C3), 81.6 (C17), 55.8, 54.2, 50.4, 45.4, 40.7, 40.3, 39.0, 35.7, 31.5, 30.4, 25.8 
(C20), 23.2, 20.7, 20.3, 13.9 (C18), 13.2 (C19); LRMS (+EI): m/z 302 (10%, 
[C20H30O2]+
●), 287 (100%), 269 (60%), 245 (55%), 229 (25%), 217 (10%), 173 
(10%), 163 (30%), 147 (25%), 135 (25%), 121 (60%), 107 (40%), 91 (35%), 79 
(40%), 67 (25%), 55 (25%); HRMS (+EI): found 302.2238, [C20H30O3]+
● requires 
302.2246. 
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5.1.2.3.14 2α,3α-episulfinyl-17α-methyl-5α-androstan-17β-ol (HS) 
A dry flask containing 2α,3α-epithio-17α-methyl-5α-
androstan-17β-ol H (30 mg, 93.6 µmol) under a nitrogen 
atmosphere was treated dropwise with a solution of 
DMDO 9,10 in acetone (0.098 M, 5.0 mL, 490 µmol, 5.2 eq) 
and stirred at room temperature for 90 min. The reaction was diluted with ethyl 
acetate (10 mL), washed with aqueous sodium metabisulfite solution (10% w/v, 
10 mL), water (10 mL), saturated aqueous sodium chloride solution (10 mL), dried 
with anhydrous magnesium sulfate and concentrated in vacuo. The crude residue 
was purified by column chromatography (20% EtOAc/hexanes, silica pre-treated 
with NEt3 (5% v/v)) to afford the title compound HS (27 mg, 86%) as a white solid. 
Rf 0.17 (40% EtOAc/hexanes); mp 135-140 oC; [α]25D -5 (c 0.4, CHCl3); 1H NMR 
(400 MHz, CDCl3): 3.24 (dt, J 3.5 Hz, 10.5 Hz, 1H, C3-H), 3.11 (dd, J 5.6 Hz, 10.8 Hz, 
1H, C2-H), 2.45 (dd, J 10.5 Hz, 16.0 Hz, 1H, C1-H), 2.18 (dd, J 4.3 Hz, 15.5 Hz, 1H, C4-
H), 1.80-0.33 (m, 18H), 1.17 (s, 3H, C20-H3), 0.81 (s, 3H, C18-H3), 0.78 (s, 3H, C19-
H3), OH not observed; 13C NMR (100 MHz, CDCl3): 81.7 (C20), 53.8, 53.5 (C2 or C3), 
51.3 (C2 or C3), 50.6, 45.4, 40.6, 39.0, 36.6, 35.6, 33.3, 31.6, 31.1, 28.9, 25.9 (C20), 
25.7, 23.3, 20.5, 14.0 (C18), 12.7 (C19); LRMS (+EI): m/z 336 (10%, [C20H32O2S]+
●), 
288 (40%, [C20H32O]+
●), 270 (30%), 255 (100%, [C19H27]+
●), 234 (40%), 230 
(55%), 216 (55%), 201 (20%), 176 (45%), 161 (45%), 147 (40%), 121 (25%), 107 
(45%), 93 (45%), 81 (40%), 55 (30%); HRMS (+EI): found 336.2123, [C20H32O2S]+
● 
requires 336.2123. 
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5.1.2.3.15 17α-methyl-5α-androst-2-en-17β-ol 17-sulfate, ammonium salt 
(MS) 
Sulfation was performed by minor modification to a known 
literature procedure 25. A solution of 17α-methyl-5α-androst-
2-en-17β-ol M (3.0 mg, assumed 10.4 µmol) in dioxane (500 
µL) was treated with a solution of sulfur trioxide-pyridine 
complex (50 mg, 314 µmol, 30.2 eq) in DMF (500 µL) and 
stirred at room temperature for 4 h. The reaction was diluted with water (2 mL) 
and subjected to purification by SPE. An Oasis WAX SPE cartridge (6 cc) was pre-
conditioned with methanol (3 mL) followed by water (15 mL). The reaction 
mixture (3 mL) was then loaded onto the cartridge and washed with a solution of 
formic acid in water (2% v/v, 15 mL), water (15 mL) and methanol (15 mL). 
Elution with saturated aqueous ammonia solution in methanol (5% v/v, 15 mL) 
afforded the title compound MS as a 95:5 inseparable mixture of Δ2-3 and Δ3-4 
alkene isomers with >98% conversion 25. Data is reported for the major isomer 
where appropriate. Rf 0.55 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (400 MHz, CD3OD): 
5.61-5.50 (m, 2H, C2-H and C3-H), 2.63 (ddd, J 3.4 Hz, 12.4 Hz, 14.8 Hz, 1H, C16-H), 
1.98-0.70 (m, 19H), 1.50 (s, 3H, C20-H3), 0.93 (s, 3H, C18-H3), 0.80 (s, 3H, C19-H3); 
13C NMR (100 MHz, CD3OD): 126.9 (C2 or C3), 126.7 (C2 or C3), 94.4 (C17), 55.6, 
50.3, 48.3, 43.0, 41.0, 37.7, 36.0, 35.8, 33.0, 32.8, 31.4, 29.9, 24.5, 23.3, 21.6, 15.2 
(C18), 12.1 (C19); LRMS (-ESI): 367 (100%, [C20H31O4S]-), 111 (15%), 97 (10%, 
[HSO4]-); HRMS (-ESI): found 367.1944, [C20H31O4S]- requires 367.1943. 
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5.1.2.3.16 General procedure for the small scale Luche reduction of enones 
(D1-D10) 
Small scale reduction was performed using modified Luche conditions 26. A 
solution of steroid enone (1.0 mg, 3.31 µmol) and cerium chloride heptahydrate 
(10 mg, 26.8 µmol, 8.1 eq) in methanol (100 µL) was treated slowly with sodium 
borohydride (1 mg, 26.4 µmol, 8.0 eq) on ice. The resulting white slurry was then 
stirred at room temperature for 15 min. The reaction was quenched with aqueous 
hydrochloric acid (2 M, 1 mL) and subjected to purification by SPE. A Waters Sep-
Pak C18 SPE cartridge was pre-conditioned with methanol (3 mL) and water (3 
mL). The sample was loaded, washed with water (3 mL) and eluted with methanol 
(3 mL). The methanol fraction was concentrated in vacuo to afford the desired 
steroid diol, typically as a mixture of α- and β-isomers. Enones E1-E5 were 
subjected to these conditions to afford mixtures containing diols D1-D10, which 
were characterised by GCMS analysis as per section 5.1.2.4.1.  
 
5.1.2.4 Analytical methods 
5.1.2.4.1 GC-MS/MS Analysis 
Positive mode gas chromatography-tandem mass spectrometry (GC-MS/MS) 
analysis was undertaken on an Agilent 7890A GC system coupled to an Agilent 
7000 GC/MS Triple Quadrupole mass spectrometer equipped with an Agilent HP-
5MS Ultra Inert column (30 m x 250 µm x 0.25 µm). Helium was used as a carrier 
gas with a constant flow rate of 1.2 mL/min. Injection volumes of 2-5 µL were 
resolved in pulsed splitless mode. The injector temperature was set to 260 oC, and 
the MSD transfer line was set to 300 oC. The oven temperature commenced at 
180 oC with a hold time of 0.2 min, followed by a 5 oC/min ramp to 235 oC, followed 
by a 15 oC/min ramp to 265 oC, followed by a 25 oC/min ramp to 300 oC, and a final 
hold time of 10 min (total run time 24.6 min). The solvent delay was set to 6.5 min. 
Steroids were derivatised as the enol trimethylsilyl (TMS) derivative using 
MSTFA/NH4I/DTT (1000:2:4 v/w/w, 50 µL) at 80 oC for 60 min 27, reconstituted in 
n-dodecane (50 µL) prior to analysis, and monitored for the radical cation ([M]+●) 
using +EI.  
 
166 
5.1.2.4.2 LC-HRAM Analysis 
Positive mode liquid chromatography-high resolution accurate mass (LC-HRAM) 
analysis was undertaken using an Agilent 1290 Infinity II LC system coupled to an 
Agilent 6545 Q-TOF mass spectrometer equipped with a Waters Sun-Fire C18 
column (100 mm x 2.1 mm, 3.5 µm) eluting with a gradient consisting of the 
following mobile phases, A: 0.1% formic acid in water, B: 0.1% formic acid in 
methanol, gradient: 0-1 min Α-Β (95:5 v/v), 1-15 min Α-Β (95:5 v/v) to Α-Β (5:95 
v/v), 15-19 min Α-Β (5:95 v/v), 5 min re-equilibration, flow rate 0.4 mL min-1. 
Unconjugated steroids and steroid glucuronides were monitored for the proton 
adduct ([M+H]+) using HESI in positive full scan or targeted MS/MS mode. 
Negative mode LC-HRAM analysis was undertaken on the same instrument using a 
Phenomenex (Torrance CA, USA) Gemini C18 column (50 mm x 2 mm, 5 µm), 
eluting with a gradient consisting of the following mobile phases, A: aqueous 
ammonium acetate (0.01 M, pH 9.0), B: 0.1% acetic acid in acetonitrile, gradient: 0-
2 min Α-Β (99:1 v/v), 2-8.5 min Α-Β (99:1 v/v) to Α-Β (20:80 v/v), 2.7 min re-
equilibration, flow rate 0.5 mL min-1. Steroid glucuronide and sulfate conjugates 
were monitored for the anion ([M-H]-) using HESI in negative full-scan or targeted 
MS/MS mode. 
 
5.1.2.5 In vivo equine metabolism study 
5.1.2.5.1 Animal administration 
Animal administration was approved by the Racing NSW Animal Care and Ethics 
Committee. A sample of synthetic hemapolin (200 mg) was administered orally as 
a suspension in water by way of a nasogastric tube to a thoroughbred gelding 
(21 years old, 580 kg), with samples of blood and urine collected at 0, 1, 2, 4, 6, 8, 
12, and 24 h post-administration, and daily thereafter up to 7 d post 
administration. The samples were stored at −20 oC until required for analysis. 
 
5.1.2.5.2 Extraction of blood samples 
The blood samples were centrifuged (3000 rpm, 10 min) and the plasma was 
decanted into new vials. Unused plasma was stored frozen at -20 oC. An aliquot of 
plasma (2 mL) was treated with d3-testosterone (50 ng/mL) as an internal 
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standard, and then an aqueous solution of trichloroacetic acid (10% w/v, 67 µL). 
The sample was centrifuged (3000 rpm, 10 min), the supernatant was treated with 
sodium phosphate buffer (0.1 M, pH 7.4, 2 mL), and then purified by SPE. A UCT 
Xtrackt cartridge was pre-conditioned with methanol (2 mL) and water (2 mL). 
The sample was loaded and washed with a solution of aqueous acetic acid (0.1 M, 2 
mL), and eluted with a solution of ethyl acetate/n-hexane (60% v/v, 3 mL). 
Concentration under a stream of nitrogen at 60 oC afforded a residue which was 
reconstituted in methanol-water (5:95, 200 µL) and transferred to a sealed vial for 
subsequent LC-HRAM analysis as per section 5.1.2.4.2. 
 
5.1.2.5.3 Extraction of urine samples for LC-HRAM analysis 
An aliquot of urine (2 mL) was treated with sodium phosphate buffer (0.1 M, pH 
7.4, 2 mL), and centrifuged (3000 rpm, 10 min) to pellet solids. The supernatant 
was decanted, treated with d3-testosterone (100 ng/mL urine), d3-testosterone 17-
glucuronide (100 ng/mL), and d3-testosterone 17-sulfate (100 ng/mL), and 
purified by SPE. A Waters WAX (3 cc) cartridge was preconditioned with methanol 
(2 mL) and water (2 mL). The sample was loaded and washed with an aqueous 
solution of sodium hydroxide (0.1 M, 2 mL), sodium phosphate buffer (0.1 M, pH 
7.4, 2 mL), and water (2 mL), and eluted with a solution of methanol-ethyl acetate-
diethylamine (25:25:1 v/v/v, 2 mL). Concentration under a stream of nitrogen at 
60 oC afforded a residue which was reconstituted in methanol-water (5:95, 200 µL) 
and transferred to a sealed vial for subsequent LC-HRAM analysis as per section 
5.1.2.4.2. 
 
5.1.2.5.4 Extraction of the urine samples for GC-MS/MS analysis 
An aliquot of urine (3 mL) was adjusted manually to pH 5.0-5.5 with aqueous 
hydrochloric acid solution (10% w/v), and treated with d3-testosterone (50 
ng/mL) as an internal standard. An Agilent NEXUS SPE cartridge was pre-
conditioned with methanol (3 mL) and water (3 ml). The sample was loaded and 
washed with water (3 mL), a solution of aqueous sodium hydroxide (0.1 M, 3 mL), 
additional water (3 mL), and eluted with methanol (3 mL). Concentration under a 
stream of nitrogen at 60 oC afforded a residue which was reconstituted in a 
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solution of acetyl chloride in methanol (1.0 M, 500 µL) and heated in a capped tube 
at 60 oC for 10 min. The hydrolysis reaction was quenched with a solution of 
aqueous sodium hydroxide (2 M, 3 mL), and extracted with DIPE (3.5 mL) for 30 
min. Concentration of the ether layer under a stream of nitrogen at 60 oC afforded a 
residue which was derivatised as the TMS enol ether, and subjected to GC-MS/MS 
analysis as per section 5.1.2.4.1. 
 
5.1.3 Results and Discussion 
5.1.3.1 Synthesis of hemapolin and reference materials 
As H was required on large scale (200 mg) and in high purity, a laboratory 
synthesis was undertaken. Synthetic H was prepared from epiandrosterone in 6 
synthetic steps in 6% overall yield through a novel synthetic strategy. The 
experimental procedures, characterisation data, and copies of the 1H NMR, 
13C NMR, and +EI LRMS or -ESI LRMS are included in the supporting information 
for this chapter, but have been excluded from the final electronic version of this 
thesis due to concerns over the potential for the misuse of this information in the 
illicit manufacture of new designer steroids. Requests for this information from 
legitimate parties can be made to Associate Professor Malcolm McLeod. Enones 
E1-E4 were prepared from M, mestanolone, or epiandrosterone as described 
below. Briefly, bromination of mestanolone 21 with PTAB cleanly afforded the C2-
bromide, which was eliminated by treatment with LiBr and Li2CO3 in anhydrous 
DMF to afford E3 (Scheme 5.1) 23. Subsequent treatment of E3 with hydrogen 
peroxide under basic conditions afforded epoxide 22, which was subjected to 
Wharton conditions to selectively generate diol D1 21,28. This diol was oxidised 
with PCC to afford E1, which was subsequently reduced under modified Luche 
conditions to afford a mixture containing diols D1, and D2 26. Enone E2 (Scheme 
5.2) was prepared from M by formation of the bromohydrin, followed by oxidation 
to the bromoketone, and subsequent elimination using the conditions outlined 
above. Luche reduction of E2 afforded a mixture of diols D3 and D4. A small 
amount (~15%) of E3 formed alongside E2, presumably resulting from the 
formation of the undesired C2-bromohydrin, which was carried through the 
subsequent steps. Treatment of E2 with hydrogen peroxide afforded epoxide 23 in 
pure form after column chromatography, which was converted to diol D7 under 
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Wharton conditions as outlined above. Subsequent oxidation afforded E4, which 
was reduced as above to afford a mixture containing diols D7 and D8. The 1H NMR 
analysis of the alkene protons in deuterated chloroform agreed with the proposed 
structures of the enone reference materials: enone E1 produced a pair of doublet 
of triplets at 6.65 ppm (C3-H, J=10.1 Hz, J=3.9 Hz) and 5.80 ppm (C2-H, J=10.1 Hz, 
J=2.1 Hz); E2 produced a pair of doublets at 6.56 ppm (C4-H, J=9.8 Hz) and 5.96 
ppm (C3-H, J=9.8 Hz); E3 produced a pair of doublets at 7.14 ppm (C1-H, J=10.2 
Hz) and 5.85 ppm (C2-H, J=10.2 Hz); E4 produced a doublet of doublet of doublets 
at 6.79 ppm (C2-H, J=10.1 Hz, J=6.0 Hz, J=2.3 Hz), and a doublet of doublets at 5.98 
ppm (C3-H, J=10.1 Hz, J=3.0 Hz) and; E5 displayed a singlet at 5.73 ppm (C4-H). 
These signals distinguish between the different chemical environments of the 
steroid A-ring, and matched the expected multiplet splitting patterns. 
 
Scheme 5.1: Synthesis of enones E1, and E3, and their corresponding diols 
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Scheme 5.2: Synthesis of enones E2, and E4, and their corresponding diols 
 
Diols D5, and D6 were obtained by reduction of E3 (Scheme 5.1), while diols D9, 
and D10 were obtained by reduction of E5 (not shown). Based on observations 
reported by Okano et al for a related epithio-steroid, we also expected a hemapolin 
sulfoxide metabolite HS, which was afforded in low yield by treatment of H with 
hydrogen peroxide in acetic acid 29. In our hands M was observed as the major 
product of this reaction, so alternate milder conditions for the synthesis of HS 
were investigated. Treatment of H with DMDO 9,10 effected the mild generation of 
HS as the major product (Scheme 5.3). This compound proved unstable at room 
temperature, decomposing slowly to generate M over the course of several days. 
However, storage at lower temperatures (<0 oC) resulted in minimal 
decomposition over longer periods of time. Madol 17-sulfate MS was prepared 
from M in high conversion (>98%) using established conditions (Scheme 5.3) 25. 
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Scheme 5.3: Synthesis of hemapolin S-oxide (HS), and madol 17-sulfate (MS) 
 
 
5.1.3.2 In vivo equine metabolites 
To date, there have been no reported studies detailing the metabolism of H in 
equine systems. To address this, an in vivo administration study was undertaken in 
which a synthetically prepared sample of hemapolin (200 mg) was administered to 
a thoroughbred gelding, with collection of blood, and urine samples occurring up 
to 7 d post-administration. Sample preparation employed SPE using UCT Xtrackt, 
Waters Oasis WAX, or Agilent NEXUS cartridges as specified in section 5.1.2.5, to 
afford extracts suitable for LC-HRAM and GC-MS/MS analysis. The LC-HRAM data 
were examined using mass filters for predicted metabolites formed from up to 
three metabolic transformations including oxidation, reduction and hydroxylation, 
with or without subsequent sulfation or glucuronylation. Metabolite peaks were 
identified where exact masses were observed within ±10 ppm of the predicted 
accurate mass. For GC-MS/MS data, the metabolites were identified by full scan or 
product ion spectra, and comparison to a urine blank. Metabolites identified by 
LC–HRAM or GC-MS/MS were matched against synthesised reference materials 
where available. 
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Figure 5.1: Proposed phase I metabolism of hemapolin in the horse; 
AMatched to reference material. BStructure undefined. CIdentified in blood. 
DIdentified in urine. O, oxidation; R, reduction; H, hydroxylation; E, 
elimination 
 
5.1.3.3 Analysis of blood metabolites 
Positive mode LC-HRAM analysis showed that H was metabolised extensively in 
the A-ring (Table 5.2). Analysis of blood samples showed two oxidised and 
hydroxylated madol phase I metabolites (E2, and E4), which were confirmed 
against synthetic reference materials. Under our LC conditions we observed that 
the reference materials for enones E2, and E3 had identical retention times, 
although E2 displayed a prominent ion at m/z 227 in common with the observed 
metabolite. In contrast, E3 displayed a prominent ion at m/z 201 which was not 
common with the observed metabolite. A previous study of the equine in vitro 
metabolism of M (used as a 3:1 mixture of Δ2-3 and Δ3-4 alkene isomers) has been 
reported which identified E3 as the major equine metabolite by GC-MS/MS 
analysis after TMS derivatisation 13. However, reference materials for E1, E2, or E4 
were not examined in this study, and as a result the identities of the equine 
metabolites could have inadvertently been misassigned. Alternatively, there could 
be subtle differences in the metabolism of M in vitro compared to the metabolism 
of H in vivo. In the present study, a pure isomer of H was used which affords 
greater certainty over the metabolic fate of this compound. No matches were 
observed for reference materials H, M, E1, E3, E5, D1-D10, or HS in the blood 
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samples by positive mode LC-HRAM analysis. Additionally, no phase II metabolites 
were observed in the blood samples.  
 
Analysis of the data obtained from the blood samples by positive mode LC-HRAM 
analysis with an aim to identify metabolites containing an intact episulfide based 
on knowledge of their +ESI fragmentation, and by comparison to H reference 
material, were unsuccessful 29. Additionally, searching for intact sulfoxide 
metabolites such as HS was similarly unsuccessful. It has been proposed that 
epithio-steroids can be oxidised to the corresponding sulfoxides, which can then 
undergo dethionylation, and then subsequent phase I metabolism in vivo 29–31. 
Episulfides and sulfoxides are known to be chemically unstable 1,32, and as a result 
dethionylation is likely to be a facile process which could occur enzymatically, or 
even under the ambient physiological conditions in the horse. As such, it is not 
surprising that no metabolites were observed to contain an intact episulfide, or 
sulfoxide, as upon ingestion H is likely to be rapidly metabolised to the 
corresponding alkene M, which could then be further metabolised. Oxidation of M 
to generate the enone metabolites is likely to occur via one of two pathways. 
Oxidation of M by a cytochrome P450-mediated process could afford an epoxide, 
which could be opened to afford an allylic alcohol, with subsequent oxidation to 
the corresponding enone 30,33. In the present study which employs isomerically 
pure H, such a pathway would be expected to result in enones E2 and E3 (Figure 
5.2). 
Figure 5.2: Proposed cytochrome P450-mediated epoxidation of M leading to 
enones E2 and E3 
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Table 5.1: In vivo equine metabolites observed by GC-MS/MS 
Metabolite Precursor ion and MS/MS fragments 
(m/z) (% of base peak), [collision 
energy]A 
RT 
(min) 
A 
Precursor 
ion 
Theoretical 
m/z 
E4 446 (70%), 431 (100%), 195 (70%), 
179 (50%), 149 (40%), [5 eV] 
13.96        
B, C 
[M]+● 446.3 
E2 446 (100%), 356 (10%), 251 (15%), 
207 (20%), 179 (15%), [5 eV] 
14.16     
B, D 
[M]+● 446.3 
hydroxylated 
madol M1 
448 (100%), 433 (25%), 358 (50%), 
343 (50%), 297 (50%), 284 (75%), 268 
(60%), 253 (70%), 246 (45%), 215 
(90%), 195 (60%), 162 (30%), 147 
(25%), [10 eV] 
11.42      
B 
[M]+● 448.3 
hydroxylated 
madol M2 
448 (15%), 231 (100%), 217 (5%), 173 
(5%), 143 (10%), [10 eV] 
13.61      
B 
[M]+● 448.3 
hydroxylated 
madol M3 
448 (25%), 231 (100%), 172 (5%), 
[10 eV] 
13.79      
B 
[M]+● 448.3 
hydroxylated 
madol M4 
448 (15%), 433 (55%), 358 (40%), 343 
(25%), 268 (25%), 226 (25%), 213 
(20%), 197 (20%), 182 (20%), 149 
(15%), 143 (100%), 117 (15%), 73 
(25%), [10 eV] 
13.96      
B, E, F 
[M]+● 448.3 
hydroxylated 
madol M5 
448 (35%), 433 (10%), 143 (100%), 
[5 eV] 
14.09     
B, E, F, G 
[M]+● 448.3 
hydroxylated 
madol M6 
448 (100%), 433 (30%), 358 (70%), 
343 (45%), 301 (30%), 268 (60%), 253 
(75%), 240 (30%), 226 (40%), 215 
(60%), 183 (45%), 159 (30%), 143 
(70%), 123 (15%), 106 (15%), [10 eV] 
14.52      
B 
[M]+● 448.3 
dihydroxylated 
madol M7 
536 (100%), 231 (45%), 202 (15%), 
143 (20%), [5 eV] 
15.29      
B 
[M]+● 536.4 
dihydroxylated 
madol M8 
536 (100%), 446 (10%), 341 (20%), 
251 (20%), 196 (50%), 156 (50%), 143 
(10%), [5 eV] 
15.75      
B 
[M]+● 536.4 
dihydroxylated 
madol M9 
536 (100%), 341 (25%), 266 (15%), 
231 (20%), 212 (10%), 196 (60%), 181 
(25%), 156 (30%), 143 (15%), 117 
(70%), [10 eV] 
16.71     
B 
[M]+● 536.4 
dihydroxylated 
and reduced 
madol M10 
538 (100%), 523 (5%), 453 (45%), 439 
(50%), 349 (90%), 259 (35%), 233 
(5%), 197 (5%), 169 (5%), 144 (20%), 
73 (40%) [10 eV] 
16.70     
B 
[M]+● 538.4 
trihydroxylated 
madol M11 
626 (15%), 231 (100%), 143 (10%), 
[10 eV] 
15.75     
B 
[M]+● 626.4 
trihydroxylated 
madol M12 
626 (15%), 231 (100%), 143 (10%), 
[10 eV] 
16.71     
B 
[M]+● 626.4 
AFrom targeted MS/MS data acquisition on the Agilent GC instrument using conditions specified for 
positive mode analysis (section 2.4.1). BMetabolite observed in urine sample analysis. CMatched 
against E4 reference material. DMatched against E2 reference material. EMatched against mixed 
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D3/D4 reference material. FMatched against mixed D7/D8 reference material. GMatched against 
D7 reference material.  
 
Table 5.2: In vivo equine metabolites observed by LC-HRAM 
Metabolite Precursor ion and MS/MS fragments 
(m/z) (% of base peak), [collision 
energy]A 
RT 
(min) 
A 
Precursor 
ion 
Theoretical 
m/z 
E4 303.2326 (100%), 285.2214 (55%), 
267.2117 (35%), 187.1479 (15%), 
145.1015 (30%), 95.0855 (15%), 
[20 eV] 
12.84
B, C, D 
[M+H]+ 303.2315 
E2 303.2351 (55%), 285.2221 (60%), 
267.2118 (100%), 245.1898 (20%), 
227.1803 (95%), 187.1479 (50%), 
135.1170 (50%), 121.0653 (85%), 
95.0859 (90%), 69.0702 (35%), [20 eV] 
12.98
B, C, E 
[M+H]+ 303.2315 
madol sulfate S1 367.1957 (100%), 79.9572 (15%), 
[20 eV] 
5.24  
C 
[M-H]- 367.1949 
hydroxylated 
madol sulfate S2 
383.1929 (60%), 79.9575 (100%), 
[10 eV] 
4.63  
C 
[M-H]- 383.1898 
hydroxylated 
madol sulfate S3 
383.1894 (100%), 96.9574 (40%), 
[10 eV] 
6.89  
C 
[M-H]- 383.1898 
dihydroxylated 
madol sulfate S4 
399.1875 (100%), 96.9599 (50%), 
[30 eV] 
4.96  
C 
[M-H]- 399.1847 
dihydroxylated 
and reduced 
madol sulfate S5 
401.2028 (100%), 96.9598 (75%), 
[40 eV] 
5.00  
C 
[M-H]- 401.2003 
dihydroxylated 
and reduced 
madol sulfate S6 
401.2012 (100%), 223.972 (35%), 
96.9599 (90%), 79.9574 (20%), [10 eV] 
5.35  
C 
[M-H]- 401.2003 
trihydroxylated 
madol sulfate S7 
415.1789 (100%), 96.9597 (90%), 
[30 eV] 
4.27  
C 
[M-H]- 415.1796 
trihydroxylated 
madol sulfate S8 
415.1791 (100%), 96.9598 (50%), 
[30 eV] 
4.68  
C 
[M-H]- 415.1796 
hydroxylated 
madol 
glucuronide G1 
481.2765 (100%), 305.2446 (25%), 
[10 eV] 
14.82  
C 
[M+H]+ 481.2796 
oxidised and 
hydroxylated 
madol 
glucuronide G2 
479.2636 (10%), 429.3012 (25%), 
303.2316 (100%), 177.1136 (15%), 
133.0876 (50%), 89.0603 (95%), 
[20 eV] 
14.20  
C 
[M+H]+ 479.2639 
AFrom targeted MS/MS data acquisition on the Agilent LC instrument using conditions specified for 
positive mode or negative mode analysis (section 2.4.2). BMetabolite observed in blood sample 
analysis. CMetabolite observed in urine sample analysis. DMatched against E4 reference material. 
EMatched against E2 reference material.   
176 
In light of the observed metabolites E2 and E4, an alternate pathway was proposed 
which could explain the observed equine metabolite distribution. Mechanistically, 
P450 enzymes perform hydroxylation through a sequence involving hydrogen 
atom abstraction to form a carbon-centred radical, followed by rapid hydroxyl 
radical recombination. Abstraction of a hydrogen atom at C4 would result in an 
allylic radical which could then undergo radical recombination at C2 or C4, 
resulting in allylic alcohols D3/D4, or D7/D8 which could be subsequently 
oxidised to the corresponding enones E2 and E4 respectively 30,34–36. Evidence for 
the allylic rearrangement required to access the double-bond isomerised 
hydroxylated metabolites has been reported 34,36. In the present study, abstraction 
of the hydrogen at C4 would result in enones E2 and E4 (Figure 5.3), whilst the 
alternative abstraction of the hydrogen atom at C1 would result in enones E1, and 
E3. The exclusive formation of enones E2 and E4 as the equine metabolites could 
potentially be explained by the steric environment surrounding C4, as this position 
is less hindered than the environment at C1, due to the adjacent methyl group at 
C10. Alternatively, this selectivity could be rationalised through cytochrome P450 
enzyme-substrate interactions. 
 
Figure 5.3: Proposed cytochrome P450-mediated hydroxylation of M leading 
to enones E2 and E4 
 
 
5.1.3.4 Analysis of phase I urinary metabolites 
Positive mode ESI LC-HRAM analysis showed two oxidised and hydroxylated 
madol phase I metabolites, which were identical to those found in the blood 
samples (Table 5.2). These metabolites were confirmed against synthetic reference 
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materials E2, and E4. No matches were observed for reference standards H, M, E1, 
E3, E5, D1-D10, or HS in the urine samples by positive mode LC-HRAM analysis.  
 
Analysis by EI GC-MS/MS also identified E2 and E4 as the major urinary 
metabolites and these were also matched to reference materials (Table 5.1). Under 
the GC-MS/MS conditions employed, enones E2 and E3 were separated 
chromatographically, which allowed identification of the equine metabolite E2. A 
combination of retention time, and the presence of an ion at m/z 179 which was 
common to the observed metabolite and E2 reference material, and the absence of 
ions at m/z 201 and m/z 145 which were observed only in the E3 reference 
material, were used to confirm the identity of the equine metabolite against 
reference materials. The ion counts for the urinary metabolites (~102) were 
substantially lower than those of the reference materials (~104), due to their low 
urinary concentration, which led to differences in the ion profiles of the observed 
metabolites and reference materials (Figure 5.4, and 5.5). Although there were 
differences in the number of ions observed, the major ions for the urinary 
metabolites were still identified in the reference materials, and were within the 
Association of Official Racing Chemists (AORC) mass spectrometry criteria 37. 
Analysis by GC-MS/MS also identified a number of additional metabolites which 
were not observed by LC-HRAM analysis. A number of the observed metabolites 
were steroid diols, or triols, which are known to be difficult to ionise under +ESI 
conditions common to LC analysis 38,39. However, as the sample preparation 
involved acid hydrolysis of the phase II steroid conjugates, only the corresponding 
phase I metabolites were observed. In addition to the major enone metabolites, 
other major metabolites observed by GC-MS/MS analysis included four 
hydroxylated madol metabolites (M1-M3, M6). Minor metabolites were observed 
including two hydroxylated madol metabolites (M4 and M5), three dihydroxylated 
madol metabolites (M7-M9), one dihydroxylated and reduced metabolite (M10), 
and two trihydroxylated metabolites (M11 and M12).  
 
The minor metabolites M4 and M5 were both observed to match reference 
materials by retention time for both D3/D4, and D7/D8, preventing their 
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unambiguous identification. The retention time for the observed metabolite M4 
(RT 13.96 min) closely matched one peak in both the mixed D3/D4 and D7/D8 
reference materials. The absence of metabolite M4 ions at m/z 358 and m/z 149, 
and the presence of an additional ion at m/z 240 in the corresponding peak of the 
D3/D4 reference material, suggested a closer match with the D7/D8 reference 
material. As the 4α-hydroxy isomer D7 was prepared in pure form, and matches 
with the second eluting peak (RT 14.07 min) of the mixed D7/D8 reference 
material, the identity of M4 was tentatively assigned as the 4β-hydroxy isomer D8. 
In contrast, the metabolite M5 (RT 14.09 min) afforded only a few fragment ions, 
none of which could be used to differentiate between the mixed D3/D4 and 
D7/D8 reference materials. It is likely that the low urinary concentration of this 
minor metabolite affords poor sensitivity in the observed GC-MS/MS data, 
preventing its unambiguous assignment. However, since both of the enones (E2, 
and E4) were observed as major metabolites, it is also likely that the 
corresponding diol metabolites D3, D4, D7, and D8 would also be present. 
Additionally, as the D3/D4 reference material was prepared as a mixture, it would 
not be possible to assign the stereochemistry of these products to a particular 
metabolite peak. No reference materials were available for the major metabolites 
M2 and M3, however these were tentatively assigned as a pair of 16α/β-
hydroxylated madol metabolites, based on the observed m/z 231 fragment ion, 
which has been previously reported to be characteristic of 16-hydroxylated-17-
methylated steroids 40. This fragment ion was also observed for minor metabolites 
M7, M9, M11, and M12, which were also tentatively assigned to contain 
16-hydroxylation. No matches were observed for reference standards H, M, E1, E3, 
E5, D1-D2, D5-D6, D9-D10, or HS in the urine samples by GC-MS/MS. 
Unsurprisingly, subjecting H reference material to GC-MS/MS analysis resulted in 
decomposition of the episulfide on heating or derivatisation to generate M, 
however as no metabolites were observed to contain an intact episulfide, or 
sulfoxide by LC-HRAM analysis, it is unlikely that these metabolites would be 
present in the urine samples. 
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Figure 5.4: Extracted ion chromatograms showing targeted GC-MS/MS 
spectra (5 eV) of a) E2 identified in the 4 h urine, b) E2 reference material 
a) 
b) 
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Figure 5.5: Extracted ion chromatograms showing targeted GC-MS/MS 
spectra (5 eV) of a) E4 identified in the 4 h urine, b) E4 reference material 
a) 
b) 
 
 
5.1.3.5 Analysis of phase II urinary metabolites 
Positive and negative mode LC-HRAM analysis identified a number of phase II 
conjugates that corresponded to the phase I metabolites described in the previous 
sections (Table 5.2). Analysis of the urine samples identified one madol sulfate 
metabolite S1, two hydroxylated madol sulfates S2 and S3, one dihydroxylated 
madol sulfate S4, two dihydroxylated and reduced madol sulfates S5 and S6, two 
trihydroxylated madol sulfates S7 and S8, one hydroxylated madol glucuronide G1, 
and one oxidised and hydroxylated madol glucuronide G2. The reference material 
for MS did not match the retention time for S1, even though there is only one 
potential site for sulfation. Additionally, comparison of the LC-HRAM spectrum of 
S1 to MS showed that S1 did not exhibit the expected [HSO4]- fragment of m/z 
96.9601, but instead afforded the [SO3]-
● fragment m/z 79.9572 25. Tertiary steroid 
sulfates such as MS have been observed to hydrolyse with inversion of 
configuration to generate the epimeric 17α-hydroxy compounds 41–43, which could 
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potentially then be re-sulfated. As such, these metabolites have been tentatively 
assigned as a 17-epi-madol sulfate. Unfortunately, there was no reference material 
available for the corresponding 17-epi-madol compound to confirm this 
assignment.  
 
Although a number of the key phase II metabolites were observed by LC-HRAM 
analysis, a number of the major phase I metabolites were only observed by GC-
MS/MS analysis. While the use of HRAM affords a higher degree of confidence for 
the detected metabolites, which is particularly important at very low metabolite 
concentrations, the inability to detect phase I steroid diols and triols by LC-HRAM 
is a major limitation for screening. In light of the advantages afford by both 
methods of analysis, the use of both LC-HRAM and GC-MS/MS in conjunction with 
each other is recommended for the detection of H misuse in equine sports. 
 
5.1.3.6 Excretion profiling of the major equine metabolites 
One of the aims of this study was to identify potential metabolites to incorporate 
into anti-doping screening protocols. The excretion of the major enone and diol 
metabolites, as determined by GC-MS/MS analysis, was established through a 
response ratio plot of metabolite signal intensity relative to d3-testosterone as an 
internal standard. In order to enhance sensitivity, and assist in the translation to a 
routine screening protocol, a series of multiple reaction monitoring (MRM) 
transitions were identified from the most intense ion peaks observed in the 
product ion spectra. The excretion profiles of the enone metabolites E2, and E4, 
were established, in addition to the diol metabolites M1-M6. The excretion profile 
of E4 is shown below (Figure 5.6), and the excretion profiles of E2, and M1-M6 are 
included in the supporting information. 
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Figure 5.6: GC-MS/MS excretion profile of metabolite E4 
 
The enone metabolite E4 was observed up to 72 h post-administration by 
monitoring for the MRM transitions 431  179, and 446  431, in contrast to E2 
which was observed up to 12 h post-administration by monitoring for the 
transition 446  179. For the diol metabolites M2 and M3, the most sensitive 
transitions appeared to be 448  231, which was observed up to 48 h post-
administration, and 448  143, which was observed up to 8 h post-administration. 
The remaining metabolites M1, M4-M6 were observed by monitoring for the 
transition 448  143, and were all observed up to 8 h post-administration. The 
AORC mass spectrometry criteria requires the use of at minimum three fragment 
ions at unit mass resolution, or two fragment ions at HRAM resolution in order to 
confirm a metabolite 37, and as such E4, M2, and M3 appeared to be the most 
suitable metabolites for screening purposes.  
 
5.1.4 Conclusions 
Designer steroids such as hemapolin (H) have the potential to harm the integrity of 
sporting competition if left unchecked. The metabolism of hemapolin was 
investigated in equine systems for the first time by an in vivo administration study. 
The enone metabolites 17β-hydroxy-17α-methyl-5α-androstan-3-en-2-one E2, and 
17β-hydroxy-17α-methyl-5α-androstan-2-en-3-one E4, presumably derived from 
cytochrome P450-mediated hydroxylation and oxidation of M, were detected in 
equine blood and urine, the latter being observed up to 3 d post-administration. 
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The hydroxylated madol metabolites M1-M6 were also identified, with M2 and M3 
observed up to 48 h post-administration by MRM methods. Minor metabolites 
resulting from dihydroxylation, dihydroxylation and reduction, and 
trihydroxylation were also observed, alongside a number of phase II sulfate and 
glucuronide conjugates. These metabolites were matched against an extensive 
library of synthetically derived reference materials where available. The excretion 
of a number of the key enone and diol metabolites was profiled. These 
investigations have identified the key metabolites resulting from hemapolin 
administration which can be incorporated into routine anti-doping screening and 
confirmation protocols.  
 
5.1.5 Future work 
As a number of aspects of this work remain incomplete, there are several avenues 
for future work on this project. A number of the key metabolites have been 
tentatively identified in this study based on analysis of their mass spectrometry 
behaviour, as reference materials for many of the metabolites were unavailable. 
Providing access to synthetic reference materials for these metabolites could 
unambiguously confirm their identities. The major phase I metabolites M2 and M3 
were proposed as a pair of 16α/β-hydroxylated madol isomers by GC-MS/MS 
analysis, based on the observation of a characteristic fragment ion of m/z 231. 
These compounds could potentially be confirmed through preparation of the 
corresponding C16-hydroxylated reference materials. Access to the C16α-
hydroxylated isomer could be afforded through a similar protocol as described in 
Chapter 3.2 for the synthesis of 3α-chloro-17α-methyl-5α-androstan-16α,17β-diol 
27. Access to the C16β-hydroxylated isomer could be afforded through alternative 
methods, such as the protocol reported by Hungerford et al 44.  
 
In addition to M2 and M3, the metabolites M4 and M5 have been only tentatively 
assigned. Mixed reference materials for D3/D4 and D7/D8 had similar retention 
times, and ion fragmentation patterns compared with the observed metabolite, 
and as a result their identities were not able to be unambiguously determined. The 
low sensitivity of the detected metabolites resulting from their low urinary 
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concentration also contributed to this problem. The preparation of these reference 
materials on a larger scale may facilitate their separation by column 
chromatography, which could allow for pure materials to assist in the 
identification of these metabolites. Furthermore, the observed dihydroxylated and 
reduced madol metabolite M10 could match 17α-methyl-5α-androstan-2β,3α,17β-
triol, which has been reported as a major metabolite for the in vitro human 
metabolism of M 21. Although there are expected to be differences in the 
metabolism observed in this study compared to the present study, determining the 
identity of this metabolite may prove useful for screening purposes. The synthesis 
of isomeric compounds of this type could provide reference materials which could 
be used to shed light on the identity of M10. Additionally, synthetic access to a 
variety of reference materials for metabolites M2-M5, and M10 may also allow for 
preparation of their corresponding phase II sulfate and glucuronide conjugates, 
allowing for the unambiguous assignment of other metabolites. 
 
In addition to the problems surrounding the identity of some of the phase I 
metabolites, there also remains an issue with the identity of the observed phase II 
madol sulfate metabolite S1. The reference material for MS was not observed to 
match the retention time for S1, even though there is only one potential site for 
sulfation. It is known that tertiary alcohols from C17-methylated steroids can 
undergo epimerisation in vivo at C17 via the sulfate conjugate 50–52, which could 
potentially then be re-sulfated. A similar process could also be occurring during 
the preparation of the MS reference material, to generate the epimeric madol 
compound. In light of the complicated nature of the reactivity of this metabolite, 
additional study is needed to unambiguously determine the identity of this 
metabolite. Standards of both M and 17-epi-madol should be prepared, to test how 
they behave under the sulfation conditions, and to ultimately provide reference 
materials which can be used for the assignment of S1. 
 
Finally, additional work needs to be undertaken to fully profile the excretion of the 
key equine metabolites. Although the excretion of several of the major enone (E2 
and E4), and diol (M1-M6) metabolites has been undertaken using MRM methods, 
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these only qualitatively profile the excretion of these metabolites. In addition, a 
number of these profiles make use of only one MRM transition, which is 
inadequate under AORC criteria for confirming these compounds as metabolites. 
With the provision of suitable reference materials, the excretion of the major 
metabolites E4, M2 and M3 should be quantified in equine urine, as this will allow 
determination of suitable limits of detection, and quantification which would prove 
invaluable for routine screening purposes. At present, only E4 has an available 
reference material, however even the quantification of this metabolite alone would 
provide valuable information for anti-doping screening, and should be undertaken. 
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6.1 Conclusions 
The work presented throughout this thesis highlights a number of strategies that 
can be employed for the detection of designer steroids in racehorses. This final 
chapter aims to summarise the main conclusions drawn from the work presented, 
and how they contribute to the area of anti-doping research. 
 
The literature reviewed in Chapter One highlights the tools currently available to 
anti-doping laboratories. This review has highlighted the strengths and 
weaknesses of current anti-doping strategies, and identified the areas that 
currently require additional focus. Although anti-doping laboratories are equipped 
with a variety of tools to identify instances of designer steroid misuse, they are 
often limited by a lack of information detailing the metabolism of these compounds 
in equine systems. A number of studies detailing the metabolism of designer 
steroids have been reported in recent years, and have identified some metabolites 
and markers to assist in their detection. However, the vast majority of currently 
available designer steroids have not been studied in equine systems, despite 
receiving significant attention in human sports. Studies such as these provide 
valuable information on the equine metabolism of designer steroid compounds, 
and as a result this review will hopefully assist future anti-doping research. 
 
One of the primary limitations of current anti-doping research as identified in 
Chapter One is a lack of reference materials available to anti-doping laboratories 
for use in the detection and confirmation of designer steroid misuse. In particular, 
steroid sulfate metabolites have remained relatively understudied, despite the fact 
that sulfation is known to be a key pathway in the metabolism of steroid 
compounds in equine systems. Recent advances in the use of LC-MS/MS analysis 
have also facilitated their direct detection, and as a consequence these metabolites 
are of growing importance to anti-doping laboratories. Chapter Two presents a 
new approach for the synthesis of steroid sulfate metabolites, suitable for use by 
anti-doping laboratories. This approach makes use of SPE, a technique familiar to, 
and routinely utilised by anti-doping laboratories. A library of sixteen steroid 
mono-sulfate, and twelve steroid bis-sulfate compounds has been prepared using 
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this method. A number of these compounds have not been studied previously, and 
the characterisation data available in the literature is lacking in most cases. 
Characterisation including 1H NMR, 13C NMR, and (-ESI) LRMS data has been made 
available, and these steroid compounds are now able to be prepared for use as 
reference materials by anti-doping laboratories, without the need for significant 
investment in chemical synthesis. In addition, the MS behaviour of these 
compounds has been studied, identifying the key modes of fragmentation. Steroid 
mono-sulfates were observed to give rise to ions of [M-H]-, and a fragment ion at 
m/z 97 (corresponding to [HSO4]-). A fragment ion of m/z 80 (corresponding to 
[SO3]-
●) was also observed in some instances. Steroid bis-sulfates gave rise to 
[M-2H]2-, and [M-H]- ions, together with the fragment ions [M-2H-HSO4]-, m/z 97, 
m/z 81 (corresponding to loss of [HSO3]-), and m/z 80. The key fragmentation 
mode appears to be loss of the [HSO4]- anion to give rise to the fragment ion 
[M-2H-HSO4]-, with an increase in m/z of the resulting fragment ion. This unique 
fragmentation mode formed the basis of a common ion loss scan (CIL) method for 
the untargeted detection of steroid bis-sulfate compounds. The developed CIL 
approach allowed for the untargeted detection of endogenous bis-sulfates at the 
low ng/mL range. This method allowed for the detection of steroid bis-sulfates 
corresponding to a number of different steroid classes in urine samples obtained 
from healthy volunteers, and will hopefully be suitable for the detection of other 
classes of steroid bis-conjugates such as bis-glucuronides, bis-sulfate-glucuronides, 
or other multiply-charged metabolites. The ability to detect endogenous bis-sulfate 
metabolites could potentially assist in monitoring for EAAS misuse, or even for the 
detection of designer steroid misuse, and as such broadens the utility of this 
method for use in anti-doping laboratories. 
 
The detection of novel anabolic agents intended for doping purposes remains a 
significant problem in both human and equine sports. The greatest hurdle to 
responding effectively to this problem is often obtaining intelligence regarding the 
availability of designer steroids, and therefore identifying the most likely 
candidates for misuse. Chapter Three presents a study in which an unknown 
sample (determined to contain 3α/β-chloro-17α-methyl-5α-androsta-17β-ol) was 
seized by law-enforcement. A workflow was developed which details an effective 
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response to the threat of new designer steroid compounds, suitable for adoption 
by anti-doping laboratories. Central to this approach was the use of synthetically-
derived reference materials, androgen bioassays, and in vitro metabolism. The 
availability (or lack thereof) of steroid reference materials is a common theme 
throughout this work, and this study highlights the utility of high quality chemical 
synthesis in anti-doping research. Androgen bioassays provide a useful way to 
gauge the threat a particular compounds poses to anti-doping laboratories, and 
may eventually have applications in routine screening. The use of in vitro 
techniques to study the metabolism of designer steroids is highlighted as an 
alternative to in vivo administration, particularly when it is difficult to justify these 
on ethical grounds. These studies identified the key metabolites resulting from 
metabolism of 3α-chloro-17α-methyl-5α-androsta-17β-ol, and in particular, 
highlighted the need for the study of these compounds specifically in equine 
systems, as the major metabolite resulting from equine in vitro metabolism (3α-
chloro-17α-methyl-5α-androsta-16α,17β-diol) did not match the major metabolite 
resulting from human in vitro metabolism (17α-methyl-5α-androstan-3α,17β-
diol). The data obtained from these studies was then used to develop and evaluate 
the translation into routine anti-doping screening protocols, which will hopefully 
allow for detection of these compounds in human and equine sports. 
 
The work presented in Chapter Four builds on the work presented in Chapter Two 
and Chapter Three, and presents two separate studies detailing the metabolism of 
the designer steroids furazadrol ([1’,2’]isoxazolo[4’,5’:2,3]-5α-androstan-17β-ol), 
and superdrol (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one). In the first 
study, the in vivo equine metabolism of furazadrol is presented alongside a 
comparative in vitro phase I metabolism study. Following the controlled 
administration of furazadrol to a thoroughbred racehorse, the key in vivo 
metabolites furazadrol 17-sulfate, furazadrol 17-glucuronide, and epifurazadrol 
17-glucuronide were identified and matched to synthetically derived reference 
materials. Additionally, a number of minor metabolites were observed resulting 
from hydroxylation, and oxidation and hydroxylation, together with sulfate or 
glucuronide conjugation. Enzymatic hydrolysis of the phase II sulfate and 
glucuronide metabolites by Pseudomonas aeruginosa arylsulfatase and Escherichia 
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coli β-glucuronidase provided additional evidence for the identity of these 
metabolites. The key metabolites, furazadrol 17-sulfate and furazadrol 17-
glucuronide, were quantified in equine urine to established an excretion profile, 
and suitable limits of detection. The comparative in vitro phase I study was also 
undertaken and identified all but two of the minor in vivo phase I metabolites 
observed after hydrolysis of the urine samples. These investigations identified the 
key urinary metabolites of furazadrol following oral administration, which can be 
incorporated into anti-doping screening and confirmation procedures. This study 
highlights the value of synthetically derived reference materials, and in vitro 
techniques in studying the metabolism of designer steroids. 
 
The second study described in Chapter Four presents an investigation into the 
in vitro study of phase II steroid metabolism, which is currently under-studied in 
anti-doping research. Phase II sulfation was undertaken through the addition of 
UDPGA and PAPS to the in vitro reaction employed in Chapter 4.2. Alternative 
conditions for phase II sulfation were explored in which ATP, and Na2SO4 were 
used in place of PAPS. Employing UDPGA, ATP, and Na2SO4 for the metabolism of 
superdrol identified 3β-RSS, and a reduced superdrol glucuronide G2 as the major 
metabolites, alongside minor metabolites including two hydroxylated superdrol 
sulfates, a reduced and hydroxylated superdrol sulfate, a superdrol glucuronide, 
3β-RSG, and two reduced and hydroxylated superdrol glucuronides. The major 
3β-RSS, and minor 3β-RSG metabolites were confirmed against 2α,17α-dimethyl-
5α-androstan-3β,17β-diol 3-sulfate, and 2α,17α-dimethyl-5α-androstan-3β,17β-
diol 3-glucuronide reference materials respectively. The phase II conjugates 
observed appeared to correlate well with the phase I metabolites identified in 
previously reported equine and human in vitro studies. The in vitro metabolism of 
furazadrol was also explored using both phase II systems, with comparison to the 
in vivo study reported in Chapter 4.2. Following phase II metabolism with UDPGA 
and PAPS, the major in vivo metabolites FS, IFS, EFS, FG, IFG, and EFG were all 
confirmed by matching to reference materials. In addition, a number of minor 
metabolites were observed, including six hydroxylated furazadrol sulfate 
metabolites, one oxidised and hydroxylated furazadrol sulfate metabolite, five 
hydroxylated furazadrol glucuronide metabolites, and two oxidised and 
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hydroxylated furazadrol glucuronide metabolites. Only one of the minor sulfate 
metabolites observed using these conditions was observed to match the in vivo 
profile. The use of UDPGA, ATP, and Na2SO4 generated a comparable in vitro 
profile, with identification of the same major in vivo metabolites, as well as a 
number of minor metabolites including six hydroxylated furazadrol sulfate 
metabolites, one oxidised and hydroxylated furazadrol sulfate metabolite, two 
hydroxylated furazadrol glucuronide metabolites, and three oxidised and 
hydroxylated furazadrol glucuronide metabolites. Only one of the minor sulfate 
metabolites observed using these conditions was observed to match the in vivo 
profile, suggesting that these conditions may be a better choice for generating 
some in vivo metabolites. Although some of the minor in vivo designer metabolites 
were also identified in this work, the ability of these systems to fully predict in vivo 
metabolism is currently limited, and it is hoped that future work will improve the 
ability to accurately predict the in vivo metabolism of steroid compounds solely 
from in vitro results. 
 
Chapter Five draws on the lessons learnt throughout the previous chapters and 
details a study of the designer steroid hemapolin (2α,3β-epithio-17α-methyl-5α-
androstan-17β-ol). Synthetic hemapolin was prepared through a novel synthetic 
strategy, and was used in an equine in vivo administration study. Following 
controlled administration, the key in vivo enone metabolites 17β-hydroxy-17α-
methyl-5α-androst-3-en-2-one E2, and 17β-hydroxy-17α-methyl-5α-androst-2-en-4-
one E4, were identified in equine blood and urine, and were matched to 
synthetically derived reference materials. Additional minor metabolites were 
observed, resulting from hydroxylation, dihydroxylation, dihydroxylation and 
reduction, and trihydroxylation, with and without phase II sulfation or 
glucuronylation. A number of these were tentatively assigned by comparison to 
reference materials, which were considered essential to assign the identity of the 
key enone, and diol metabolites. The excretion profiles of these metabolites were 
established, with the major enone, and diol metabolites E4, E2, M2, and M3 
observed up to 72 h, 8 h, 48 h, and 48 h post-administration respectively. A 
number of aspects of this work currently remain incomplete, however this study 
has identified the key metabolites resulting from hemapolin administration which 
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can be incorporated into routine anti-doping screening and confirmation protocols 
in the future. 
 
Overall, the work presented in this thesis contributes to a number of important 
areas of anti-doping research. First and foremost, this work addresses the issue of 
access to reference materials, which is a major limitation in current anti-doping 
laboratories. Through the development of simple methodology for the in-house 
synthesis of steroid sulfates, as well as the synthesis of the designer steroids 3α-
chloro-17α-methyl-5α-androstan-17β-ol, furazadrol, hemapolin, and their 
respective phase I and phase II metabolites, we have expanded the range of 
reference materials available to anti-doping laboratories for use in routine 
screening and confirmatory analysis. Secondly, this work addresses some of the 
current limitations of in vitro technologies for the study of steroid metabolism. A 
common criticism of in vitro methods is their suggested inability to replicate in vivo 
results, and this work addresses these concerns though the development of 
alternative in vitro methodologies which have been observed to generate in vivo 
metabolites, including phase II sulfate and glucuronide metabolites. Finally, this 
work helps to translate these results into meaningful screening protocols which 
can be adopted by anti-doping laboratories. This has been achieved through the 
identification of the key metabolites resulting from steroid administration, the 
determination of their respective excretion profiles, determination of suitable 
limits of detection and quantification, and the provision of reference materials to 
anti-doping laboratories. It is hoped that this work can be used by anti-doping 
laboratories to detect instances of misuse of designer steroids, and as a platform 
for future research to develop new strategies for the detection of designer steroids. 
 
6.2 Future work 
The work presented throughout this thesis has identified a number of aspects 
which could be the target of future research. As previously discussed, the review 
presented in Chapter One has identified a number of limitations of current anti-
doping analysis which could become the subject of future research. A number of 
designer steroids which are currently available have not been previously studied 
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in equine systems, although they have gained attention in human sports 1–3. 
Additionally, new supplements are constantly coming onto the market which will 
require study in the future. The work presented throughout this thesis will 
hopefully prove a suitable template upon which to undertake future research. 
Additionally, the review has highlighted the growing importance of LC-MS analysis 
in anti-doping laboratories, which is facilitating the direct detection of phase II 
metabolites. These metabolites are likely to become important markers of drug 
detection in the future, and developing methods which can utilise these markers 
would likely benefit anti-doping laboratories greatly. It would also be prudent to 
review the scientific literature on the application of phase II conjugates in 
screening and confirmation, which would hopefully provide useful data to anti-
doping laboratories, and provide further direction to future research. 
 
Access to steroid-sulfate metabolites has been provided through the methodology 
presented in Chapter Two. The use of these compounds as reference materials will 
facilitate the future development of LC-based analyses, and potentially provide 
additional tools to assist in confirmatory analysis. Whilst sulfate metabolites are 
straightforward to prepare, another class of metabolites, steroid glucuronides, are 
currently lacking reliable and simple methodology for their synthesis. The 
synthesis of steroid mono-glucuronides, bis-glucuronides, and mixed bis-sulfate-
glucuronides would benefit from the development of simple methodology for the 
synthesis of these materials, and these compounds could be subjected to a 
systematic study similar to the one presented in Chapter 2.3. Recent work within 
the McLeod group has developed an enzymatic β-glucuronylsynthase method for 
the synthesis of steroid glucuronides 4, however it is currently limited by a small 
substrate scope and poor reaction yields. It is hoped that improvements to this 
enzyme may provide future access to these classes of compounds, and facilitate 
their study and incorporation into routine anti-doping screening. Additionally, the 
constant ion loss method developed in Chapter 2.3 should be employed in anti-
doping laboratories for the detection of steroid bis-sulfate metabolites, potentially 
allowing for the detection of new steroid metabolites. This methodology could also 
be applied to other bis-metabolites, such as bis-glucuronides, and mixed bis-
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sulfate-glucuronides, allowing for the untargeted detection of new classes of 
steroid metabolites. 
 
The identification of new supplements containing unknown steroid compounds is 
a growing concern, and the workflow developed in Chapter Three should allow 
anti-doping laboratories to respond more effectively to the threat of designer 
steroids in future. The use of androgen bioassays is gaining importance for 
screening 5,6, as these assays can rapidly detect samples containing anabolic agents 
which can then be flagged for further testing. Future testing of new supplements 
using these methods could provide valuable intelligence to anti-doping 
laboratories and law enforcement, providing direction to future research. 
 
In vivo studies have been a mainstay of steroid metabolism; however, the use of 
animal studies is not without its risks to the health and well-being of the animal 
researcher. The use of in vitro techniques to replicate steroid metabolism would 
reduce the need for in vivo studies, but cannot be used routinely until reliable 
protocols are developed which can replicate in vivo metabolism. Methodology has 
been developed in Chapter Four which attempts to address these concerns, and 
has shown that the incorporation of phase II co-factors into in vitro systems can 
successfully generate phase II metabolites. The use of PAPS to generate phase II 
metabolites has been successfully replaced with cheaper reagents, and although 
UDPGA is much cheaper to purchase compared to PAPS, it can still be prohibitively 
expensive, preventing its use in some instances. The development of alternative 
conditions for phase II glucuronylation could facilitate their incorporation into in 
vitro techniques, and the incorporation of phase II metabolism is likely to more 
accurately reflect the metabolism observed in vivo. The phase II co-factor UDPGA 
(AU$100 for 25 mg, Sigma Aldrich 7) is required for glucuronylation in vivo, and is 
known to be generated from uridine 5’-diphosphoglucose (UDP-glucose, AU$87 
per 100 mg, Sigma Aldrich 8) in a NADH-dependant process 9. The incorporation of 
UDP-glucose and NADH could be a viable substitute for UDPGA, as the enzymes 
required for the biosynthesis of UDPGA should likely be contained within the liver 
S9 fraction. By making the study of phase II metabolism affordable, through the use 
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of affordable co-factor systems, it is hoped that it will be used more routinely to 
study phase II metabolism; eventually resulting in in vitro systems capable of fully 
replicating in vivo metabolism. 
 
A number of aspects of the work presented in Chapter Five require future work, 
and have been discussed in detail previously. Briefly, the identification of a number 
of hemapolin metabolites requires additional work to confirm the identity of these 
metabolites against reference materials. Additionally, the excretion of the key 
enone and diol metabolites will require further work to complete. Ultimately, it is 
hoped that completing this work will provide valuable information about this of 
this intriguing designer steroid for use in anti-doping screening  
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corrections to this thesis were made (May 2017), this review was accepted for 
publication in the journal Drug Testing and Analysis. The full citation for this work 
is as follows: 
 
Waller, C. C.; McLeod, M. D, Drug Testing and Analysis 2016, A review of designer 
anabolic steroids in equine sports, DOI: 10.1002/dta.2112 
 
A copy of the full text article has been reproduced in Appendix A, with permission 
of John Wiley and Sons via Rightslink (License Number: 3994540395974). 
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In the period between when this thesis was submitted (September 2016) and the 
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publication in the journal Analytical Chemistry. The full citation for this work is as 
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